JOURNAL OF PHARMACEUTICAL SCIENCES

A publication of the American Pharmaceutical Association

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 64
JANUARY TO DECEMBER, 1975

Published monthly under the supervision of the Board of Trustees

MARY H. FERGUSON
Editor

L. LUAN CORRIGAN
Assistant Editor

SHELLY ELLIOTT
Production Editor

JANET D. SHOFF
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

LELAND J. ARNEY
Publications Director

EDITORIAL ADVISORY BOARD

Lynn R. Brady
William O. Foye
Harry B. Kostenbauder
Gerhard Levy
Carl J. Lintner, Jr.
G. Victor Rossi

© Copyright 1975 by the American Pharmaceutical Association; all rights reserved.

AUTHOR INDEX

A

Abadie, F., *see* Gérardin, A., 1940
Abbatiello, E. R., and Catuogno, J., effects of cyproterone acetate on uterine motility in rats, 452
Abolin, C. R., *see* Crouthamel, W. G., 1726
Abramson, H. N., *see* Wormser, H. C., 1514, 1882
Abtahi, F., *see* Lalezari, I., 1250
Actor, P., *see* Holl, W. W., 1232
Adir, J., enterohepatic circulation of tetracycline in rats, 1847
Afghahi, F., Yazdany, S., and Lalezari, I., synthesis and antibacterial and antifungal activities of 5-nitro-2-furfurylidene polyhalophenoxyacethydrazides VIII, 858
——*see* Lalezari, I., 698
Ahmad, N., *see* Bederka, J. P., Jr., 528
Akers, M. J., *see* Chien, Y. W., 1632
Alam, M., Trieff, N. M., Ray, S. M., and Hudson, J. E., isolation and partial characterization of toxins from the dinoflagellate *Gymnodinium breve* Davis, 865
Albert, K. S., *see* Sullivan, T. J., 1723
Ali, B., Kumar, R., Parmar, S. S., Dwivedi, C., and Harbison, R. D., antihemolytic and anticonvulsant activities of 1-(2,4-dichloro/2,4,5-trichlorophenoxyacetyl)-4-alkyl/arylthiosemicarbazides and their inhibition of NAD-dependent oxidations and monoamine oxidase, 1329
Alleguez, C., *see* Kupchik, E. J., 1259
Allwood, M. C., Hambleton, R., and Beverley, S., pressure changes in bottles during sterilization by autoclaving, 333
Amer, M. S., and Kreighbaum, W. E., cyclic nucleotide phosphodiesterases: properties, activators, inhibitors, structure–activity relationships, and possible role in drug development, 1
Ames, M. M., *see* Smith, R. N., 599
Amidon, G. L., *see* Yalkowsky, S. H., 48
Amin, K. N., *see* Nelson, K. G., 350
Amin, Y. M., and Nagwekar, J. B., mechanistic evaluation of modifications of distribution pharmacokinetic parameters of model organic anions in presence of a model renal tubular secretion inhibitor in rats, 1813
——and Nagwekar, J. B., utilization of model compounds to evaluate effects of slight chemical modifications on their distribution pharmacokinetic parameters in rats and mechanisms inferred for their transmembrane transport, 1804
Amirjahed, A. K., and Blake, M. I., deviation of dielectric constant from ideality for certain binary solvent systems, 1569
Anderson, J. A., *see* Bajwa, R. S., 343
Anderson, W. L., *see* Ziegler, H. W., 1026
Anmo, T., *see* Washitake, M., 397
Antal, E. J., Jaffe, J. M., Poust, R. I., and Colaizzi, J. L., bioequivalency of doxycycline products, 2015
Arita, T., *see* Washitake, M., 397
Ascione, P. P., and Chrekian, G. P., automated high-pressure liquid chromatographic analysis of aspirin, phenacetin, and caffeine, 1029
Asgharian, R., *see* Shafiee, A., 1570
Asker, A. F., *see* Whitworth, C. W., 2018
Asleson, G. L., *see* Stoel, L. J., 1635
Atwell, S. H., Green, V. A., and Haney, W. G., development and evaluation of method for simultaneous determination of phenobarbital and diphenylhydantoin in plasma by high-pressure liquid chromatography, 806
Auslander, D. E., Feimeister, A., and Sciarrone, B. J., drug–biomolecule interactions: interaction of gentamicin with lipid monomolecular films, 516
Autian, J. *see* Hung, G. W. C., 1492
——*see* Singh, A. R., 1347
Axelson, J. E., *see* Gibaldi, M., 359
Aynilian, G. H., Bell, C. L., and Farnsworth, N. R., alkaloids of *Vinca* species V: structure elucidation of herbadine, an alkaloid isolated from *Vinca libanotica*, 341
Ayres, J. W., Lorskulsint, D., and Lock, A., absorption of ^{3}H-benzocaine from ointments following rectal administration in rats, 1958
Azarnoff, D. L., *see* Huffman, D. H., 433

B

Badaly, A., *see* Lalezari, I., 1250
Bailey, K., and Gagné, D., distinction of synthetic cannabidiol, cannabichromene, and cannabivarin by GLC using on-column methylation, 1719
Baines, R., *see* Tin-Wa, M., 2024
Bajwa, R. S., and Anderson, J. A., conversion of agroclavine to setoclavine and isosetoclavine in cell-free extracts from *Claviceps* sp. SD 58 and in a thioglycolate–iron (II) system, 343
Baker, H. A., *see* Dimmock, J. R., 995
Ballard, B. E., lidocaine hydrochloride absorption from a subcutaneous site, 781
Banker, G. S., *see* Nadkarni, P. D., 1554
Barcza, S., and Houlihan, W. J., structure determination of the anorexic agent mazindol, 829
Bardos, T. J., *see* Lalka, D., 230
Barnett, A., *see* Malick, J. B., 1066
Barrett, D., and Fell, J. T., effect of aging on physical properties of phenylbutazone tablets, 335
Barthwal, J. P., *see* Chaturvedi, A. K., 454
Bass, G. E., *see* Dillingham, E. O., 883
Bassaris, H., *see* Nightingale, C. H., 712
Bates, T. R., and Carrigan, P. J., apparent absorption kinetics of micronized griseofulvin after its oral administration on single- and multiple-dose regimens to rats as a corn oil-in-water emulsion and aqueous suspension, 1475
——and Sequeira, J. A., bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans, 793
——and Sequeira, J. A. L., use of 24-hr urinary excretion data to assess bioavailability of griseofulvin in humans, 709
Batzer, O. F., *see* Harner, M., 1961
Bauer, L., *see* Falk, A. J., 1838
——*see* Gearien, J. E., 152
Bauernfeind, J. C., *see* Newmark, H. L., 655
Bauguess, C. T., Fincher, J. H., Sadik, F., and Hartman, C. W., blood concentration profiles of acetaminophen following oral administration of fatty acid esters of acetaminophen with pancreatic lipase to dogs, 1489
——Sadik, F., Fincher, J. H., and Hartman, C. W., hydrolysis of fatty acid esters of acetaminophen in buffered pancreatic lipase systems I, 117
Bayne, W. F., Rogers, G., and Crisologo, N., assay for acetazolamide in plasma, 402
——Tao, F. T., and Crisologo, N., submicrogram assay for scopolamine in plasma and urine, 288
Beam, R. E., *see* Sheehan, M., 2004
Bederka, J. P., Jr., Davitiyananda, D., Moses, M. L., and Ahmad, N., drug–biomolecule interactions: drug toxicity and vitamin coenzyme depletion, 528
Beiser, C., *see* Tan, H. S. I., 1207
Beisler, J. A., and Hillery, S. S., antitumor agents II: nitrogen analogs of mycophenolic acid, 84
Bej, A. J., *see* Wolters, R. J., 2013
Bell, C. L., *see* Aynilian, G. H., 341
——*see* Falk, A. J., 1838
Bender, A. D., Post, A., Meier, J. P., Higson, J. E., and Reichard, G., Jr., plasma protein binding of drugs as a function of age in adult human subjects, 1711
Benjamin, E. J., *see* Magarian, R. A., 1626
Bennett, I. F., *see* Nash, J. F., 429
Benson, W. R., *see* Doyle, T. D., 1525
Berg, J., *see* Chien, Y. W., 1776
Berlin, C., *see* Corder, C. N., 785
Bertelsmann, R. E., novel, low cost approach to digitizing tablet hardness values, 1578
Besch, H. R., Jr., *see* Witty, T. R., 1248
Bettis, J. W., *see* Wiseman, E. H., 1469
Beverley, S., *see* Allwood, M. C., 333
Beyer, W. F., and Gleason, D. D., laboratory automation of high-pressure liquid chromatography, 1557
Bhatia, V. N., *see* Bhutani, B. R., 135
——*see* Opankunle, W. O., 1023
Bhattacharya, S. K., *see* Ghosal, S., 80, 1082
Bhutani, B. R., and Bhatia, V. N., drying rates of tablet granulations I: effect of certain granulating adjuvants on drying rates, 135
——*see* Opankunle, W. O., 1023
Bianchi, C., and Ceriotti, G., chemical and pharmacological investigations of constituents of *Eleutherine bulbosa* (Miller) Urb. (Iridaceae), 1305
Bianchi, R., *see* Salmona, M., 1561
Biehl, E. R., *see* Graham, R. E., 226, 1013
Bielech, M. F., *see* Moskalyk, R. E., 1406
Bighley, L. D., and McDonnell, J. P., high-speed liquid chromatographic analysis of sulfasalazine (salicylazosulfapyridine), 1549
Billets, S., *see* Corbett, M. D., 1715
——*see* Turner, C. E., 810
Billow, J. A., and Speaker, T. J., unexpected sulfuration reaction of 1-substituted azulenes, 862
Binder, H., *see* Bloch, R., 832
Bingel, A. S., *see* Farnsworth, N. R., 535, 717
Bird, A. E., Hansch analysis of interaction of haptens with benzylpenicilloyl antibodies, 1671
Bisalion, S., and Tawashi, R., growth of calcium oxalate in gel systems, 458
Bishara, R. H., Rutherford, B. S., and Dinner, A., GLC determination of 17α-ethynylestriol 3-cyclopentyl ether, 1210
Blaha, J. M., Knevel, A. M., and Hem, S. L., high-pressure liquid chromatographic analysis of penicillin G potassium and its degradation products, 1384
Blair, A. D., Forrey, A. W., Meijsen, B. T., and Cutler, R. E., assay of flucytosine and furosemide by high-pressure liquid chromatography, 1334
Blair, D. C., *see* Sullivan, T. J., 1723
Blake, M. I., Crespi, H. L., and Katz, J. J., studies with deuterated drugs, 367
——*see* Amirjahed, A. K., 1569
——*see* Rhodes, H. J., 1386
Bloch, R., Kraicer, P. F., Binder, H., and Lobel, E., composite membrane estradiol implant, 832
Bode, D. W., *see* Rhodes, H. J., 1386
Bodor, N., *see* Repta, A. J., 392
Bogdansky, F. M., measurement of surface color and color difference of tablet colorants by tristimulus colorimetry, 323
Bohidar, N. R., Restaino, F. A., and Schwartz, J. B., selecting key parameters in pharmaceutical formulations by principal component analysis, 966
Bolliger, G., *see* Pettit, G. R., 2023
Bomer, K. A., *see* Gupta, V. D., 1199
Bondi, J. V., *see* Kwan, K. C., 1639
Boots, M. R., *see* Boots, S. G., 1262, 1949
Boots, S. G., and Boots, M. R., new synthesis of (*RS*)-carnitine chloride, 1262
——and Boots, M. R., synthesis and biological evaluation of potential hypoglycemic agents I: carnitine analogs, 1949
Bopp, R. J., *see* Nash, J. F., 429
Borazan, H. N., theoretical considerations on mononuclear aggregations of mixed nucleosides in dilute aqueous solutions based upon osmometric measurements, 770
Borchard, R. E., Welborn, M. E., Wiekhorst, W. B., Wilson, D. W., and Hansen, L. G., pharma-

cokinetics of polychlorinated biphenyl components in swine and sheep after a single oral dose, 1294
Borodkin, S., and Tucker, F. E., linear drug release from laminated hydroxypropyl cellulose–polyvinyl acetate films, 1289
Bottari, F., DiColo, G., Nannipieri, E., Saettone, M. F., and Serafini, M. F., evaluation of a dynamic permeation technique for studying drug–macromolecule interactions, 946
Brady, L. W., *see* Heindel, N. D., 687
Brand, H. P., *see* Griffin, W. J., 1821
Breimer, D. D., relative bioavailability of cyclobarbital calcium from aqueous solution compared to tablets, 1576
Brochmann-Hanssen, E., and Richter, W. J., opium alkaloids XV: isolation of stepholidine, 1040
Brooke, D., sieve cuts as monodisperse powders in dissolution studies, 1409
Brooks, M. A., D'Arconte, L., de Silva, J. A. F., Chen, G., and Crowley, C., spectrofluorometric determination of the antibiotic lasalocid in blood, 1874
Brown, K. F., *see* Pedersen, P. V., 1192, 1981
Brown, M. W., *in vitro* antibacterial activity of drugs against human intestinal anaerobic bacteria, 700
Brown, R. L., *see* McGinity, J. W., 1528
Brown, V. H., *see* Johnson, H., 693
Browning, R. S., *see* Dombrowski, L. J., 643
Brumleve, S. J., *see* Singh, S. P., 1245
Brunson, M. K., *see* Nash, J. F., 429
Bruzzese, T., Cambieri, M., and Recusani, F., synthesis and biological properties of alkyl esters of polyene antibiotics, 462
Buckley, J. P., *see* Dubinsky, B., 1647
Bugg, C. E., *see* Cook, W. J., 221
Buhr, C. A., *see* Page, D. P., 140
Burckhalter, J. H., *see* Sinsheimer, J. E., 925
Burks, T. F., *see* Davis, C. M., 170
Burns, H. D., *see* Heindel, N. D., 687
Butler, K. W., drug–biomolecule interactions: spin-probe study of effects of anesthetics on membrane lipids, 497
Butterfield, A. G., Hughes, D. W., Wilson, W. L., and Pound, N. J., simultaneous high-speed liquid chromatographic determination of tetracycline and rolitetracycline in rolitetracycline formulations, 316
——Lodge, B. A., Pound, N. J., and Sears, R. W., combined assay, identification, and foreign related steroids test for methandrostenolone by high-speed liquid chromatography, 441

C

Cadwallader, D. E., Jun, H. W., and Chen, L.-K., nitrofurantoin solubility in aqueous urea solutions, 886
——*see* Ku, S.-H., 1818
Cakiryildiz, C., Mehta, P. J., Rahmen, W., and Schoenleber, D., dissolution studies with a multichannel continuous-flow apparatus, 1692
Cambieri, M., *see* Bruzzese, T., 462
Camier, M., *see* Griffin, J. H., 507
Cammarata, A., thermodynamics of gaseous anesthesia of mice, 2025
——Smith, J., and Willett, N. P., pharmacokinetic model for a primary antibody response, 1325
Canaham, D. H., *see* Malik, S. N., 987
Cannon, J. G., and Garst, J. E., preparation and Baeyer–Villiger reaction of certain 2-carbalkoxycyclopropyl methyl ketones, 1059
Capomacchia, A. C., and Schulman, S. G., confirmation of iminoacridan structure of singly protonated 9-aminoacridine, 1256
——*see* Schulman, S. G., 982
Cardona, R. A., *see* Kupchik, E. J., 1259
Carlson, G. L., *see* Hall, I. H., 235
Carlson, G. P., *see* Whitaker, D. M., 1258
Carrigan, P. J., *see* Bates, T. R., 1475
Carson, N. A., *see* Page, D. P., 140
Carstensen, J. T., and Patel, M., dissolution patterns of polydisperse powders: oxalic acid dihydrate, 1770
——and Pothisiri, P., decomposition of *p*-aminosalicylic acid in the solid state, 37
——*see* Patel, M., 1651
——*see* Pothisiri, P., 1931
——*see* Zoglio, M. A., 1869
Cascella, P. J., *see* Feldman, S., 1713
Cassady, J. M., *see* Rezábek, K., 1045
Catalfomo, P., *see* Peters, J. E., 176
Catania, P. N., and King, J. C., inhibition of *Pseudomonas* burn wound infection by mafenide dry foam, 339
——and King, J. C., inhibition of supraeschar and subeschar *Pseudomonas* infection by silver sulfadiazine dry foam, 457
Cates, L. A., *see* Lemke, T. L., 1375
Catuogno, J., *see* Abbatiello, E. R., 452
Cerina, D., *see* Pečar, M., 970
Ceriotti, G., *see* Bianchi, C., 1305
Chafetz, L., *see* Daly, R. E., 1999
Chan, J., and Lee, K. H., effect of uridine diphospho-*N*-acetylglucosamine and sodium salicylate on L-glutamine-D-fructose-6-phosphate aminotransferase activity from rat gastric mucosa, 1182
Chang, B. L., Nuessle, N. O., and Haney, W. G., Jr., characterization of hydrogen bonding between selected barbiturates and polyethylene glycol 4000 by IR spectral analysis, 1787
Chang, D. T. T., *see* Gonzalez, M. A., 99
Chang, T. L., *see* Kuhlman, C. F., 1581
Chatten, L. G., *see* Moskalyk, R. E., 1406
Chatterji, D., *see* Paulssen, R. B., 1300
Chaturvedi, A. K., Barthwal, J. P., Parmar, S. S., and Stenberg, V. I., anticonvulsant activity of *N,N'*-bis[3-(3-substituted urea)propyl]piperazines, 454
——*see* Chaudhari, S. K., 614
Chaudhari, S. K., Verma, M., Chaturvedi, A. K., and Parmar, S. S., substituted thiazolidones: selective inhibition of nicotinamide adenine dinucleotide-dependent oxidations and evaluation of their CNS activity, 614
Chaudhuri, R. K., *see* Ghosal, S., 80, 888
Chemburkar, P. B., and Joslin, R. S., effect of flavoring oils on preservative concentrations in oral liquid dosage forms, 414
Chen, G., *see* Brooks, M. A., 1874
Chen, L.-K., *see* Cadwallader, D. E., 886
Cheng, C. C , *see* Cho, M. J., 1825
Cheng, L. K., Levitt, M., and Fung, H.-L., fluorescence reactions of fluorescamine with levodopa and its derivatives: fluorescence assay of 3-methoxy-4-hydroxyphenylalanine in levodopa dosage forms, 839
Chien, Y. W., Akers, M. J., and Yonan, P. K., effect of pKb on lipophilic binding of disopyramide derivatives to human plasma, 1632
——Lambert, H. J., and Lin, T. K., linear relationships between plasma binding and lipophilicity of disopyramide derivatives, 961
——Lambert, H. J., and Lin, T. K., solution–solubility dependency of controlled release of drug from polymer matrix: mathematical analysis, 1643
——Lambert, H. J., and Sanvordeker, D. R., interaction of metronidazole with metallic ions of biological importance, 957
——Mares, S. E., Berg, J., Huber, S., Lambert, H. J., and King, K. F., controlled drug release from polymeric delivery devices III: *in vitro–in vivo* correlation for intravaginal release of ethynodiol diacetate from silicone devices in rabbits, 1776
——*see* Sanvordeker, D. R., 1797
Chignell, C. F., drug–biomolecule interactions: topographical study of active site of erythrocyte carbonic anhydrase using spin-labeled sulfanilamide drugs, 512
Chiou, C. Y., cytolytic effects of bromoacetylcholine on neuroblastoma *in vitro*, 469
Chiou, W. L., estimation of hepatic first-pass effect of acetaminophen in humans after oral administration, 1734
——and Hsiao, J.-H., fluorocarbon aerosol propellants V: binding interaction with human albumin, 1052
——*see* Niazi, S., 763, 1538
——*see* Peng, G. W., 1577
Cho, A. K., *see* Schaeffer, J. C., 1462
Cho, M. J., and Schnabel, R., group contribution data obtained by ion-pair extraction of prostaglandin B_2 with aliphatic amines, 1894
——Repta, A. J., Cheng, C. C., Zee-Cheng, K. Y., Higuchi, T., and Pitman, I. H., solubilization and stabilization of the cytotoxic agent coralyne, 1825
Cho, Y. M., *see* Lemke, T. L., 1375
Choulis, N. H., and Papadopoulos, H., timed-release tablets containing quinine sulfate, 1033
Chowhan, Z. T., and Pritchard, R., release of corticoids from oleaginous ointment bases containing drug in suspension, 754
Chrekian, G. P., *see* Ascione, P. P., 1029
Chu, M.-Y., *see* Chu, S.-H., 1343
Chu, S.-H., Shiue, C.-Y., and Chu, M.-Y., synthesis and cytotoxicity of 6-selenopurine arabinoside and related compounds, 1343
Chun, A. H. C., *see* Hoffman, D. J., 1668, 1702
Claiborne, R. C., *see* Johnson, K. L., 1657
Clark, E. C., *see* Hundt, H. K. L., 1041
Cleary, G. W., *see* Zatz, J. L., 1534
Cochran, T. G., *see* Lo, A., 1707
Cohen, A. I., *see* Kripalani, K. J., 1351
Cohen, D. M., *see* Molins, D., 123
Cohen, J., *see* Sadée, W., 998
Cohen, J. S., *see* Griffin, J. H., 507
Cohen, P., *see* Griffin, J. H., 507
Colaizzi, J. L., *see* Antal, E. J., 2015
——*see* Jaffe, J. M., 2028
Cole, J. R., *see* Jolad, S. D., 1889
——*see* Torrance, S. J., 887
Collett, J. H., and Koo, L., interaction of substituted benzoic acids with polysorbate 20 micelles, 1253
Combs, A. B., *see* McGinity, J. W., 889
Cone, E. J., Gorodetzky, C. W., and Yeh, S. Y., biosynthesis, isolation, and identification of 6β-hydroxynaltrexone, a major human metabolite of naltrexone, 618
Conine, J. W., ketonitrophenols from mestranol and related compounds, 777
Constantine, G. H., Jr., *see* Peters, J. E., 176
Conway, W. D., Lee, F. H., and Neufeld, L., determination of dicumarol metabolites in bile of rats, 1158
——*see* Gibaldi, M., 359
Cook, W. J , and Bugg, C. E., crystal structures of azathioprine dihydrate and 6-methylmercaptopurine trihydrate, 221
Corbett, M. D., and Billets, S., characterization of poison oak urushiol, 1715
Cordell, G. A., *see* Farnsworth, N. R., 535, 717
Corder, C. N., Klaniecki, T. S., McDonald, R. H., Jr., and Berlin, C., fluorometric assay of bethanidine in plasma, 785
Cowherd, C. M., *see* Lee, K.-H., 1572
Crain, A. V. R., *see* Dombrowski, L. J., 643
Crane, F. A., *see* Farnsworth, N. R., 535, 717
——*see* Tin-Wa, M., 2024
Crespi, H. L., *see* Blake, M. I., 367
Cressman, W. A., Lopez, B., and Sumner, D., determination of tolmetin in human plasma by GLC and spectrophotometric procedures, 1965
Crisologo, N., *see* Bayne, W. F., 288, 402
Crouthamel, W. G., Abolin, C. R., Hsieh, J., and Lim, J. K., intestinal pH as a factor in selection of animal models for bioavailability testing, 1726
——Diamond, L., Dittert, L. W., and Doluisio, J. T., drug absorption VII: influence of mesenteric blood flow on intestinal drug absorption in dogs, 664
Crowley, C., *see* Brooks, M. A., 1874
Cunningham, A., *see* Thompson, G. R., 320
Cussler, E. L., *see* DeMartine, M. L., 976
Cutler, R. E., *see* Blair, A. D., 1334

D

Dajani, E. S., *see* Sanvordeker, D. R., 1877
Daly, R. E., Lomner, J. J., and Chafetz, L., selective assay of benzoyl peroxide in lotions and creams, 1999

Dar, M. S., *see* Zirvi, K. A., 649
D'Arconte, L., *see* Brooks, M. A., 1874
Dare, J. G., *see* Griffin, W. J., 1821
Davis, C. M., and Burks, T. F., simple isolated perfused artery preparation: vasoconstrictor evaluation, 170
Davis, S. S., *see* Mukhayer, G. I., 147
Davitiyananda, D., *see* Bederka, J. P., Jr., 528
De, A. U., and Pal, D., possible antineoplastic agents I, 262
——and Saha, B. P., indolizines II: search for potential oral hypoglycemic agents, 249
De, K. K., *see* Shiau, G. T., 646
Dean, F. H., *see* Holloway, C. E., 1078
Debnath, P. K., *see* Ghosal, S., 1082
DeFrancisco, M., *see* Feldman, S., 1713
DeGraw, J. I., Engstrom, J. S., and Willis, E., synthesis of *d*-pilocarpine-*N*-$^{14}CH_3$, 1700
——*see* Johnson, H., 693
Dehner, E. J., *see* Schwartz, J. B., 328
de Lara, A. J. L., *see* Gupta, V. D., 2001
Delorefice, S. B., *see* Loeffler, L. J., 1170
deLuna, F. A., *see* Tocco, D. B., 1879
De Marchi, F., *see* Mardente, S., 1866
DeMartino, M. L., and Cussler, E. L., predicting subjective spreadability, viscosity, and stickiness, 976
DeNardo, J. J., *see* Rhodes, H. J., 1386
De Ritter, E., *see* Newmark, H. L., 655
DeSante, K. A., *see* DiSanto, A. R., 109
de Silva, J. A. F., *see* Brooks, M. A., 1874
DeYoung, J. L., *see* Notari, R. E., 1148
Dhabhar, D. J., *see* Heyd, A., 1697
Dhawan, B. N., *see* Kar, K., 258
Diamantis, W., *see* Sofia, R. D., 1321
Diamond, L., *see* Crouthamel, W. G., 664
DiColo, G., *see* Bottari, F., 946
Dillingham, E. O., *see* Powers, L. J., 883
Dimmock, J. R., and Taylor, W. G., evaluation of nuclear-substituted styryl ketones and related compounds for antitumor and cytotoxic properties, 241
——Turner, W. A., and Baker, H. A., antimicrobial evaluation of diastereoisomeric 2-dimethylaminomethyl-6-phenylcyclohexanols and related esters, 995
Dinner, A., *see* Bishara, R. H., 1210
DiSanto, A. R., and DeSante, K. A., bioavailability and pharmacokinetics of prednisone in humans, 109
Dittert, L. W., *see* Crouthamel, W. G., 664
Dittmar, D., *see* Poust, R. I., 1583
Dixon, W. R., Earley, J., and Postma, E., radioimmunoassay of chlordiazepoxide in plasma, 937
Dobrinska, M. R., and Welling, P. G., blood levels from a sustained-release dosage form, 1728
Doluisio, J. T., *see* Crouthamel, W. G., 664
Dombrowski, L. J., Crain, A. V. R., Browning, R. S., and Pratt, E. L., determination of 17-monochloroacetylajmaline and its metabolite in plasma by TLC-fluorescence detection, 643
Donahue, J. J., *see* Moros, S. A., 1229
Donbrow, M., and Friedman, M., timed release from polymeric films containing drugs and kinetics of drug release, 76
Dorman, D. E., *see* Tafur, S., 1953
Dorsett, P. H., Kerstine, E. E., and Powers, L. J., antiviral activity of gossypol and apogossypol, 1073
Doty, M. S., *see* Santos, G. A., 1704
Douglas, J. F., *see* Edelson, J., 1316
Doukas, P. H., Speaker, T. J., and Thompson, R. S., azulene analogs of pharmacological agents III: acute toxicity and local anesthetic activity of azulylamides and azulenecarboxamides, 158
Doulakas, J., new color reaction for determination of bacitracin in ophthalmic ointments, 307
Doyle, T. D., Stewart, J. M., Filipescu, N., and Benson, W. R., configuration of dienestrol, 1525
Drach, J. C., *see* Law, F. C. P., 1421
Dreyfuss, J., Shaw, J. M., Wong, K. K., and Schreiber, E. C., metabolism of 8-(methylthio)-cyclic 3′,5′-adenosine monophosphate by rats and dogs after oral or intravenous dosing and *in vitro* by subcellular preparations of dog liver, 1604
Driscoll, J. S., *see* Khan, A. H., 295
Dubinsky, B., Kinnard, W. J., Jr., and Buckley, J. P., effects of selected drugs on an auditory or thalamic conditioned stimulus eliciting recruitment in the cat, 1647
Dubois, R. J., Lin, C.-C. L., and Michel, B. L., synthesis of sparsomycin analogs as potential antitumor agents, 825
Duncan, A. E. W., *see* Tocco, D. J., 1879
Dwivedi, C., *see* Ali, B., 1329
——*see* Gupta, A. K., 1001

E

Earley, J., *see* Dixon, W. R., 937
Ebert, W. R., *see* Hom, F. S., 851
Eblan, A. R., Moustafa, M. A., Khalil, S. A., and Motawi, M. M., succinylsulfathiazole crystal forms II: effect of additives on kinetics of interconversion, 1481
——*see* Moustafa, M. A., 1485
Eckelman, W. C., Karesh, S. M., and Reba, R. C., new compounds: fatty acid and long chain hydrocarbon derivatives containing a strong chelating agent, 704
Edelson, J., Douglas, J. F., Ludwig, B. J., Schuster, E. B., and Shahinian, S., absorption, distribution, and metabolic fate of 7-chloro-3,3a-dihydro-2-methyl-2*H*,9*H*-isoxazolo-(3,2-*b*)(1,3)-benzoxazin-9-one in rats, dogs, and humans, 1316
El-Antably, S. M., Soine, T. O., Shaath, N. A., and Gupta, P. K., synthesis and blood pressure lowering activity of benzylic ethers of 2-diethylaminoethanol and a related diamine, 1423
Eldawy, M. A., Tawfik, A. S., and Elshabouri, S. R., rapid, sensitive colorimetric method for determination of ethinyl estradiol, 1221
Ellis, E. F., *see* Koysooko, R., 299
Ellis, K. O., *see* Schwan, T. J., 337, 1047
——and Stohs, S. J., chromatography on lipophilic dextran gels for fractionation of low molecular weight compounds II: separation of cardiac glycosides from cardiac aglycones, 163
——and Stohs, S. J., chromatography on lipophilic dextran gels for fractionation of low molecular weight compounds I: steroid digitonides, 161
Elshabouri, S. R., *see* Eldawy, M. A., 1221
Enever, R. P., Li Wan Po, A., Millard, B. J., and Shotton, E., decomposition of amitriptyline hydrochloride in aqueous solution: identification of decomposition products, 1497
Eng, R., Lindberg, S., White, K., and Spitznagle, L. A., tissue distribution of *N*-^{14}C-azure C (methylthionine) in the rat, 1068
Engstrom, J. S., *see* DeGraw, J. I., 1700
——*see* Johnson, H., 693
Erhardt, P. W., and Soine, T. O., stereochemical preferences for curarimimetic neuromuscular junction blockade I: enantiomeric monoquaternary amines as probes, 53

F

Fabregas, J. L., and Margalet, A., GLC trace analysis of dextromethorphan and bromhexine salts in pharmaceutical preparations, 1005
Fakouhi, T., *see* Zirvi, K. A., 649
Falk, A. J., Smolenski, S. J., Bauer, L., and Bell, C. L., isolation and identification of three new flavones from *Achillea millefolium* L., 1838
Fanelli, R., *see* Salmona, M., 1561
Farnsworth, N. R., Bingel, A. S., Cordell, G. A., Crane, F. A., and Fong, H. H. S., potential value of plants as sources of new antifertility agents I, 535
——Bingel, A. S., Cordell, G. A., Crane, F. A., and Fong, H. H. S., potential value of plants as sources of new antifertility agents II, 717
——*see* Aynilian, G. H., 341
——*see* Marks, W. H., 1674
——*see* Tin-Wa, M., 2024
——*see* Weiss, S. G., 95
Feinstein, W., and Sciarra, J. J., determination of 17-hydroxycorticosteroids in human urine, 1050
——and Sciarra, J. J., development and evaluation of a dexamethasone timed-release aerosol formulation, 408
Felder, E., Pitrè, D., and Grandi, M., automated procedure for determination of free aromatic amine in water-soluble radiopaques, 684
Feldman, S., DeFrancisco, M., and Cascella, P. J., activity of local anesthetic agents in goldfish, 1713
Fell, J. T., *see* Barrett, D., 335
Felmeister, A., *see* Auslander, D. E., 516
Ferguson, G. G., and Keller, W. J., monoamine oxidase inhibiting activity of a series of (±)-4-methoxy-β-hydroxyphenethylamines, 1431
Filan, J., *see* Holl, W. W., 1232
Filipescu, N., *see* Doyle, T. D., 1525
Fincher, J. H., *see* Bauguess, C. T., 117, 1489
Finkel, J. M., fluorometric assay of thioguanine, 121
Finn, C., *see* Sadée, W., 998
Fishman, S., determination of estrogens in dosage forms by fluorescence using dansyl chloride, 674
Flinn, P. E., *see* Page, D. P., 140
Floss, H. G., *see* Režábek, K., 1045
Flynn, G. L., *see* Yalkowsky, S. H., 48
——*see* Yotsuyanagi, T., 71
Fong, H. H. S., *see* Farnsworth, N. R., 535, 717
——*see* Marks, W. H., 1674
Forist, A. A., *see* Kaiser, D. G., 2011
Formaini, N., *see* Kupchik, E. J., 1259
Forrey, A. W., *see* Blair, A. D., 1334
Foye, W. O., Kauffman, J. M., Lanzillo, J. J., and LaSala, E. F., antiradiation compounds XV: condensations of carbon disulfide with amino, chloro, cyanomethyl, and sulfonamido heterocycles, 1371
——Lanzillo, J. J., Lowe, Y. H., and Kauffman, J. M., synthesis and antimalarial activity of heterocyclic alkyl disulfides, thiosulfates, and dithio acid derivatives, 211
Frank, C. W., *see* Schlecht, K. D., 352
——*see* Stoel, L. J., 1635
Frank, S. G., inclusion compounds, 1585
French, W. N., Matsui, F. F., and Smith, S. J., determination of major impurity in chlordiazepoxide formulations and drug substance, 1545
——Matsui, F., Smith, S. J., and Wood, R. J., colorimetric analysis of hexachlorophene in topical formulations, 125
Friberg, S., and Larsson, L., partition of an organophosphorus compound, dichlorvos, between liquid and liquid crystalline phases, 822
Friedman, M., *see* Donbrow, M., 76
Friel, P., *see* Levy, R. H., 302
Funderburk, M. J., *see* Hufford, C. D., 789
Fung, H.-L., *see* Levitt, M., 839
Fusari, S. A., *see* Poust, R. I., 1583

G

Gagné, D., *see* Bailey, K., 1719
Gammans, R. E., *see* Stewart, J. T., 1061
Garai, A. S., *see* Harris, P. A., 1574
Garrett, E. R., and Lewis, J. K., kinetics and mechanisms of drug action on microorganisms XXII: effects of aminosidine with and without organism pretreatment with bacteriostatic agents, 1936
——and Villalonga, F. A., kinetics and mechanisms of monolayer interactions III: models to explain time-dependent effects of injected cetrimonium bromide, 1782
Garst, J. E., *see* Cannon, J. G., 1059
Gearien, J. E., and Klein, M., isolation of 19α-H-lupeol from *Maclura pomifera*, 104
——Bauer, L., Klein, M., and Levine, B., structure of lupeol and its 19α-H-isomer, 152
Genensh, A. A., Soine, T. O., and Shaath, N. A., stereochemical preferences for curarimimetic neuromuscular junction blockage II: enantiomeric bisquaternary amines as probes, 62
——*see* Soine, T. O., 67
Gérardin, A., Abadie, F., and Laffont, J., GLC determination of carbamazepine suitable for pharmacokinetic studies, 1940

Gershon, H., Parmegiani, R., Giannasio, V. R., and Krull, I. S., amino acid analogs III: new synthesis of monomethyl- and monophenylglutamic acids, 1855
Ghandi, H. I., *see* Kowarski, C. R., 696
Gharbo, S. A., and Gosser, L. A., microdetermination of ergocalciferol (vitamin D_2) in pharmaceutical preparations by differential spectroscopy using trifluoroacetic acid in the absence of vitamin A, 1196
Ghosal, S., and Chaudhuri, R. K., chemical constituents of Gentianaceae XVI: antitubercular activity of xanthones of *Canscora decussata* Schult, 888
——Mazumder, U. K., Bhattacharya, S. K., and Debnath, P. K., synthesis and neuromuscular blocking activity of a 3,3′-bisbufotenidine analog, 1082
——Sharma, P. V., Chaudhuri, R. K., and Bhattacharya, S. K., chemical constituents of Gentianaceae XIV: tetraoxygenated and pentaoxygenated xanthones of *Swertia purpurascens* Wall., 80
Ghoul, D. C., *see* Gordon, G. R., 1205
Giannasio, V. R., *see* Gershon, H., 1855
Gibaldi, M., comparison of observed and predicted bioavailability of nortriptyline in humans following oral administration, 1036
——and Grundhofer, B., bioavailability of aspirin from commercial suppositories, 1064
——Axelson, J. E., and Conway, W. D., disposition of *N,N*-bis(phenylcarbamoylmethyl)dimethyl ammonium chloride in the rat: an interesting example of first-pass metabolism, 359
——Grundhofer, B., and Levy, G., time course and dose dependence of antacid effect on urine pH, 2003
Giesecke, A. H., Jr., *see* Samuelson, R. J., 861
Gleason, D. D., *see* Beyer, W. F., 1557
Goldfarb, A. L., *see* Koup, J. R., 2008
Golman, K., absorption of metrizamide from cerebrospinal fluid in blood: pharmacokinetics in humans, 405
Gomaa, C., and Taha, A., unit-dose assay of tropine alkaloids and their synthetic analogs, 1398
Gonzalez, M. A., Tozer, T. N., and Chang, D. T., nonlinear tissue disposition: salicylic acid in rat brain, 99
Goodhart, F. W., *see* Haleblian, J. K., 1085
Gordon, G. R., Ghoul, D. C., and Peters, J. H., identification and quantitation of impurities in dapsone preparations, 1205
Gorodetzky, C. W., *see* Cone, E. J., 618
Gosser, L. A., *see* Gharbo, S. A., 1196
Gouda, M. W., *see* Jodhka, G. S., 1858
——*see* Khalafallah, N., 991
——*see* Malik, S. N., 987
Graham, J. H., analysis of individual thyroid tablets, 1393
Graham, R. E., Biehl, E. R., Kenner, C. T., Luttrell, G. H., and Middleton, D. L., reduction of blue tetrazolium by corticosteroids, 226
——Kenner, C. T., and Biehl, E. R., determination of iodochlorhydroxyquin and corticosteroids in pharmaceutical formulations, 1013
Grandi, M., *see* Felder, E., 684
Green, J. H., *see* Levy, R. H., 302
Green, V. A., *see* Atwell, S. H., 806
Greene, D. S., *see* Nightingale, C. H., 1899
Gregory, F. J., *see* Santilli, A. A., 1057
Griffin, J. H., Cohen, J. S., Cohen, P., and Carnier, M., drug–biomolecule interactions: proton magnetic resonance studies of complex formation between bovine neurophysins and oxytocin at molecular level, 507
Griffin, W. J., Brand, H. P., and Dare, J. G., analysis of *Duboisia myoporoides* R. Br. and *Duboisia leichhardtii* F. Muell, 1821
Grossman, D., *see* Maulding, H. V., 1833
Gruber, V. F., *see* Vandenheuvel, W. J. A., 1309
Gruden, E. E., *see* Jato, J. G., 943
Grundhofer, B., *see* Gibaldi, M., 1064, 2003
Gupta, A. K., Dwivedi, C., Gupta, T. K., Parmar, S. S., and Harbison, R. D., synthesis of 2-(*N*-arylcarboxamide)-3-substituted ethoxyindoles and their monoamine oxidase inhibitory and anticonvulsant activities, 1001
——*see* Parmar, S. S., 154
Gupta, J. K., *see* Lahiri, S. C., 172
Gupta, L., *see* Joshi, K. C., 1428
Gupta, P. K., *see* El-Antably, S. M., 1423
Gupta, T. K., *see* Gupta, A. K., 1001
——*see* Parmar, S. S., 154
Gupta, V. D., and Bomer, K. A., quantitative determination of phenol in phenolated calamine lotion USP, 1199
——and de Lara, A. J. L., colorimetric determinations of chlorpheniramine maleate, ephedrine hydrochloride, and guaiacolsulfonate potassium in a cough syrup, 2001

H

Haddadin, M. J., Higuchi, T., and Stella, V., acylation of phenol by cyclic and acyclic anhydrides in anhydrous acetic acid, 1766
——Higuchi, T., and Stella, V., solvolytic reactions of cyclic anhydrides in anhydrous acetic acid, 1759
Hadley, K. W., *see* Holley, J. H., 892
——*see* Turner, C. E., 810
Hajratwala, B. R., kinetics of sulfite-induced anaerobic degradation of epinephrine, 45
Haleblian, J. K., characterization of habits and crystalline modification of solids and their pharmaceutical applications, 1269
——and Goodhart, F. W., pharmaceutical sciences—1974: literature review of pharmaceutics, 1085
Haley, T. J., asbestosis: a reassessment of the overall problem, 1435
Hall, I. H., Lamb, R. G., Mar, M.-H. H., Carlson, G. L., and Plantadosi, C., cycloalkanones V: synthesis, distribution, and effects on triglyceride metabolism, 235
Hall, L. H., Kier, L. B., and Murray, W. J., molecular connectivity II: relationship to water solubility and boiling point, 1974
——*see* Kier, L. B., 1971
——*see* Murray, W. J., 1978
Hambleton, R., *see* Allwood, M. C., 333
Hamer, M., Batzer, O. F., Moats, M. J., Wu, C. C., and Lira, E. P., synthesis of 2-pyridyl-α-toluenesulfonates as antimalarials, 1961
Hamilton, C. M., *see* Moros, S. A., 1229
Hammarlund, E. R., *see* Sapp, C., 1884
Han, S. K., *see* Schott, H., 658
Haney, W. G., *see* Atwell, S. H., 806
——*see* Chang, B. L., 1787
Hanley, W. S., *see* Soine, T. O., 67
Hansch, C., Silipo, C., and Steller, E. E., formulation of *de novo* substituent constants in correlation analysis: inhibition of dihydrofolate reductase by 2,4-diamino-5-(3,4-dichlorophenyl)-6-substituted pyrimidines, 1186
——*see* Smith, R. N., 599
Hansen, L. G., *see* Borchard, R. E., 1294
Harbison, R. D., *see* Ali, B., 1329
——*see* Gupta, A. K., 1001
Haring, R., *see* Johnson, R., 1007
Harmon, R. E., *see* Shiau, G. T., 646
Harpootlian, H., *see* Thomas, R. C., 1360, 1366
Harrigan, D. J., and Levy, G., concentration dependence of ethanol effect on intestinal absorption of theophylline in rats, 897
Harris, D. L., *see* Lee, K.-H., 1077
Harris, P. A., Garai, A. S., and Valenzuela, M. A., reduction of doxorubicin (adriamycin) bone marrow toxicity, 1574
Hartman, A. W., Nesbitt, R. U., Jr., Smith, F. M., and Nuessle, N. O., viscosities of acacia and sodium alginate after sterilization by cobalt-60, 802
Hartman, C. W., *see* Bauguess, C. T., 117, 1489
Hasegawa, M., Takai, H., and Matsubara, I., metabolic fate of flurazepam II: a new potent metabolite obtained by *in vitro* liver drug-metabolizing enzyme system, 1732
Haslam, J., *see* Okada, H., 1665
Hayton, W. L., effects of normal alcohols on intestinal absorption of salicylic acid, sulfapyridine, and prednisolone in rats, 1450
Heindel, N. D., and Schaeffer, L. A., cyanogen condensations as a route to 3-amino-2-imino-1,3-benzothiazine-4-ones with CNS depression potential, 1425
——Risch, V. R., Burns, H. D., Honda, T., Brady, L. W., and Micalizzi, M., syntheses and tissue distribution of ^{99m}Tc-sulfonylureas, 687
Hem, S. L., *see* Blaha, J. M., 1384
——*see* Kerkhof, N. J., 940, 2030
——*see* Nail, S. L., 1166
——*see* White, J. L., 468
Heman-Ackah, S. M., microbial kinetics of drug action against Gram-positive and Gram-negative organisms II: effect of clindamycin on *Staphylococcus aureus* and *Escherichia coli*, 1612
——microbial kinetics of drug action against Gram-positive and Gram-negative organisms III: effect of lincomycin and clindamycin combinations on *Staphylococcus aureus* and *Escherichia coli*, 1621
Henry, J. T., *see* Turner, C. E., 357
Herald, C. L., *see* Pettit, G. R., 2023
Hester, D. W., *see* Honigberg, I. L., 1201
Heveran, J. E., *see* Moros, S. A., 1229
Heyd, A., and Dhabhar, D. J., enhancing fluidity of concentrated antacid suspensions, 1697
Higson, J. E., *see* Bender, A. D., 1711
Higuchi, T., *see* Cho, M. J., 1825
——*see* Haddadin, M. J., 1759, 1766
——*see* Kovach, I. M., 1070
——*see* Kreilgård, B., 1850
——*see* Lindenbaum, S., 1887
——*see* Paulssen, R. B., 1300
——*see* Repta, A. J., 392
Higuchi, W. I., *see* Molokhia, A. M., 2029
——*see* Turi, J. S., 622, 627, 631
——*see* Yotsuyanagi, T., 71
Hill, J. A., *see* McGinity, J. W., 356, 1566
Hillery, S. S., *see* Beisler, J. A., 84
Hinds, C. J., *see* Loeffler, L. J., 1890
Ho, N. F. H., *see* Turi, J. S., 622, 627, 631
——*see* Yotsuyanagi, T., 71
Hodgkins, T. G., *see* Munson, J. W., 1043
Hoener, B., *see* Sokoloski, T. D., 1892
Hoffman, D. J., and Chun, A. H. C., GLC determination of plasma drug levels after oral administration of clorazepate potassium salts, 1668
——and Chun, A. H. C., paramethadione and metabolite serum levels in humans after a single oral paramethadione dose, 1702
Hoffmann, T. J., *see* Thompson, R. D., 1863
Hofmann, A. F., *see* Molokhia, A. M., 2029
Holl, W. W., O'Brien, M., Filan, J., Mazeika, T. R., Post, A., Pitkin, D., and Actor, P., automated spectrophotometric assay of cefazolin, 1232
Holley, J. H., Hadley, K. W., and Turner, C. E., constituents of *Cannabis sativa* L. XI: cannabidiol and cannabichromene in samples of known geographical origin, 892
——*see* Turner, C. E., 810
Holloway, C. E., and Dean, F. H., ^{13}C-NMR study of aqueous glutaraldehyde equilibria, 1078
Höltje, H.-D., and Kier, L. B., nature of anionic or α-site of cholinesterase, 418
Hom, F. S., Veresh, S. A., and Ebert, W. R., soft gelatin capsules II: oxygen permeability study of capsule shells, 851
Honda, T., *see* Heindel, N. D., 687
Hong, D. D., *see* Sinsheimer, J. E., 925
Hong, H. S. C., Steltenkamp, R. J., and Smith, N. L., quantitative analysis of tribromsalan in blood and urine, 2007
——Steltenkamp, R. J., and Smith, N. L., quantitative analysis of triclocarban in blood, 860
Honigberg, I. L., Stewart, J. T., Smith, A. P., and Hester, D. W., liquid chromatography in pharmaceutical analysis III: separation of diuretic–antihypertensive mixtures, 1201
——Stewart, J. T., Smith, A. P., Plunkett, R. D., and Justice, E. L., liquid chromatography in pharmaceutical analysis IV: determination of antispasmodic mixtures, 1389
Horvat, B., *see* Pečar, M., 970
Hou, J. P., and Restivo, A., epicillin and ampicillin: crystalline modifications and their physico-

chemical differences, 710
Houlihan, W. J., *see* Barcza, S., 829
Houston, J. B., and Levy, G., effect of carbonated beverages and of an antiemetic containing carbohydrate and phosphoric acid on riboflavin bioavailability and salicylamide biotransformation in humans, 1504
——and Levy, G., effect of various alcohols on intestinal net water flux and theophylline absorption in rats, 607
Howell, J. R., mathematical formulation for nonuniform multiple dosing, 464
Hsi, R. S. P., *see* Thomas, R. C., 1360
Hsiao, J.-H., *see* Chiou, W. L., 1052
Hsieh, J., *see* Crouthamel, W. G., 1726
Huang, H.-C., *see* Lee, K.-H., 1077
Huber, S., *see* Chien, Y. W., 1776
Hudgins, P. M., and Stubbins, J. F., interactions of acetylcholine mustard with acetylcholinesterase, 1419
Hudson, J. E., *see* Alam, M., 865
Huettemann, R. E., and Shroff, A. P., high-pressure liquid chromatographic analysis of triflubazam and its metabolites in human and animal blood and urine, 1339
Huffman, C. W., *see* Traxler, J. T., 1943
Huffman, D. H., Manion, C. V., and Azarnoff, D. L., intersubject variation in absorption of digoxin in normal volunteers, 433
Hufford, C. D., Funderburk, M. J., Morgan, J. M., and Robertson, L. W., two antimicrobial alkaloids from heartwood of *Liriodendron tulipifera* L., 789
Hughes, D. W., *see* Butterfield, A. G., 316
Hundt, H. K. L., Clark, E. C., and Muller, F. O., GLC determination of phendimetrazine in serum, 1041
Hung, G. W. C., Nunez, L. J., and Autian, J., correlation of kinetic parameters and thermal behavior of segmented polyurethane elastomers with biological responses, 1492
Hwang, S., *see* Yotsuyanagi, T., 71

I

Ibuka, T., *see* Lee, K.-H., 1077
Idson, B., percutaneous absorption, 901
Imai, K., *see* Nakamori, R., 1071
Innes, D. L., *see* Tansy, M. F., 1174
Ismail, S., *see* Nabih, I., 460
Isozaki, S., *see* Suzuki, T., 895
Iturrian, W. B., *see* Jun, H. W., 1843
Ivashkiv, E., colorimetric determination of peptide antibiotics: in-process assay of cyclic octapeptidic antibiotics in fermentation broths, 1401

J

Jaffe, J. M., effect of propantheline on nitrofurantoin absorption, 1729
——Strum, J. D., Martineau, P. C., and Colaizzi, J. L., relationship between quinidine plasma and saliva levels in humans, 2028
——*see* Antal, E. J., 2015
Jagodic, V., *see* Sinsheimer, J. E., 925
Jarowski, C. I., and Pytelewski, R., utility of fasting essential amino acid plasma levels in formulation of nutritionally adequate diets III: lowering of rat serum cholesterol levels by lysine supplementation, 690
——*see* Patel, S. P., 869
——*see* Raja, P. K., 691
Jato, J. G., Lake, L. M., Grunden, E. E., and Johnson, B. M., effect of deoxyuridine coadministration on toxicity and antitumor activity of fluorouracil and floxuridine, 943
Javidan, S., and Mrtek, R. G., microbiological determination of drug partitioning IV: drug–protein interactions, 420
Jeter, D. T., *see* Johnson, K. L., 1657
Jewell, C. F., Jr., *see* Naik, D. V., 1243
Jodhka, G. S., Gouda, M. W., Medora, R. S., and Khalil, S. A., inhibitory effect of dioctyl sodium sulfosuccinate on trypsin activity, 1858
Johnson, B. M., *see* Jato, J. G., 943
Johnson, H., DeGraw, J., Engstrom, J., Skinner, W. A., Brown, V. H., Skidmore, D., and Maibach, H. I., topical mosquito repellents VII: alkyl triethylene glycol monoethers, 693
Johnson, K. L., Jeter, D. T., and Claiborne, R. C., high-pressure liquid chromatographic determination of sulfamethazine residue in bovine tissue, 1657
Johnson, R., Masserano, R., Haring, R., Kho, B., and Schilling, G., quantitative GLC determination of conjugated estrogens in raw materials and finished dosage forms, 1007
Jolad, S. D., Wiedhopf, R. M., and Cole, J. R., tumor-inhibitory agent from *Montezuma speciosissima* (Malvaceae), 1889
Jones, P. R., Malmberg, C. E., and McGrattan, C., synthesis, spectral properties, and antibacterial activity of synthetic precursors of macrocyclic oxa- and thia-substituted benzolactones and benzoketones, 1240
Jones, W. E., *see* Tafur, S., 1953
Joshi, K. C., Singh, V. K., Mehta, D. S., Sharma, R. C., and Gupta, L., fluorinated quinazolones III: synthesis and CNS depressant activity of fluorinated quinazolone derivatives, 1428
Joslin, R. S., *see* Chemburkar, P. B., 414
Judd, G. F., *see* Pettit, G. R., 2023
Judy, R. W., *see* Thomas, R. C., 1360
Jun, H. W., Iturrian, W. B., Stewart, J. T., and Lee, B. H., quantitative GLC determination of pentylenetetrazol in biological fluids, 1843
——Luzzi, L. A., and Ma, J. K. H., drug–biomolecule interactions: fluorescence studies on interaction of aminonaphthalenesulfonic acid derivatives with serum albumins, 493
——*see* Cadwallader, D. E., 886
Jusko, W. J., *see* Koup, J. R., 2008
——*see* Lalka, D., 230
Justice, E. L., *see* Honigberg, I. L., 1389

K

Kaiser, D. G., and Forist, A. A., fluorometric determination of 2,3-bis(*p*-methoxyphenyl)imidazo-[1,2-*a*]pyrimidine in biological materials, 2011
——*see* VanGiessen, G. J., 798
Kallus, F. T., *see* Samuelson, R. J., 861
Kar, K., Puri, V. N., Patnaik, G. K., Sur, R. N., Dhawan, B. N., Kulshrestha, D. K., and Rastogi, R. P., spasmolytic constituents of *Cedrus deodara* (Roxb.) Loud: pharmacological evaluation of himachalol, 258
Karesh, S. M., *see* Eckelman, W. C., 704
Kato, G., drug–biomolecule interactions: binding study of substrate and inhibitors to acetylcholinesterase using NMR, 488
Katz, J. J., *see* Blake, M. I., 367
Kauffman, J. M., *see* Foye, W. O., 211, 1371
Kaul, P. N., *see* Lehr, R. E., 950
Kavanagh, F., automated system for analytical microbiology V: calibration lines for antibiotics, 844
——microbiological diffusion assay II: design and applications, 1224
Kellaway, I. W., and Marriott, C., correlations between physical and drug release characteristics of polyethylene glycol suppositories, 1162
Keller, W. J., *see* Ferguson, G. G., 1431
Kendall, F. M., *see* Tansy, M. F., 1174
Kenner, C. T., *see* Graham, R. E., 226, 1013
Kerkhof, N. J., Hem, S. L., and White, J. L., vehicle for stabilizing aluminum hydroxide gel, 2030
——White, J. L., and Hem, S. L., effect of dilution on reactivity and structure of aluminum hydroxide gel, 940
Kerstine, E. E., *see* Dorsett, P. H., 1073
Khalafallah, N., Gouda, M. W., and Khalil, S. A., effect of surfactants on absorption through membranes IV: effects of dioctyl sodium sulfosuccinate on absorption of a poorly absorbable drug, phenolsulfonphthalein, in humans, 991
Khalil, S. A., *see* Ebian, A. R., 1481
——*see* Jodhka, G. S., 1858
——*see* Khalafallah, N., 991
——*see* Moustafa, M. A., 1485
Khan, A. H., and Driscoll, J. S., active antitumor components in a decomposed amino sugar I: effect of sugar structure on activity, 295
Khan, K. A., and Rhodes, C. T., disintegration properties of calcium phosphate dibasic dihydrate tablets, 166
——and Rhodes, C. T., effect of compaction on particle size, 444
——and Rhodes, C. T., water-sorption properties of tablet disintegrants, 447
Kho, B., *see* Johnson, R., 1007
Khoyi, M. A., *see* Lalezari, I., 1250
Kier, L. B., Hall, L. H., Murray, W. J., and Randić, M., molecular connectivity I: relationship to nonspecific local anesthesia, 1971
——*see* Hall, L. H., 1974
——*see* Höltje, H.-D., 418
——*see* Murray, W. J., 1978
Kikugawa, K., transformation of 2,2′-anhydro-1-β-D-arabinofuranosylcytosine induced by hydrogen peroxide, 424
Kildsig, D. O., *see* Nadkarni, P. D., 1554
Killion, K., *see* Rao, K. V., 345
Kim, D. H., *see* Santilli, A. A., 1057
King, J. C., *see* Catania, P. N., 339, 457
King, K. F., *see* Chien, Y. W., 1776
Kinnard, W. J., Jr., *see* Dubinsky, B., 1647
Kirk, P. W., Jr., *see* Peters, J. E., 176
Kissinger, P. T., *see* Riggin, R. M., 680
Klaniecki, T. S., *see* Corder, C. N., 785
Klein, M., *see* Gearien, J. E., 104, 152
Knevel, A. M., *see* Blaha, J. M., 1384
Koo, L., *see* Collett, J. H., 1253
Kornet, M. J., Thio, P. A., Malone, N., and Lubawy, W. C., antiarrhythmic activity of 3-amino-3-methyloxindoles, 639
Koski, R. G., *see* Niedermayer, A. O., 1531
Kostenbauder, H. B., *see* Ong, J. T. H., 1378
Koup, J. R., Jusko, W. J., and Goldfarb, A. L., pH-dependent secretion of procainamide into saliva, 2008
Kovach, I. M., Pitman, I. H., and Higuchi, T., amino acid esters of phenolic drugs as potentially useful prodrugs, 1070
Kowarski, C. R., and Ghandi, H. I., complex formation between menadione and cetylethylmorpholinium ethosulfate: effect on UV photodegradation of menadione, 696
Koysooko, R., Ellis, E. F., and Levy, G., effect of ethanol on theophylline absorption in humans, 299
Kraicer, P. F., *see* Bloch, R., 832
Kramer, P. A., *see* Nadkarni, P. D., 1554
Krauth, C. A., *see* Shealy, Y. F., 177
Kreighbaum, W. E., *see* Amer, M. S., 1
Kreilgård, B., Higuchi, T., and Repta, A. J., complexation in formulation of parenteral solutions: solubilization of the cytotoxic agent hexamethylmelamine by complexation with gentisic acid species, 1850
Kripalani, K. J., Cohen, A. I., Weliky, I., and Schreiber, E. C., metabolism of triamcinolone acetonide-21-phosphate in dogs, monkeys, and rats, 1351
Krishna, G., *see* Rao, G. S., 1579
Krull, I. S., *see* Gershon, H., 1855
Ku, S.-H., and Cadwallader, D. E., behavior of erythrocytes in ternary solvent systems, 1818
Kuhlman, C. F., Chang, T. L., and Nelson, G. L., application of mixed electron-impact–chemical ionization high-resolution mass spectrometry to a medicinal agent, 1581
Kujundžić, N., *see* Pečar, M., 970
Kulshrestha, D. K., *see* Kar, K., 258
Kumar, R., *see* Ali, B., 1329
Kupchik, E. J., Pisano, M. A., Raghunath, A. V., Cardona, R. A., Formaini, N., and Alleguez, C., synthesis and antimicrobial activity of *N*-substituted *N′*-cyano-*S*-(triorganostannyl)isothioureas, 1259
Kwan, K. C., Bondi, J. V., and Yeh, K. C., bioavailability assessment under quasi- and nonsteady-state conditions I: theoretical considerations, 1639

L

Lacey, J. C., Jr., and Pruitt, K. M., drug–biomolecule interactions: interactions of mononucleo-

tides and polybasic amino acids, 473
Lach, J. L., *see* Pope, D. G., 466
Laffont, J., *see* Gérardin, A., 1940
Lahiri, S. C., Gupta, J. K., and Mondal, A. K., *N*-substituted indanamines as potential hypoglycemic agents, 172
Lai, C.-M., *see* Yacobi, A., 1995
Lake, L. M., *see* Jato, J. G., 943
Lakszner, K., *see* Salmona, M., 1561
Lalezari, I., and Afghahi, F., synthesis and evaluation of antitumor activity of 1-[*N,N*-bis(2-chloroethyl)sulfamoylphenyl] - 3,3 - dialkyltriazenes, 698
——Shafiee, A., Badaly, A., Salimi, M. M., Khoyi, M. A., Abtahi, F., and Zarrindast, M. R., synthesis and pharmacological activity of 5-substituted 2-(*N,N*-dialkylaminoethyl)amino- and 2-*N*-methylpiperazinyl-1,3,4-thiadiazoles, 1250
——*see* Afghahi, F., 858
——*see* Shafiee, A., 1570
Lalka, D., Jusko, W. J., and Bardos, T. J., reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems II: comparative pharmacokinetics in dogs, 230
Lamb, R. G., *see* Hall, I. H., 235
Lamberi, H. J., *see* Chien, Y. W., 957, 961, 1643, 1776
——*see* Sanvordeker, D. R., 1797
Lampman, T., *see* Levy, G., 890
Lanzillo, J. J., *see* Foye, W. O., 211, 1371
Larsson, L., *see* Friberg, S., 822
LaSala, E. F., *see* Foye, W. O., 1371
La Via, A. L., *see* McGinity, J. W., 356
Law, F. C. P., Drach, J. C., and Sinsheimer, J. E., effects of nitrogen dioxide and 3-methylcholanthrene on pulmonary enzymes, 1421
Lawrence, W. H., *see* Singh, A. R., 1347
Leafe, T. D., *see* Yolles, S., 115, 348
Ledis, S., *see* Tsou, K. C., 1418
Lee, B. H., *see* Jun, H. W., 1843
Lee, F. H., *see* Conway, W. D., 1158
Lee, K.-H., Cowherd, C. M., and Wolo, M. T., antitumor agents XV: deoxyelephantopin, an antitumor principle from *Elephantopus carolinianus* Willd., 1572
——Ibuka, T., Huang, H.-C., and Harris, D. L., antitumor agents XIV: molephantinin, a new potent antitumor sesquiterpene lactone from *Elephantopus mollis*, 1077
Lee, K. H., *see* Chan, J., 1182
——*see* Thompkins, L., 760
Lehr, R. E., and Kaul, P. N., chlorpromazine metabolism IV: quaternization as a key to determination of picomoles of chlorpromazine and other tertiary amine drugs, 950
Lemke, T. L., Cates, L. A., Steenberg, M., and Cho, Y. M., analogs of the anorexic mazindol, 1375
Levine, B., *see* Gearien, J. E., 152
Levitt, M., *see* Cheng, L. K., 839
Levy, G., and Lampman, T., relationship between pH of saliva and pH of urine, 890
——*see* Gibaldi, M., 2003
——*see* Harrigan, D. J., 897
——*see* Houston, J. B., 607, 1504
——*see* Koysooko, R., 299
——*see* Øie, S., 1433
——*see* Soda, D. M., 1928
——*see* Yacobi, A., 1660, 1995
Levy, R. H., Lockard, J. S., Green, J. R., Friel, P., and Martis, L., pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration, 302
——*see* Simons, K. J., 1967
Lewis, J. K., *see* Garrett, E. R., 1936
Lilledahl, R. L., Ryan, C. F., and Piepho, R. W., hypothermic response following administration of 2-amino-4-pentenoic acid (allylglycine), 835
Lim, J. K., *see* Crouthamel, W. G., 1726
Lin, C.-C. L., *see* Dubois, R. J., 825
Lin, S.-K., Tin-Wa, M., and Taylor, E. H., microbial transformation of aspidospermine, 2021
Lin, T. K., *see* Chien, Y. W., 961, 1643
——*see* Sanvordeker, D. R., 1797
Lindberg, S., *see* Eng, R., 1068
Lindenbaum, S., and Higuchi, T., binding of bile acids to cholestyramine at gastric pH conditions, 1887
Lira, E. P., *see* Hamer, M., 1961
——*see* Traxler, J. T., 1943
Li Wan Po, A., *see* Enever, R. P., 1497
Lo, A., Shefter, E., and Cochran, T. G., analysis of *N*-glycosyl bond length in crystal structures of nucleosides and nucleotides, 1707
Lobel, E., *see* Bloch, R., 832
Lock A., *see* Ayres, J. W., 1958
Lockard, J. S., *see* Levy, R. H., 302
Locock, R. A., *see* Moskalyk, R. E., 1406
Lodge, B. A., *see* Butterfield, A. G., 441
Loeffler, L. J., and Delorefice, S. B., potential fibrinolytic agents: versatile synthetic route to novel 4-(branched alkyl)benzoic acids *via* β-monosubstituted or β,β-disubstituted styrene-4-carboxylic acids, 1170
——and Hinds, C. J., isolation of lysergide (LSD) with agarose-bound antibodies to lysergic acid, 1890
Logsdon, E. E., *see* Tafur, S., 1953
Lomner, J. J., *see* Daly, R. E., 1999
Loo, J. C. K., Rowe, M., and McGilveray, I. J., effect of an antacid on absorption of digoxin in dogs, 1727
Lopez, B., *see* Cressman, W. A., 1965
Lord, M., *see* Sapp, C., 1884
Lorskulsint, D., *see* Ayres, J. W., 1958
Lovering, E. G., McGilveray, I. J., McMillan, I., and Tostowaryk, W., comparative bioavailabilities from truncated blood level curves, 1521
Lowe, Y. H., *see* Foye, W. O., 211
Lubawy, W. C., *see* Kornet, M. J., 639
Ludwig, B. J., *see* Edelson, J., 1316
——*see* Sofia, R. D., 1321
Lundell, S., *see* Ylitalo, P., 1264
Luttrell, G. H., *see* Graham, R. E., 226
Luzzi, L. A., *see* Jun, H. W., 493

M

Ma, J. K. H., *see* Jun, H. W., 493
Madan, P. L., variability in system for automated determination of dissolution rate, 1080
Magarian, R. A., and Benjamin, E. J., synthesis of cyclopropyl analogs of stilbene and stilbenediol as possible antiestrogens, 1626
Maibach, H. I., *see* Johnson, H., 693
Maitai, C. K., and Mugera, G. M., excretion of the active principle of *Catha edulis* (Miraa) in human urine, 702
Malbica, J. O., and Monson, K. R., new and expedient determination of atenolol in biological samples, 1992
Malick, J. B., and Barnett, A., central *versus* peripheral anticholinergic activity as assessed by two *in vivo* procedures in mice, 1066
Malicky, J. L., *see* Moskalyk, R. E., 292
Malik, S. N., Canaham, D. H., and Gouda, M. W., effect of surfactants on absorption through membranes III: effects of dioctyl sodium sulfosuccinate and poloxalene on absorption of a poorly absorbable drug, phenolsulfonphthalein, in rats, 987
Malinowski, H. J., and Smith, W. E., use of fractional design to evaluate granulations prepared by spheronization, 1688
Malmberg, C. E., *see* Jones, P. R., 1240
Malone, N., *see* Kornet, M. J., 639
Maness, D. D., and Yakatan, G. J., fluorescence characteristics of benzodiazepines in strong acid, 651
Manion, C. V., *see* Huffman, D. H., 433
Manohar, V., Murthy, S. V. K. N., Sirsi, M., Rao, G. R., and Rao, P. L. N., antidermatophytic activity of 2-thiotetrahydro-1,3,5-thiadiazines and isothiocyanates, 164
Mar, M.-H. H., *see* Hall, I. H., 235
Mardente, S., and De Marchi, F., GLC determination of hexadiphane in pharmaceutical preparations, 1866
Mares, S. E., *see* Chien, Y. W., 1776
Margalet, A., *see* Fabregas, J. L., 1005
Margosis, N., GLC analysis of griseofulvin: a collaborative study, 1020
Marks, W. H., Fong, H. H. S., Tin-Wa, M., and Farnsworth, N. R., cytotoxic principles of *Parquetina nigrescens* (Afzel.) Bullock (Asclepiadaceae), 1674
Marriott, C., *see* Kellaway, I. W., 1162
Martin, A. N., *see* McGinity, J. W., 889
Martin, E. T., *see* Schwartz, J. B., 328
Martin, J. S., *see* Tansy, M. F., 1174
Martineau, P. C., *see* Jaffe, J. M., 2028
Martis, L., *see* Levy, R. H., 302
Masoud, A. N., systematic identification of drugs of abuse I: spot tests, 841
Masserano, R., *see* Johnson, R., 1007
Matsubara, I., *see* Hasegawa, M., 1732
Matsui, F., *see* French, W. N., 125, 1545
Maulding, H. V., and Michaelis, A. F., practical kinetics II: quantitation of procaine stability by TLC, 275
——Nazareno, J. P., Pearson, J. E., and Michaelis, A. F., practical kinetics III: benzodiazepine hydrolysis, 278
——Polesuk, J., and Rosenbaum, D., practical kinetics I: quantitation of barbiturate stability by TLC, 272
——Turi, P., Grossman, D., and Nazareno, J. P., solvolysis of a substituted imidazoline, mazindol, 1833
——*see* Nally, J., 437
——*see* Zoglio, M. A., 1381
Mazeika, T. R., *see* Holl, W. W., 1232
Mazumder, U. K., *see* Ghosal, S., 1082
McDonald, R. H., Jr., *see* Corder, C. N., 785
McDonnell, J. P., *see* Bighley, L. D., 1549
McGilveray, I. J., *see* Loo, J. C. K., 1727
——*see* Lovering, E. G., 1521
McGinity, J. W., and Brown, R. L., stabilizing effect of inorganic phosphate salts on antibiotic–steroid ophthalmic preparations, 1528
——and Hill, J. A., influence of monovalent and divalent electrolytes on sorption of neomycin sulfate to attapulgite and montmorillonite clays, 1566
——Combs, A. B., and Martin, A. N., improved method for microencapsulation of soluble pharmaceuticals, 889
——Hill, J. A., and La Via, A. L., influence of peroxide impurities in polyethylene glycols on drug stability, 356
McGrattan, C., *see* Jones, P. R., 1240
McIlhenny, H. M., *see* Wiseman, E. H., 1469
McKamey, M. R., and Spitznagle, L. A., chromatographic, mass spectral, and visible light absorption characteristics of toluidine blue O and related dyes, 1456
McMillan, I., *see* Lovering, E. G., 1521
McNulty, P. B., effect of polysorbate 60 on interphase transport of cholesterol, 1500
McQuinn, R. L., *see* Yeh, S. Y., 1237
Medora, R. S., *see* Jodhka, G. S., 1858
Mehta, D. S., *see* Joshi, K. C., 1428
Mehta, P. J., *see* Cakiryildiz, C., 1692
Meier, J. P., *see* Bender, A. D., 1711
Meijsen, B. T., *see* Blair, A. D., 1334
Merlaux-Brochu, A., and Paiement, J., drug release from a lipophilic ointment base as influenced by chain length of added surfactant, 1055
Meyer, F. J., *see* Yolles, S., 115, 348
Mezei, M., *see* Ryan, K. J., 671
Micalizzi, M., *see* Heindel, N. D., 687
Michaelis, A. F., *see* Maulding, H. V., 275, 278
Michel, B. L., *see* Dubois, R. J., 825
Middleton, D. L., *see* Graham, R. E., 226
Millard, B. J., *see* Enever, R. P., 1497
Misra, R. S., *see* Singh, S. P., 1245
Mlinarevic, B., *see* Pečar, M., 970
Moats, M. J., *see* Hamer, M., 1961
——*see* Traxler, J. T., 1943
Mole, M. L., Jr., *see* Turner, C. E., 810
Molins, D., Wong, C. K., Cohen, D. M., and Munnelly, K. P., high-pressure liquid chromatographic determination of chlorpropamide in tablet formulations, 123
Molokhia, A. M., Higuchi, W. I., and Hofmann, A. F., dissolution of model gallstones in bile acid solutions I: implications for T-tube infusion treatment of retained common duct stones with

the cholate system, 2029
——*see* Yotsuyanagi, T., 71
Mondal, A. K., *see* Lahiri, S. C., 172
Monson, K. R., *see* Malbica, J. O., 1992
Morgan, J. M., *see* Hufford, C. D., 789
Moros, S. A., Hamilton, C. M., Heveran, J. E., Donahue, J. J., and Oliveri-Vigh, S., automated constant-current coulometric assay system for ascorbic acid and sodium ascorbate, 1229
Morozowich, W., and Williams, R. G., liquid chromatography of clindamycin 2-phosphate on triethylaminoethyl cellulose, 313
Moses, M. L., *see* Bederka, J. P., Jr., 528
Moskalyk, R. E., and Malicky, J. L., alkylation by secondary alcohols III: fusion of medicinal sulfanilamides with benzhydrol, 292
——Locock, R. A., Chatten, L. G., Veltman, A. M., and Bielech, M. F., determination of polythiazide in pharmaceutical dosage forms by high-pressure liquid chromatography, 1406
Motawi, M. M., *see* Ebian, A. R., 1481
——*see* Moustafa, M. A., 1485
Moustafa, M. A., Ebian, A. R., Khalil, S. A., and Motawi, M. M., succinylsulfathiazole crystal forms III: crystal growth studies, 1485
——*see* Ebian, A. R., 1481
Mrtek, R. G., *see* Javidan, S., 420
Mufson, D., Triyanond, K., and Ravin, L. J., cholelithiasis chemotherapy: an *in vitro* approach, 362
Mugera, G. M., *see* Maitai, C. K., 702
Mukhayer, G. I., Davis, S. S., and Tomlinson, E., automated conductimetric titrimeter: use in studying ionic solute–solute interactions, 147
Muller, F. O., *see* Hundt, H. K. L., 1041
Munnelly, K. P., *see* Molins, D., 123
Munson, J. W., and Hodgkins, T. G., colorimetric determination of formaldehyde *via* free radical formation, 1043
Murray, W. J., Hall, L. H., and Kier, L. B., molecular connectivity III: relationship to partition coefficients, 1978
——*see* Hall, L. H., 1974
——*see* Kier, L. B., 1971
Murthy, S. V. K. N., *see* Manohar, V., 164
Mussini, E., *see* Salmona, M., 1561
Musto, J. D., *see* Warner, V. D., 1563

N

Nabih, I., Ismail, S., and Nasr, M., synthesis of (4-quinolinoamino)aminoalkyltetrahydronaphthalene derivatives for possible antimalarial activity, 460
Nadkarni, P. D., Kildsig, D. O., Kramer, P. A., and Banker, G. S., effect of surface roughness and coating solvent in film adhesion to tablets, 1554
Nagami, G. T., *see* Schaeffer, J. C., 1462
Nagwekar, J. B., *see* Amin, Y. M., 1804, 1813
Naik, D. F., Jewell, C. F., Jr., and Schulman, S. G., binding of cupric ions to bovine serum albumin, 1243
——Paul, W. L., and Schulman, S. G., fluorometric determination of drug–protein association constants: binding of pamaquine by bovine serum albumin, 1677
——*see* Schulman, S. G., 982
Nail, S. L., White, J. L., and Hem, S. L., comparison of IR spectroscopic analysis and X-ray diffraction of aluminum hydroxide gel, 1166
Naito, S.-I., and Yamamoto, T., stability, absorption, excretion, and distribution of nafiverine, 253
Nakamori, R., Tanaka, F., Nojiri, T., Yoshino, H., Okumura, M., and Imai, K., phenol formation from alkylparabens by bacteria, 1071
Nakano, M., *see* Washitake, M., 397
Nally, J., Nazareno, J., Polesuk, J., and Maulding, H. V., alcoholysis of medicinally active 5-aminodibenzo[*a,d*]cycloheptenes, 437
Nannipieri, E., *see* Bottari, F., 946
Nash, J. F., Bennett, I. F., Bopp, R. J., Brunson, M. K., and Sullivan, H. R., quantitation of propoxyphene and its major metabolites in heroin addict plasma after large dose administration of propoxyphene napsylate, 429
Nasr, M., *see* Nabih, I., 460
Nasseri-Nouri, P., *see* Shafiee, A., 1570
Nazareno, J., *see* Nally, J., 437
——*see* Maulding, H. V., 278, 1833
Nelson, D. A., *see* Perrin, J. H., 361
Nelson, G. L., *see* Kuhlman, C. F., 1581
Nelson, K. G., and Amin, K. N., determination of stability constants of stannous fluoride complexes by potentiostatic titration, 350
——and Shah, A. C., convective diffusion model for a transport-controlled dissolution rate process, 610
——*see* Shah, A. C., 1518
Nesbitt, R. U., Jr., *see* Hartman, A. W., 802
Neufeld, L., *see* Conway, W. D., 1158
Newman, E. C., *see* Stoel, L. J., 1635
Newmark, H. L., Pool, W., Bauernfeind, J. C., and De Ritter, E., biopharmaceutic factors in parenteral administration of vitamin E, 655
Niazi, S., and Chiou, W. L., fluorocarbon aerosol propellants VI: interspecies differences in solubilities in blood and plasma and their possible implications in toxicity studies, 1538
——and Chiou, W. L., fluorocarbon aerosol propellants IV: pharmacokinetics of trichloromonofluoromethane following single and multiple dosing in dogs, 763
Nichol, C. A., *see* Sigel, C. W., 973
Niebergall, P. J., Sugita, E. T., and Schnaare, R. L., rapid methods for bioavailability determination utilizing urinary excretion data, 1721
Niedermayer, A. O., and Koski, R. G., GLC determination of 7-chloro-5,11-dihydrodibenz[*b,e*]-[1,4]oxazepine-5-carboxamide in serum or plasma, 1531
Nietrzeba, R., *see* Tsou, K. C., 1418
Nightingale, C. H., Bassaris, H., Tilton, R., and Quintiliani, R., changes in pharmacokinetics of cefazolin due to stress, 712
——Greene, D. S., and Quintiliani, R., pharmacokinetics and clinical use of cephalosporin antibiotics, 1899
Nobles, W. L., *see* Varma, R. S., 881
Nojiri, T., *see* Nakamori, R., 1071
Notari, R. E., and DeYoung, J. L., kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions, 1148
Nuessle, N. O., *see* Chang, B. L., 1787
——*see* Hartman, A. W., 802
Nunez, L. J., *see* Hung, G. W. C., 1492

O

Obiorah, B. A., *see* Shotton, E., 1213
O'Brien, M., *see* Holl, W. W., 1232
O'Dell, C. A., *see* Shealy, Y. F., 177, 954
Ohkuma, T., *see* Suzuki, T., 895
Ohie, S., and Levy, G., effect of plasma protein binding on elimination of bilirubin, 1433
Okada, H., Stella, V., Haslam, J., and Yata, N., photolytic degradation of α-[(dibutylamino)-methyl]-6,8-dichloro-2-(3′,4′-dichlorophenyl)-4-quinoline methanol: an experimental antimalarial, 1665
Okumura, M., *see* Nakamori, R., 1071
Oliveri-Vigh, S., *see* Moros, S. A., 1229
Ong, J. T. H., and Kostenbauder, H. B., effect of self-association on rate of penicillin G degradation in concentrated aqueous solutions, 1378
Opankunle, W. O., Bhutani, B. R., and Bhatia, V. N., drying rates of tablet granulations II: effect of particle size and granular densities, 1023

P

Page, D. P., Carson, N. A., Buhr, C. A., Flinn, P. E., Wells, C. E., and Randall, M. T., stability study of nitroglycerin sublingual tablets, 140
Palement, J., *see* Mériaux-Brochu, A., 1055
Pal, D., *see* De, A. U., 262
Papadopoulos, H., *see* Choulis, N. H., 1033
Parekh, K. B., Shelver, W. H., Tsai, A.-Y. S., and Reopelle, R., synthesis of potential adrenergic blocking agents: 2-substituted aminomethylnaphtho(2,3-*b*)-1,4-dioxans, 875
Park, C. S., *see* Smolen, V. F., 520
Parmar, S. S., Gupta, A. K., Gupta, T. K., and Stenberg, V. I., synthesis of substituted benzylidinohydrazines and their monoamine oxidase inhibitory and anticonvulsant properties, 154
——*see* Ali, B., 1329
——*see* Chaturvedi, A. K., 454
——*see* Chaudhari, S. K., 614
——*see* Gupta, A. K., 1001
——*see* Singh, S. P., 1245
Parmegiani, R., *see* Gershon, H., 1855
Parrott, E. L., influence of particle size on rectal absorption of aspirin, 878
Patel, M., and Carstensen, J. T., nonsink dissolution rate equations, 1651
——*see* Carstensen, J. T., 1770
Patel, S. P., and Jarowski, C. I., oral absorption efficiency of acid-labile antibiotics from lipid–drug delivery systems, 869
Patnaik, G. K., *see* Kar, K., 258
Patton, T. F., and Robinson, J. R., influence of topical anesthesia on tear dynamics and ocular drug bioavailability in albino rabbits, 267
——and Robinson, J. R., ocular evaluation of polyvinyl alcohol vehicle in rabbits, 1312
Paul, C. J., *see* Whitehouse, L. W., 819
Paul, W. L., *see* Naik, D. V., 1677
Paulssen, R. B., Chatterji, D., Higuchi, T., and Pitman, I. H., acylation of ascorbic acid in water, 1300
Pearson, J. E., *see* Maulding, H. V., 278
Pečar, M., Kujundžić, N., Milnarević, B., Čerina, D., Horvat, B., and Verić, M., aqueous mixture of pyrrolidone-5-hydroxamic acid–iron (III) complexes: isolation and characterization of tris(pyrrolidone-5-hydroxamato)iron (III), 970
Pedersen, P. V., and Brown, K. F., dissolution profile in relation to initial particle distribution, 1192
——and Brown, K. F., size distribution effects in multiparticulate dissolution, 1981
Peng, G. W., and Chiou, W. L., fluorocarbon aerosol propellants VII: interaction studies with human and bovine globulins using partition coefficient method, 1577
Penner, M. H., assay of sulfacetamide sodium ophthalmic solutions by high-pressure liquid chromatography, 1017
Perdue, R. E., Jr., *see* Weiss, S. G., 95
Perrin, J. H., and Nelson, D. A., reduced binding of sulfaethidole to bovine serum albumin in presence of benzalkonium chloride, 361
——and Vallner, J. J., preliminary investigations of intrinsic and extrinsic optical activity as purity criterion for human serum albumins, 1508
Peters, J. E., Catalfomo, P., Constantine, G. H., Jr., and Kirk, P. W., Jr., free amino acids in higher marine fungi, 176
Peters, J. H., *see* Gordon, G. R., 1205
Pettit, G. R., Herald, C. L., Judd, G. F., Bolliger, G., and Thayer, P. S., antineoplastic and cytotoxic components of desert *Baileya*, 2023
Plantadosi, C., *see* Hall, I. H., 235
Plepho, R. W., *see* Liliedahl, R. L., 835
Pisano, M. A., *see* Kupchik, E. J., 1259
Pitkin, D., *see* Holl, W. W., 1232
Pitman, I. H., *see* Cho, M. J., 1825
——*see* Kovach, I. M., 1070
——*see* Paulssen, R. B., 1300
——*see* Rork, G. S., 216
Pitrè, D., *see* Felder, E., 684
Plakogiannis, F. M., determination of sigma and pi constants of quinolinium acid derivatives, 867
——and Saad, A. M., spectrophotometric determination of acetaminophen and dichloralantipyrine in capsules, 1547
Plunkett, R. D., *see* Honigberg, I. L., 1389
Polak, Lj., *see* Sinsheimer, J. E., 925
Polesuk, J., *see* Maulding, H. V., 272
——*see* Nally, J., 437
Pool, W., *see* Newmark, H. L., 655
Pope, D. G., and Lach, J. L., quantitation, elimination, and discussion of decomposition product interference in *N*-acetyl-*p*-aminophenol colorimetry, 466
Post, A., *see* Bender, A. D., 1711
——*see* Holl, W. W., 1232

——*see* Staiger, D. B., 1396
Postma, E., *see* Dixon, W. R., 937
Pothisiri, P., and Carstensen, J. T., solid-state decomposition of *para*-substituted salicylic acids, 1931
——*see* Carstensen, J. T., 37
Pound, N. J., and Sears, R. W., simultaneous determination of phenylbutazone and oxyphenbutazone in plasma by high-speed liquid chromatography, 284
——*see* Butterfield, A. G., 316, 441
Poust, R. I., Fusari, S. A., and Dittmar, D., methodological differences in correlating digoxin dissolution with bioavailability, 1583
——*see* Antal, E. J., 2015
Powers, L. J., Dillingham, E. O., and Bass, G. E., synthesis and CMC determination of a series of aliphatic diamines, 883
——*see* Dorsett, P. H., 1073
Pratt, E. L., *see* Dombrowski, L. J., 643
Price, J. C., *see* Zia, H., 1177
Pritchard, R., *see* Chowhan, Z. T., 754
Pruitt, K. M., *see* Lacey, J. C., Jr., 473
Puri, V. N., *see* Kar, K., 258
Pytelewski, R., *see* Jarowski, C. I., 690

Q

Quintiliani, R., *see* Nightingale, C. H., 712, 1899

R

Raghunath, A. V., *see* Kupchik, E. J., 1259
Rahmen, W., *see* Cakiryildiz, C., 1692
Raja, P. K., and Jarowski, C. I., utility of fasting essential amino acid plasma levels in formulation of nutritionally adequate diets IV: lowering of human plasma cholesterol and triglyceride levels by lysine and tryptophan supplementation, 691
Randall, M. T., *see* Page, D. P., 140
Randić, M., *see* Kier, L. B., 1971
Rao, G. R., *see* Manohar, V., 164
Rao, G. S., and Krishna, G., drug–nitrite interactions: formation of *N*-nitroso, C-nitroso, and nitro compounds from sodium nitrite and various drugs under physiological conditions, 1579
Rao, K. V., Tanrikut, Y., and Killion, K., fluorometric and GLC analyses of aristolochic acid, 345
Rao, P. L. N., *see* Manohar, V., 164
Rastogi, R. P., *see* Kar, K., 258
Ratchik, E. M., and Viswanathan, V., GLC determination of saccharin in pharmaceutical products, 133
Rattie, E. S., *see* Ravin, L. J., 1830
Ravin, L. J., Shami, E. G., and Rattie, E. S., micelle formation and its relationship to solubility behavior of 2-butyl-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride, 1830
——*see* Mufson, D., 362
Rawson, B. J., *see* Repta, A. J., 392
Ray, S. M., *see* Alam, M., 865
Reba, R. C., *see* Eckelman, W. C., 704
Recusani, F., *see* Bruzzese, T., 462
Reichard, G., Jr., *see* Bender, A. D., 1711
Remers, W. A., *see* Witty, T. R., 1248
Renner, J. A., *see* Romano, S. J., 1412
Reopelle, R., *see* Parekh, K. B., 875
Repta, A. J., Rawson, B. J., Shaffer, R. D., Sloan, K. B., Bodor, N., and Higuchi, T., rational development of a soluble prodrug of a cytotoxic nucleoside: preparation and properties of arabinosyladenine 5′-formate, 392
——*see* Cho, M. J., 1825
——*see* Kreilgård, B., 1850
Restaino, F. A., *see* Bohidar, N. R., 966
Restivo, A., *see* Hou, J. P., 710
Reynolds, A. K., simple method for monitoring flow rate during gravity perfusion, 1730
Režábek, K., Cassidy, J. M., and Floss, H. G., nidation inhibition by simple ergoline derivatives, 1045
Rhodes, C. T., *see* Khan, K. A., 166, 444, 447
Rhodes, H. J., DeNardo, J. J., Bode, D. W., and Blake, M. I., differentiating nonaqueous titration of aspirin, acetaminophen, and salicylamide mixtures, 1386
Richard, A. J., ultracentrifugal study of effect of sodium chloride on micelle size of fusidate sodium, 873
Richter, W. J., *see* Brochmann-Hanssen, E., 1040
Riggin, R. M., Schmidt, A. L., and Kissinger, P. T., determination of acetaminophen in pharmaceutical preparations and body fluids by high-performance liquid chromatography with electrochemical detection, 680
Rikihisa, T., *see* Suzuki, T., 895
Risch, V. R., *see* Heindel, N. D., 687
Robertson, J. H., *see* Tsuji, K., 1542
Robertson, L. W., *see* Hufford, C. D., 789
Robinson, J. R., *see* Patton, T. F., 267, 1312
——*see* Sieg, J. W., 931
Rogers, G., *see* Bayne, W. F., 402
Romano, S. J., and Renner, J. A., comparison of analytical methods for residual ethylene oxide analysis, 1412
Rork, G. S., and Pitman, I. H., bisulfite-ion-catalyzed degradation of fluorouracil, 216
Rosazza, J. P., *see* Smith, R. V., 1737
Roseman, T. J., controlled release from matrix systems, 1731
Rosenbaum, D., *see* Maulding, H. V., 272
Rosenkranz, H. S., *see* Wlodkowski, T. J., 1235
Rowe, M., *see* Loo, J. C. K., 1727
Roy, T., *see* Schulman, S. G., 982
Rutherford, B. S., *see* Bishara, R. H., 1210
Ryan, C. F., *see* Liliedahl, R. L., 835
Ryan, K. J., and Mezei, M., *in vivo* method for monitoring polysorbate 85 effect on epidermal permeability, 671

S

Saad, A. M., *see* Plakogiannis, F. M., 1547
Sadée, W., Staroscik, J., Finn, C., and Cohen, J., determination of (±)-1,2-bis(3,5-dioxopiperazinyl)propane plasma levels in rats, rabbits, and humans by GLC and mass fragmentography, 998
Sadik, F., *see* Bauguess, C. T., 117, 1489
Saettone, M. F., *see* Bottari, F., 946
Saha, B. P., *see* De, A. U., 249
Sakmar, E., *see* Sullivan, T. J., 1723
Salimi, M. M., *see* Lalezari, I., 1250
Salmona, M., Lakszner, K., Fanelli, R., Saronio, C., Bianchi, R., and Mussini, E., relationship of *in vitro* hydrolysis of 17-chloroacetylajmaline and 17-acetylajmaline in different animal species, 1561
Samuelson, R. J., Giesecke, A. H., Jr., and Kallus, F. T., clindamycin phosphate: neuromuscular and blood pressure effects in cats, 861
Santilli, A. A., Kim, D. H., and Gregory, F. J., antitubercular activity of substituted 5-oxo-1-thiocarbamoyl-3-pyrazoline-4-alkanoic acid derivatives, 1057
Santos, G. A., and Doty, M. S., IR studies on carrageenan of *Ahnfeltia concinna*, a marine red alga, 1704
Sanvordeker, D. R., and Dajani, E. Z., *in vitro* adsorption of diphenoxylate hydrochloride on activated charcoal and its relationship to pharmacological effects of drug *in vivo* I, 1877
——Chien, Y. W., Lin, T. K., and Lambert, H. J., binding of metronidazole and its derivatives to plasma proteins: an assessment of drug binding phenomenon, 1797
——*see* Chien, Y. W., 957
Sapp, C., Lord, M., and Hammarlund, E. R., sodium chloride equivalents, cryoscopic properties, and hemolytic effects of certain medicinals in aqueous solution III: supplemental values, 1884
Saronio, C., *see* Salmona, M., 1561
Schaeffer, J. C., Cho, A. K., Nagami, G. T., and Takimoto, G. S., inhibition of synaptosomal accumulation of *l*-norepinephrine I: *N*-arylalkyl and *N*-aryloxyalkyl *dl*-amphetamines and related compounds, 1462
Schaeffer, L. A., *see* Heindel, N. D., 1425
Schilling, G., *see* Johnson, R., 1007
Schlecht, K. D., and Frank, C. W., dehydration of tetracycline, 352
Schmidt, A. L., *see* Riggin, R. M., 680
Schnaare, R. L., *see* Niebergall, P. J., 1721
Schnabel, R., *see* Cho, M. J., 1894
Schoenleber, D., *see* Cakiryildiz, C., 1692
Schott, H., and Han, S. K., effect of inorganic additives on solutions of nonionic surfactants II, 658
Schreiber, E. C., *see* Dreyfuss, J., 1604
——*see* Kripalani, K. J., 1351
Schulman, S. G., Naik, D. V., Capomacchia, A. C., and Roy, T., electronic spectra and electronic structures of some antimicrobials derived from proflavine, 982
——*see* Capomacchia, A. C., 1256
——*see* Naik, D. V., 1243, 1677
Schuster, E. B., *see* Edelson, J., 1316
Schwan, T. R., and Ellis, K. O., 5-chloro-2-pyrimidinyl analog of dantrolene, 337
——and Ellis, K. O., positional isomer of the muscle relaxant dantrolene, 1047
Schwartz, J. B., Martin, E. T., and Dehner, E. J., intragranular starch: comparison of starch USP and modified cornstarch, 328
——*see* Restaino, F. A., 966
Sciarra, J. J., *see* Feinstein, W., 408, 1050
Sciarrone, B. J., *see* Auslander, D. E., 516
Sears, R. W., *see* Butterfield, A. G., 441
——*see* Pound, N. J., 284
Sequeira, J. A. L., *see* Bates, T. R., 709, 793
Serafini, M. F., *see* Bottari, F., 946
Settle, D. A., *see* Stewart, J. T., 1403
Shaath, N. A., *see* El-Antably, S. M., 1423
——*see* Genenah, A. A., 62
——*see* Soine, T. O., 67
Shade, J. T., *see* Ziegler, H. W., 1026
Shaffer, R. D., *see* Repta, A. J., 392
Shafiee, A., Lalezari, I., Nasseri-Nouri, P., and Asgharian, R., alkaloids of *Papaver orientale* and *Papaver pseudo-orientale*, 1570
——*see* Lalezari, I., 1250
Shah, A. C., and Nelson, K. G., evaluation of a convective diffusion drug dissolution rate model, 1518
——*see* Nelson, K. G., 610
Shahinian, S., *see* Edelson, J., 1316
Shami, E. G., *see* Ravin, L. J., 1830
Sharma, P. V., *see* Ghosal, S., 80
Sharma, R. C., *see* Joshi, K. C., 1428
Shaw, J. M., *see* Dreyfuss, J., 1604
Shealy, Y. F., and O'Dell, C. A., synthesis of 5-(3,3 - disubstituted -1- triazenyl)imidazole -4- carbonitriles, 954
——O'Dell, C. A., and Krauth, C. A., 5-[3-(2-chloroethyl)-1-triazenyl]imidazole - 4 - carboxamide and a possible mechanism of action of 5-[3,3-bis(2-chloroethyl) - 1 - triazenyl]imidazole-4-carboxamide, 177
Sheehan, M., and Beam, R. E., GLC determination of underivatized carbamazepine in whole blood, 2004
Shefter, E., *see* Lo, A., 1707
Shelver, W. H., *see* Parekh, K. B., 875
Shiau, G. T., De, K. K., and Harmon, R. E., alkylthiocolchicines and *N*-deacetylalkylthiocolchicines and their antileukemic activity, 646
Shipman, C., Jr., *see* Turi, J. S., 622, 627, 631
Shiue, C.-Y., *see* Chu, S.-H., 1343
Shohet, J. S., analysis of pholcodine in cough preparations, 1011
Shotton, E., and Obiorah, B. A., effect of physical properties on compression characteristics, 1213
——*see* Enever, R. P., 1497
Shroff, A. P., *see* Huettemann, R. E., 1339
Sieg, J. W., and Robinson, J. R., vehicle effects on ocular drug bioavailability I: evaluation of fluorometholone, 931
Sigel, C. W., Woolley, J. L., Jr., and Nichol, C. A., specific TLC tissue residue determination of sulfadiazine following fluorescamine derivatization, 973
Silipo, C., *see* Hansch, C., 1186
Simons, K. J., and Levy, R. H., GLC determination

of procainamide in biological fluids, 1967
Singh, A. R., Lawrence, H. W., and Autian, J., maternal–fetal transfer of ^{14}C-di-2-ethylhexyl phthalate in ^{14}C-diethyl phthalate in rats, 1347
Singh, S. P., Misra, R. S., Parmar, S. S., and Brumleve, S. J., synthesis of 2-(4-arylthiosemicarbazidocarbonylthio)benzthiazoles and their monamine oxidase inhibitory and anticonvulsant properties, 1245
Singh, V. K., *see* Joshi, K. C., 1418
Sinkula, A. A., and Yalkowsky, S. H., rationale for design of biologically reversible drug derivatives: prodrugs, 181
Sinsheimer, J. E., Jagodic, V., Polak, Lj., Hong, D. D., and Burckhalter, J. H., polycyclic aromatic isothiocyanate compounds as fluorescent labeling reagents, 925
——*see* Law, F. C. P., 1421
——*see* Tay, L. K., 471
Sirsi, M., *see* Manohar, V., 164
Skidmore, D., *see* Johnson, H., 693
Skinner, W. A., *see* Johnson, H., 693
Slaunwhite, W. D., and Solo, A. J., improved synthesis of 18-hydroxydeoxycorticosterone, 168
Sloan, K. B., *see* Repta, A. J., 392
Smith, A. P., *see* Honigberg, I. L., 1201, 1389
Smith, F. M., *see* Hartman, A. W , 802
Smith, J., *see* Cammarata, A., 1325
Smith, N. L., *see* Hong, H. S. C., 860, 2007
Smith, R. N., Hansch, C., and Ames, M. M., selection of a reference partitioning system for drug design work, 599
Smith, R. V., and Rosazza, J. P., microbial models of mammalian metabolism, 1737
Smith, S. J., *see* French, W. N., 125, 1545
Smith, W. E., *see* Malinowski, H. J., 1688
Smolen, V. F., Park, C. S., and Williams, E. J., drug–biomolecule interactions: bioelectrometric study of the mechanism of carbachol interactions with the cornea and its relation to miotic activity, 520
Smolenski, S. J., *see* Falk, A. J., 1838
Soda, D. M., and Levy, G., inhibition of drug metabolism by hydroxylated metabolites: cross-inhibition and specificity, 1928
Sofia, R. D., Diamantis, W., and Ludwig, B. J., comparative anti-inflammatory, analgesic, and antipyretic activities of 7-chloro-3,3a-dihydro-2-methyl-2*H*,9*H*-isoxazolo-(3,2-*b*)(1,3)-benzoxazin-9-one and 5-chlorosalicylic acid in rats, 1321
Solne, T. O., Hanley, W. S., Shaath, N. A., and Genenah, A. A., stereochemical preferences for curarimimetic neuromuscular junction blockade III: enantiomeric bisquaternary amines related to benzoquinonium as probes, 67
——*see* El-Antably, S. M., 1423
——*see* Erhardt, P. W., 53
——*see* Genenah, A. A., 62
Sokoloski, T. D., and Hoener, B., determination of protein binding parameters in systems involving interaction between sites, 1892
Soldati, G., new compounds: addition products of heterocyclic chalcones, 355
Solo, A., J., *see* Slaunwhite, W. D., 168
Soloway, B., *see* Warner, V. C., 1563
Sondack, D. L., determination of sorbitol and mannitol in pharmaceuticals by GLC of tris-*n*-butyldiboronate esters, 128
Speaker, T. J., *see* Billow, J. A., 862
——*see* Doukas, P. H., 158
Speck, W. T., *see* Wlodkowski, T. J., 1235
Spitznagle, L. A., *see* Eng, R., 1068
——*see* McKamey, M. R., 1456
Staiger, D. B., Warren, R. J., Zarembo, J. E., and Post, A., NMR spectroscopic analysis of 2-mercapto-5-methyl-1,3,4-thiadiazole in cefazolin, 1396
Staroscik, J., *see* Sadée, W., 998
Steenberg, M., *see* Lemke, T. L., 1375
Steiger, E., *see* Tsou, K. C., 1418
Stella, V. J., nonclassical phase transfer behavior of phenylbutazone, 706
——*see* Haddadin, M. J., 1759, 1766
——*see* Okada, H., 1665
Steller, E. E., *see* Hansch, C., 1186
Steltenkamp, R. J., *see* Hong, H. S. C., 860, 2007
Stenberg, V. I., *see* Chaturvedi, A. K., 454
——*see* Parmar, S. S., 154
Stevens, M. R., GLC analysis of caffeine and codeine phosphate in pharmaceutical preparations, 1686
Stewart, J. M., *see* Doyle, T. D., 1525
Stewart, J. T., and Gammans, R. E., synthesis and biological evaluation of 2-(9-acridinyl)ethyl-*N*-substituted carbamates and their hydrochlorides and 10-*N*-oxides, 1061
——and Settle, D. A., colorimetric determination of isoniazid with 9-chloroacridine, 1403
——*see* Honigberg, I. L., 1201, 1389
——*see* Jun, H. W., 1843
Stoel, L. J., Newman, E. C., Asleson, G. L., and Frank, C. W., preparation, isolation, and identification of 4-dedimethylamino-11-methoxyanhydrotetracycline, 1635
Stohs, S. J., *see* El-Olemy, M. M., 161, 163
Streng, W. H., *see* Zoglio, M. A., 1381, 1869
Strömberg, S., *see* Vessman, J., 311
Strum, J. D., *see* Jaffe, J. M., 2028
Stubbins, J. F., *see* Hudgins, P. M., 1419
Sugita, E. T., *see* Niebergall, P. J., 1721
Sullivan, H. R., *see* Nash, J. F., 429
Sullivan, T. J., Sakmar, E., Albert, K. S., Blair, D. C., and Wagner, J. G., *in vitro* and *in vivo* availability of commercial prednisone tablets, 1723
Sumner, D., *see* Cressman, W. A., 1965
Sur, R. N., *see* Kar, K., 258
Suzuki, T., Ohkuma, T., Rikihisa, T., and Isozaki, S., improved method for sampling hepatic venous blood in the rat, 895
Svoboda, G. H., *see* Tafur, S., 1953

T

Tafur, S., Jones, W. E., Dorman, D. E., Logsdon, E. E., and Svoboda, G. H., alkaloids of *Vinca rosea* L. (*Catharanthus roseus* G. Don) XXXVI: isolation and characterization of new dimeric alkaloids, 1953
Taha, A., *see* Gomaa, C., 1398
Takai, H., *see* Hasegawa, M., 1732
Takimoto, G. S., *see* Schaeffer, J. C., 1462
Tan, H. S. I., and Beiser, C., rapid fluorometric determination of procainamide hydrochloride dosage forms, 1207
Tanaka, F., *see* Nakamori, R., 1071
Tanaka, I., *see* Washitake, M., 397
Tanner, N. S., *see* Wolters, R. J., 2013
Tanrikut, Y., *see* Rao, K. V., 345
Tansy, M. F., Innes, D. L., Martin, J. S., and Kendall, F. M., technique for assessment of local effects of substances found in bile upon opening pressure of choledochoduodenal junction, 1174
Tao, F. T., *see* Bayne, W. F., 288
Tawashi, R., *see* Bisaillon, S., 458
Tawfik, A. S., *see* Eldawy, M. A., 1221
Tay, L. K., and Sinsheimer, J. E., intestinal bacterial reduction of 4,4′-dihydroxystilbene to 4,4′-dihydroxybibenzyl, 471
Taylor, E. H., *see* Lin, S.-K., 2021
Taylor, P., drug–biomolecule interactions: mechanism of ligand interactions with carbonic anhydrase studied by magnetic resonance relaxation and rapid reaction methods, 501
Taylor, W. G., *see* Dimmock, J. R., 241
Thayer, P. S., *see* Pettit, G. R., 2023
Theeuwes, F., elementary osmotic pump, 1987
Thio, P. A., *see* Kornet, M. J., 639
Thomas, B. H., *see* Whitehouse, L. W., 819
Thomas, R. C., and Harpootlian, H., metabolism of minoxidil, a new hypotensive agent II: biotransformation following oral administration to rats, dogs, and monkeys, 1366
——Hsi, R. S. P., Harpootlian, H., and Judy, R. W., metabolism of minoxidil, a new hypotensive agent I: absorption, distribution, and excretion following administration to rats, dogs, and monkeys, 1360
Thompkins, L., and Lee, K. H., comparison of analgesic effects of isosteric variations of salicylic acid and aspirin (acetylsalicylic acid), 760
Thompson, G. R., and Cunningham, A., versatile unit for filling gelatin capsules with drugs or chemicals, 320
Thompson, R. D., and Hoffmann, T. J., determination of mercury-containing pharmaceuticals by vapor phase atomic absorption spectroscopy, 1863
Thompson, R. S., *see* Doukas, P. H., 158
Tilton, R., *see* Nightingale, C. H., 712
Tin-Wa, M., Crane, F. A., Baines, R., and Farnsworth, N. R., germination and morphine content of *Papaver somniferum* plants produced from commercially available poppy seed, 2024
——*see* Lin, S.-K., 2021
——*see* Marks, W. H., 1674
——*see* Weiss, S. G., 95
Tocco, D. J., deLuna, F. A., and Duncan, A. E. W., electron-capture GLC determination of timolol in human plasma and urine, 1879
Tomlinson, E., *see* Mukhayer, G. I., 147
Torrance, S. J., Wiedhopf, R. M., and Cole, J. R., ambrosin, tumor inhibitory agent from *Hymenoclea salsola* (Asteraceae), 887
Tostowaryk, W., *see* Lovering, E. G., 1521
Tozer, T. N., *see* Gonzalez, M. A., 99
Traxler, J. S., Moats, M. J., Lira, E. P., and Huffman, C. W., antimalarial amino alcohols II: anthraceneaminoethanols and anthraceneaminopropanols (1- and 9-substituted), 1943
Trieff, N. M., *see* Alam, M., 865
Triyanond, K., *see* Mufson, D., 362
Tsia, A.-Y. S., *see* Parekh, K. B., 875
Tsou, K. C., Ledis, S., Steiger, E., and Nietrzeba, R., facile preparation of 6-chloro-9-amino-2-hydroxyacridine, a urinary metabolite of quinacrine and quinacrine mustard, 1418
Tsuji, K., and Robertson, J. H., high-performance liquid chromatographic analysis of ampicillin, 1542
Tucker, F. E., *see* Borodkin, S., 1289
Turesky, S. S., *see* Warner, V. D., 1563
Turi, J. S., Higuchi, W. I., Ho, N. F. H., and Shipman, C., Jr., systems approach to study of solute transport across membranes using suspension cultures of mammalian cells IV: uptake and release kinetics of sterols, 627
——Ho, N. F. H., Higuchi, W. I., and Shipman, C., Jr., systems approach to study of solute transport across membranes using suspension cultures of mammalian cells V: uptake and release kinetics of cardiac glycosides by Burkitt lymphoma cells, 631
——Ho, N. F. H., Higuchi, W. I., and Shipman, C., Jr., systems approach to study of solute transport across membranes using suspension cultures of mammalian cells III: steady-state diffusion models, 622
Turi, P., *see* Maulding, H. V., 1833
Turner, C. E., and Henry, J. T., constituents of *Cannabis sativa* L. IX: stability of synthetic and naturally occurring cannabinoids in chloroform, 357
——Hadley, K. W., Holley, J. H., Billets, S., and Mole, M. L., Jr., constituents of *Cannabis sativa* L. VIII: possible biological application of a new method to separate cannabidiol and cannabichromene, 810
——*see* Holley, J. H., 892
Turner, W. A., *see* Dimmock, J. R., 995

U

Upton, R. A., simple and reliable method for serial sampling of blood from rats, 112

V

Vaidhyanathan, V. S., hydrodynamic analog model for pharmacokinetics II: critical examination of model and its contribution to pharmacokinetics, 92
——hydrodynamic analog model for pharmacokinetics I: model and its usefulness, 88
Valenzuela, M. A., *see* Harris, P. A., 1574
Vallner, J. J., *see* Perrin, J. H., 1508
VandenHeuvel, W. J. A., Gruber, V. F., Walker, R.

W., and Wolf, F. J., GLC analysis of hydrochlorothiazide in blood and plasma, 1309
VanGiessen, G. J., and Kaiser, D. G., GLC determination of ibuprofen [*dl*-2-(*p*-isobutylphenyl)propionic acid] enantiomers in biological specimens, 798
Varma, R. S., and Nobles, W. L., antiviral, antibacterial, and antifungal activities of isatin *N*-Mannich bases, 881
Veltman, A. M., *see* Moskalyk, R. E., 1406
Venkatakrishna-Bhatt, H., pithed rat blood pressure in the assay of norepinephrine, 1733
Veresh, S. A., *see* Hom, F. S., 851
Verić, M., *see* Pečar, M., 970
Verma, M., *see* Chaudhari, S. K., 614
Vessman, J., and Strömberg, S., GLC determination of nicotinamide in multivitamin formulations after conversion to nicotinonitrile, 311
Vilallonga, F. A., drug–biomolecule interactions: mechanisms and kinetics of interactions of biomolecules at interfaces, 477
——*see* Garrett, E. R., 1782
Vincek, W. C., *see* Zoglio, M. A., 1381
Viswanathan, V., *see* Ratchik, E. M., 133

W

Wagner, J. G., *see* Sullivan, T. J., 1723
Walker, R. W., *see* VandenHeuvel, W. J. A., 1309
Wan, L. S. C., effects of acids and bases on salicylic acid–cetrimide systems, 1037
Warner, V. D., Musto, J. D., Turesky, S. S., and Soloway, B., synthesis and *in vitro* evaluation of 8-hydroxyquinolines as dental plaque inhibitors, 1563
Warren, R. J., *see* Staiger, D. B., 1396
Washitake, M., Anmo, T., Tanaka, I., Arita, T., and Nakano, M., percutaneous absorption of drugs IV: percutaneous absorption of drugs from oily vehicles, 397
Weidner, L., *see* Zacchei, A. G., 814
Weiss, S. G., Tin-Wa, M., Perdue, R. E., Jr., and Farnsworth, N. R., potential anticancer agents II: antitumor and cytotoxic lignans from *Linum album* (Linaceae), 95
Welborn, M. E., *see* Borchard, R. E., 1294
Wellky, I., *see* Kripalani, K. J., 1351
Welling, P. G., dose adjustment in renal failure, 175
——*see* Dobrinska, M. R., 1728
Wells, C. E., *see* Page, D. P., 140
Westlake, W. J., demonstration of claimed "controlled-release" properties of a drug formulation, 1075
Whitaker, D. M., and Carlson, G. P., anti-inflammation mechanism of extract from *Eisenia bicyclis* (Kjellman) Setchell, 1258
White, J. L., and Hem, S. L., role of carbonate in aluminum hydroxide gel established by Raman and IR analyses, 468
——*see* Kerkhof, N. J., 940, 2030
——*see* Nail, S. L., 1166
White, K., *see* Eng, R., 1068
Whitehouse, L. W., Paul, C. J., and Thomas, B. H., effect of aspirin on fate of ^{14}C-acetaminophen in guinea pigs, 819
Whitworth, C. W., and Anker, A. F., stability of aspirin in liquid and semisolid bases V: polyglycerol esters, 2018
Wiedhopf, R. M., *see* Jolad, S. D., 1889
——*see* Torrance, S. J., 887
Wiekhorst, W. B., *see* Borchard, R. E., 1294
Wilen, G., *see* Ylitalo, P., 1264
Willekens, G. J., separation and quantitative determination of impurities in tetracycline, 1681
Willett, N. P., *see* Cammarata, A., 1325
Williams, E. J., *see* Smolen, V. F., 520
Williams, R. G., *see* Morozowich, W., 313
Willis, E., *see* DeGraw, J. I., 1700
Wilson, D. W., *see* Borchard, R. E., 1294
Wilson, W. L., *see* Butterfield, A. G., 316
Wiseman, E. H., McIlhenny, H. M., and Bettis, J. W., flumizole, a new nonsteroidal anti-inflammatory agent, 1469
Witty, T. R., Remers, W. A., and Besch, H. R., Jr., cardiotonic steroids II: 3-deoxycardenolides and 3-deoxycardanolides, 1248
Wlodkowski, T. J., Speck, W. T., and Rosenkraz, H. S., genetic effects of povidone-iodine, 1235
Wolf, F. J., *see* VandenHeuvel, W. J. A., 1309
Wolo, M. T., *see* Lee, K.-H., 1572
Wolters, R. J., Boj, A. J., and Tanner, N. S., conformationally constrained analogs of mescaline II, 2013
Wong, C. K, *see* Molins, D., 123
Wong, K. K., *see* Dreyfuss, J., 1604
Wood, N. F., GLC analysis of metronidazole in human plasma, 1048
Wood, R. J., *see* French, W. N., 125
Woodland, J. H. R., *see* Yolles, S., 348
Woolley, J. L., *see* Sigel, C. W., 973
Wormser, H. C., and Abramson, H. N., synthesis of *dl*-4ξ-(4-carboxybutyl)-5-carbethoxy-*cis*-hexahydropyrrolo[3,4-*d*]imidazol-2-one (*N*-carbethoxyazabiotin), 1514
——and Abramson, H. N., synthesis of *dl*-4ξ-(2-carboxyethyl)-*cis*-hexahydropyrrolo[3,4-*d*]imidazol-2-one (bisnorazabiotin), 1882
Wu, C. C., *see* Harner, M., 1961

X

Y

Yacobi, A., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats, 1660
——Lai, C.-M., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XV: relationship between pharmacokinetics of dicumarol and warfarin in rats, 1995
Yakatan, G. J., *see* Maness, D. D., 651
Yalkowsky, S. H., Amidon, G. L., Zografi, G., and Flynn, G. L., solubility of nonelectrolytes in polar solvents III: alkyl *p*-aminobenzoates in polar and mixed solvents, 48
——*see* Sinkula, A. A., 181
Yamamoto, T., *see* Naito, S.-I., 253
Yata, N., *see* Okada, H., 1665
Yazdany, S., *see* Afghahi, F., 858
Yeh, K. C., *see* Kwan, K. C., 1639
Yeh, S. Y., and McQuinn, R. L., GLC determination of heroin and its metabolites in human urine, 1237
——*see* Cone, E. J., 618
Ylitalo, P., Wilen, G., and Lundell, S., bioavailability of digoxin tablets in relation to their dissolution *in vitro*, 1264
Yolles, S., Leafe, T. D., and Meyer, F. J., timed-release depot for anticancer agents, 115
——Leafe, T. D., Woodland, J. H. R., and Meyer, F. J., long acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composites, 348
Yonan, P. K., *see* Chien, Y. W., 1632
York, P., application of powder failure testing equipment in assessing effect of glidants on flowability of cohesive pharmaceutical powders, 1216
Yoshino, H., *see* Nakamori, R., 1071
Yotsuyanagi, T., Molokhia, A., Hwang, S., Ho, N. F. H., Flynn, G. L., and Higuchi, W. I., systems approach to vaginal delivery of drugs I: development of *in situ* vaginal drug absorption procedure, 71

Z

Zacchei, A. G., and Weidner, L., electron-capture GLC determination of a new antiarrhythmic agent, α,α-dimethyl-4-($\alpha,\alpha,\beta,\beta$-tetrafluorophenethyl)benzylamine, in biological fluids, 814
Zakhari, N. A., *see* Soliman, S. A., 129
Zarembo, J. E., *see* Staiger, D. B., 1396
Zarrindast, M. R., *see* Lalezari, I., 1250
Zatz, J. L., contact angles on human skin, 1080
——and Cleary, G. W., molecular arrangement in monolayers containing cholesterol and dipalmitoyl lecithin, 1534
Zee-Cheng, K. Y., *see* Cho, M. J., 1825
Zia, H., and Price, J. C., binding study of sulfonylureas and phenothiazines to bovine serum albumin using difference spectrophotometry, 1177
Ziegler, H. W., Anderson, W. L., and Shade, J. T., automated method for determining calcium disodium edetate in iodinated contrast media parenterals, 1026
Zirvi, K. A., Dar, M. S., and Fakouhi, T., biochemorphology of cyclobutanecarbonylureas, 649
Zoglio, M. A., Maulding, H. V., Streng, W. H., and Vincek, W. C., nonisothermal kinetic studies III: rapid nonisothermal–isothermal method for stability prediction, 1381
——Streng, W. H., and Carstensen, J. T., diffusion model for fluidized-bed drying, 1869
Zografi, G., *see* Yalkowsky, S. H., 48

A

Abortifacients—plants with active constituents, review, 535, 717

Absorption—11 cephalosporin antibiotic derivatives, pharmacokinetics, clinical considerations, review, 1899

—digoxin, effect of antacid, dogs, 1727

—digoxin oral preparations, intersubject variations, 433

drug—effect of surfactant (dioctyl sodium sulfosuccinate) on phenolsulfonphthalein, humans, 991

drug—influence of mesenteric blood flow on intestinal absorption of sulfaethidole and haloperidol, *in situ* canine intestinal preparation, 664

drug—*in situ* vaginal procedure, equipment and equations, rabbits, 71

—effects of dioctyl sodium sulfosuccinate and poloxamer 188, rats, 987

intestinal—salicylic acid, sulfapyridine, and prednisolone, effects of normal alcohols, rats, 1450

—intestinal, tetracycline from bile and aqueous solutions, rats, 1847

intestinal—theophylline, concentration dependence of ethanol, rats, 897

kinetics—metrizamide from cerebrospinal fluid, humans, 405

kinetics, micronized griseofulvin—corn oil-in-water emulsion compared to aqueous suspension, single and multiple doses, rats, 1475

—^{14}C-labeled minoxidil after oral and intravenous administration, rats, dogs, and monkeys, 1360

—lidocaine hydrochloride from subcutaneous site, design of closed subcutaneous absorption cell, effect of pH changes, 781

—nafiverine, intramuscular, intravenous, and oral administrations, rats, rabbits, and mice, 253

—nitrofurantoin, effect of propantheline, 1729

percutaneous—review of *in vitro* and *in vivo* penetration methods, skin transport, physicochemical factors, sorption promoters, 901

percutaneous—salicylic acid and carbinoxamine from oily vehicles, intact and damaged skin, 397

rectal—effect of particle size on aspirin absorption from suppositories, 878

—theophylline, effect of ethanol, humans, 299

—triamcinolone acetonide-^{14}C-21-phosphate after intravenous and intramuscular administration, dog, monkey, and rat, 1351

Abuse drugs—systematic identification, spot tests, flow chart, 841

Acacia—viscosity changes after sterilization by cobalt-60, 802

***p*-Acetamidophenyl acetate** and dodecanoate—acetaminophen blood concentration following oral administration with pancreatic lipase, dogs, 1489

Acetaminophen—analysis in dosage forms, serum, and urine, high-performance liquid chromatography with electrochemical detection, 680

aspirin, and salicylamide mixtures—differentiating nonaqueous titration, 1386

—blood concentration profiles after oral administration of *p*-acetamidophenyl acetate and dodecanoate with pancreatic lipase, dogs, 1489

—estimation of hepatic first-pass effect, oral administration, humans, 1734

—fatty acid esters, hydrolysis in buffered pancreatic lipase systems, 117

radiolabeled—metabolism, effect of aspirin pretreatment, guinea pigs, 819

Acetaminophen–dichloralantipyrine—spectrophotometric analysis of capsule formulation, 1547

Acetazolamide—high-pressure liquid chromatographic analysis in plasma, 402

2-Acetoxycyclopropanecarboxylic acid esters—synthesis from 2-carbalkoxycyclopropyl methyl ketones, Baeyer–Villiger reaction, retention of stereochemistry, 1059

17-Acetylajmaline—*in vitro* hydrolysis, relationship to hydrolysis of 17-chloroacetylajmaline, different animal species, 1561

***N*-Acetyl-*p*-aminophenol**—direct colorimetric analysis, decomposition product interference examined, 466

Acetylcholine and acetylcholine mustard—hydrolysis by eel electroplax acetylcholinesterase, 1419

Acetylcholinesterase—anionic binding studied, receptor mapping using model interaction calculations, role of coulombic forces, 418

—binding of substrate and inhibitors, NMR, 488

—hydrolysis of acetylcholine and acetylcholine mustard, 1419

6′-Acetylpapaverine—kinetics of formation from coralynium ion, cyclization, 1825

Achillea millefolium—chromatographic isolation and spectral identification of flavone components, 1838

Acid reactivity—effects of dilution on aluminum hydroxide gel, 940

Acridine derivatives—confirmation of iminoacridan structure of singly protonated 9-aminoacridine, 1256

2-(9-Acridinyl)ethyl-*N*-substituted carbamates, hydrochlorides, and 10-*N*-oxides—synthesis, pharmacological activity, 1061

Actinomycetes—structural transformation of aspidospermine, UV, IR, and NMR spectral identification of conversion products, 2021

Acylation—ascorbic acid in water using acetic anhydride, kinetics and products *via* hydrolysis and rearrangement, 1300

—phenol by cyclic and acyclic anhydrides in anhydrous acetic acid, rate constants, mechanisms, 1766

—reversible reactions of cyclic anhydrides in anhydrous acetic acid, rate constants, mechanisms, 1759

Adenosine monophosphate—activity mimicked by 8-(methylthio)cyclic 3′,5′-adenosine monophosphate, metabolism of analog *in vivo* and *in vitro*, 1604

Adhesion—polymer films to tablet substrates, peel strength, effect of surface roughness and coating solvent, 1554

Adrenergic agents—atenolol, GLC analysis, biological samples, 1992

—timolol, extraction, derivatization, GLC analysis biological fluids, 1879

Adrenergic blocking agents, potential—synthesis and screening of 2-substituted aminomethylnaphtho(2,3-*b*)-1,4-dioxans, 875

Adriamycin—reduction of bone marrow toxicity, aortic occlusion, rabbits, 1574

Adsorption—diphenoxylate hydrochloride on charcoal and chromium oxide, pH 4 and 7, Langmuir isotherms, 1877

Aerosols—development and evaluation of dexamethasone timed-release formulation, 408

fluorocarbon propellants—interspecies differences in blood and plasma solubilities, toxicity implications, 1538

—pharmacokinetics of trichloromonofluoromethane following single and multiple doses, dogs, 763

Age—effect on binding of drugs to plasma proteins, human subjects, 1711

Aggregations, mononuclear—mixed nucleosides, dilute aqueous solutions, osmometric measurements, theoretical considerations, 770

Aging—effect on physical properties of phenylbutazone tablets, 335

Agroclavine—conversion to setoclavine and isosetoclavine, cell-free extracts from *Claviceps* sp. SD 58 and thioglycolate–iron (II), 343

Ahnfeltia concinna—isolation of carrageenan, IR identification, 1704

Ajmaline and 17-monochloroacetylajmaline—TLC determination in plasma, 643

Albumin, human and bovine serum—binding of three aminonaphthalenesulfonic acid derivatives, fluorescence enhancement, 493

human serum—intrinsic and extrinsic optical activity as a purity criterion, circular dichroism compared to other techniques, 1508

Alcohols—effect on intestinal net water flux and theophylline absorption in rats, 607

normal—effects on intestinal absorption of salicylic acid, sulfapyridine, and prednisolone, rats, 1450

—solvolysis of hydrochloride salts of diethylaminodibenzo[*a,d*]cycloheptene and related amino congeners, rate constants, 437

Alga—IR identification of carrageenan isolated from *Ahnfeltia concinna*, 1704

Alkaloids, antimicrobial—isolation and identification of dehydroglaucine and liriodenine from heartwood of *Liriodendron tulipifera*, 789

—isolation of three from *Catharanthus roseus*, characterization by UV, IR, NMR, and mass spectra, 1953

opium—isolation and identification of (−)-stepholidine, 1040

—structural transformation by actinomycetes, UV, IR, and NMR spectral identification of conversion products, 2021

Vinca species, structure elucidation of herbadine, 341

Alkyl *p*-aminobenzoates—solubility in polar and mixed solvents, equation developed for predicting solubility, 48

Alkylation—by secondary alcohols, fusion of medicinal sulfanilamides with benzhydrol, effect of reaction temperature, 292

4-Alkylbenzoic acids, branched—synthesis *via* β-mono- or β,β-disubstituted styrene-4-carboxylic acids, potential fibrinolytic agents, 1170

Alkylthiocolchicines and *N*-deacetyl-alkylthiocolchicines—synthesized from colchicine, antileukemic activity, 646

Allyl alcohols from styryl ketones and related Mannich bases—antitumor evaluation, 241

Allylglycine (2-amino-4-pentenoic acid)—effect of intraperitoneal and intraventricular administration on hypothermic response in rats, 835

Aluminum and magnesium hydroxides suspension—effect on urine pH

hydroxide gel—effect of dilution on reactivity and structure, 940

hydroxide gel—monitoring of structural changes during aging, IR and X-ray diffraction methods compared, relationship to decreased acid reactivity, 1166

hydroxide gel—role of carbonate, Raman and IR analyses, 468

hydroxide gel—vehicles for stabilization, 2030

Ambrosin—tumor inhibitory agent from *Hymenoclea salsola*, isolation and identification, 887

Amines, enantiomeric bisquaternary, related to benzoquinonium—probes for determining stereochemical preferences for curarimimetic neuromuscular junction blockade, 67

enantiomeric monoquaternary—as probes for determination of stereochemical preferences for curarimimetic neuromuscular junction blockade, 53

impurities in water-soluble radiopaques—automated determination, 684

Amino acids esters of phenolic drugs—use as prodrugs, 1070

free—content of Ascomycetes and Fungi Imperfecti determined, 176

polybasic—interactions with mononucleotides, 473

supplementation—effect of added lysine and tryptophan on human plasma cholesterol and triglyceride levels, 691
supplementation—effect of added lysine on rat serum cholesterol levels, 690
9-Aminoacridine—singly protonated, confirmation of iminoacridan structure, 1256
Amino alcohols—synthesis of substituted 1- and 9-anthraceneaminoethanols and aminopropanols, 1943
4-Aminoantipyrine—dye formation for hexachlorophene colorimetric determination, modifications to overcome interferences, 125
***p*-Aminobenzoates,** alkyl—solubility in polar and mixed solvents, equation developed for predicting solubility, 48
5-Aminodibenzo[*a,d*]cycloheptenes—alcoholic solvolysis, rate constants, 437
3-Amino-2-imino-1,3-benzothiazin-4-ones—synthesized and screened as CNS agents, 1425
Aminomethylnaphtho(2,3-*b*)-1,4-dioxans, 2-substituted—synthesized and screened as potential adrenergic blocking agents, 875
3-Amino-3-methyloxindoles—synthesis, antiarrhythmic activity, compared to lidocaine, 639
Aminonaphthalenesulfonic acid derivatives—binding to human and bovine serum albumins, fluorescence enhancement, 493
***p*-Aminophenol**—determination of trace amounts in acetaminophen preparations, high-performance liquid chromatography with electrochemical detection, 680
4-Aminoquinoline compounds—synthesized and screened for antimalarial activity, 460
Aminosalicylic acid—decomposition in the solid state, first-order decomposition patterns, 37
Aminosidine—kinetics and mechanisms of action, microorganisms, with and without pretreatment, 1936
Amino sugar, decomposed—active antitumor components, effect of sugar structure on activity, 295
Amitriptyline hydrochloride—identification of decomposition products, aqueous solution, mechanisms, 1497
Amorphous solids—preparation, characterization, and pharmaceutical application, review, 1269
Amphetamines, *N*-substituted—inhibition of synaptosomal accumulation of *l*-norepinephrine, 1462
Ampicillin—crystalline modificatic s, physicochemical properties, 710
—high-pressure liquid chromatographic analysis, 1542
Analgesic activity—7-chloro-3,3a-dihydro-2-methyl -2*H*,9*H*- isoxazolo-(3,2-*b*)(1,3)- benzoxazin-9-one and 5-chlorosalicylic acid compared in rats, 1321
Analgesics—comparison of effects of isosteric variations of salicylic acid and aspirin, 760
Anesthesia—gaseous, thermodynamics of equilibrium process, evaluation of Ferguson principle, mice, 2025
Anesthetics—effects on membrane lipids, electron spin resonance spectra, 497
local—activity of procaine hydrochloride, lidocaine hydrochloride, tetracaine hydrochloride, and dibucaine hydrochloride in producing goldfish overturn, structure–activity relationships, 1713
local—benzocaine, absorption from ointments, rectal administration, rats, 1958
nonspecific local—correlation between molecular connectivity and polarization, cavity surface areas, and biological potencies, 1971
topical—effect on tear production and solution drainage, ophthalmic drug bioavailability evaluated, rabbits, 267
Anhydrides, cyclic and acyclic—acylation of phenol in anhydrous acetic acid, rate constants, mechanisms, 1766
cyclic—solvolytic reactions in anhydrous acetic acid, rate constants, mechanisms, 1759
2,2′-Anhydro-1-β-D-arabinofuranosylcytosine—hydrogen peroxide-induced transformation, compared to cytarabine reaction, 424
1-Anilinonaphthalene-8-sulfonate—discussion of binding parameters, 1892
Animal models for bioavailability testing—intestinal pH as factor for model selection, *in situ* determination in rats, dogs, and rabbits, 1726
Antacids—effect on absorption of digoxin, dogs, 1727
—magnesium and aluminum hydroxides suspension, effect on urine pH, 2003
suspensions, concentrated—fluidized by addition of colloidal polyelectrolyte, viscosity correlated with ζ-potential, electrophoretic and viscometric measurements, 1697
—vehicles for stabilizing aluminum hydroxide gel, 2030
Anthraceneaminoethanols and aminopropanols—synthesis from anthraquinones or anthraldehydes, 1943
Antiandrogens—effect of cyproterone acetate on uterine motility, rats, 452
Antianxiety–antispasmodic agents—high-pressure liquid chromatographic analysis, method parameters, 1389
Antiarrhythmic activity—3-amino-3-methyloxindoles synthesized and screened, 639
activity—*in vitro* hydrolysis of 17-chloroacetylajmaline and 17-acetylajmaline, different animal species, 1561
agents—electron-capture GLC determination of α,α-dimethyl-4-(α,α,β,β-tetrafluorophenethyl)benzylamine in biological fluids, 814
Antibacterial activity—commonly used drugs tested against human intestinal anaerobic bacteria *in vitro*, 700
activity—evaluation of *N*-phenyl-*N*′-cyano-*S*-(triphenylstannyl)isothiourea, 1259
activity—glutaraldehyde free aldehyde content determined by ^{13}C-NMR, 1078
activity—8-hydroxyquinoline analogs, 1563
activity—sulfonic acid derivatives and thioether reaction products of 1-substituted azulenes with thionyl chloride, 862
activity—synthesis and screening of salicylic and thiosalicylic acid derivatives as precursors of macrocyclic oxa- and thia-substituted benzolactones and benzoketones, 1240
and antifungal activities—5-nitro-2-furfurylidene polyhalophenoxyacethydrazides, 858
and antifungal activities—synthesis and screening of isatin *N*-Mannich bases, 881
Antibiotics, acid labile—oral absorption efficiency of penicillin G potassium, penicillin V potassium, and erythromycin lactobionate from cholesterol, cholesteryl acetate, and β-sitosterol protective carriers, 869
—aminosidine, kinetics and mechanisms of action, microorganisms, with and without pretreatment, 1936
—automated system for analytical microbiology, calibration lines, 844
biosynthesis, cyclic octapeptide—colorimetric monitoring in fermentation broths, ion-pair formation with bromthymol blue, 1401
—11 cephalosporin derivatives, pharmacokinetics, absorption, metabolism, excretion, clinical considerations, review, 1899
combinations—effect of lincomycin and clindamycin combinations on *Staph. aureus* and *E. coli*, 1621
—epicillin and ampicillin, crystalline modifications and physicochemical differences, 710
—microbiological diffusion assay, design and application, 1224
—pharmaceutical aspects, 1085
–steroid ophthalmic preparations—stabilizing effect of inorganic phosphate salts, 1528
Antibodies—lysergide binding, coupled to agarose, isolation of lysergide, 1890
Antibody response, primary—pharmacokinetic model developed, 1325
Anticancer agents—effect of deoxyuridine coadministration on toxicity and antitumor activity of fluorouracil and floxuridine, 943
—poly(lactic acid) time-release formulations of cyclophosphamide and *cis*-dichlorodiammineplatinum (II), 115
potential—isolation and identification of antitumor and cytotoxic lignans from *L. album*, screened for activity, 95
Anticholinergic activity—determination of central *versus* peripheral cholinolytic activity, tertiary and quaternary derivatives of atropine and scopolamine, mice, 1066
Anticoagulants—comparative pharmacokinetics of dicumarol and warfarin, rats, 1995
Anticonvulsants, activity—benzylidinohydrazines, 154
activity—substituted benzthiazoles, relationship to monoamine oxidase inhibitory activity, mice, 1245
activity—synthesis and screening of 2-(*N*-arylcarboxamide)-3-substituted ethoxyindoles, mice, 1001
activity, thiazolidones—relationship to inhibition of NAD-dependent oxidations, 614
—carbamazepine derivative, GLC analysis, plasma and urine, 1940
—GLC analysis of carbamazepine in whole blood, 2004
Antidepressants—decomposition of amitriptyline hydrochloride in aqueous solution, identification of products, mechanisms, 1497
Antidermatophytic activity—2-thiotetrahydro-1,3,5-thiadiazines and isothiocyanates, 164
Antiemetic effect—carbohydrate–phosphoric acid solutions, 1504
Antiestrogens, potential—synthesis of cyclopropyl analogs of stilbene and stilbenediol, 1626
Antifertility agents—review of plant sources, classified by anatomical mechanism and folkloric route of administration, 535, 717
Antifungal activity—synthesis of six and evaluation of 11 *N*-substituted *N*′-cyano-*S*-(triorganostannyl)isothioureas, 1259
agents—synthesis and testing of alkyl esters of polyene antibiotics, 462
and antibacterial activities—5-nitro-2-furfurylidene polyhalophenoxyacethydrazides, 858
Antigens—distribution and clearance, pharmacokinetic model described for primary antibody response, 1325
Antihemolytic activity—thiosemicarbazides synthesized and tested, 1329
Antihistaminic, anticholinergic, and norepinephrine-potentiating activities—synthesis and screening of 5-substituted 2-(*N*,*N*-dialkylaminoethyl)amino- and 2-*N*-methylpiperazinyl-1,3,4-thiadiazoles, 1250
Antihypertensive activity—synthesis and screening of 2-diethylaminoethanol benzylic ethers and related diamine, 1423
–diuretic mixtures—high-pressure liquid chromatographic separation, effect of solvent composition, pH, and stationary phase polarity, 1201
Anti-inflammatory activity—7-chloro-3,3a-dihydro-2-methyl -2*H*,9*H*- isoxazolo-(3,2-*b*)(1,3)-benzoxazin-9-one and 5-chlorosalicylic acid compared in rats, 1321
activity—*Eisenia bicyclis* extract, lysosomal stabilization, 1258
agents—2,3-bis(*p*-methoxyphenyl)imidazo[1,2-*a*]pyrimidine, fluorometric analysis, biological materials, 2011
agents—flumizole (nonsteroid) activity, bioavailability, and formulation, 1469
Antileukemic activity—chloroethyltriazene, 177
activity—synthesis and screening of alkylthiocolchicines and *N*-deacetyl-alkylthiocolchicines, 646
activity—triazenylimidazolecarbonitriles screened, 954
agents—5-azacytidine, kinetics and mechanisms of degradation in aqueous solutions, 1148
Antimalarials, activity—(4-quinolinoamino)aminoalkyltetrahydronaphthalene derivatives, 460
agents, potential—syntheses of methyl- and phenylglutamic acids, 1855
agents, potential—synthesis, screening of heterocyclic alkyl disulfides, thiosulfates, dithio

acid derivatives, 211
potential—synthesis and screening of 2-pyridyl-α-toluenesulfonates, 1961
Antimicrobials, activity—comparison of clindamycin on *Staphylococcus aureus* and *Escherichia coli*, 1612
activity—dehydroglaucine and liriodenine, isolated and identified from *Liriodendron tulipifera*, 789
activity—screening of diastereoisomeric 2-dimethylaminomethyl-6-phenylcyclohexanols and esters, 995
—3,6-diaminoacridine derivatives, electronic spectra and electronic structures, 982
Antineoplastic agents—hydrogen peroxide-induced transformation of 2,2′-anhydro-1-β-D-arabinofuranosylcytosine, compared to cytarabine, 424
agents, potential—isolated from *Baileya multiradiata*, biological evaluation, 2023
agents, potential—synthesis and screening of thalidomide and glutarimide derivatives, 262
agents—reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems, comparative pharmacokinetics in dogs, 230
agents—reduction of doxorubicin bone marrow toxicity, aortic occlusion, rabbits, 1574
agents—screening of indolizine derivatives, 249
activity—synthesis and screening of 2-(9-acridinyl)ethyl-*N*-substituted carbamates, hydrochlorides, and 10-*N*-oxides, 1061
Antioxidants—butylated hydroxytoluene, propyl gallate, 356
—effect on epinephrine degradation, kinetics of sulfite-induced anaerobic degradation, 45
Antiplaque activity—8-hydroxyquinoline analogs, 1563
Antipyretic activity—7-chloro-3,3a-dihydro-2-methyl -2*H*,9*H*- isoxazolo-(3,2-*b*)(1,3)- benzoxazin-9-one and 5-chlorosalicylic acid compared in rats, 1321
Antipyrine—biotransformation, effect of 4-hydroxyantipyrine, rats, 1928
Antiradiation compounds—condensations of carbon disulfide with amino, chloro, cyanomethyl, and sulfonamido heterocycles, 1371
Antispasmodic mixtures—high-pressure liquid chromatographic analysis, method parameters, 1389
Antitubercular activity—synthesis and screening of substituted 5-oxo-1-thiocarbamoyl-3-pyrazoline-4-alkanoic acid derivatives, 1057
Antitumor activity—decomposed amino sugar, 295
activity—nuclear-substituted styryl ketones and related Mannich bases and allyl alcohols, 241
activity—six of 22 synthesized sulfamoylphenyltriazenes screened, 698
agents—isolation and identification of ambrosin from *Hymenoclea salsola*, 887
agents, potential—deoxyelephantopin, major constituent of *Elephantopus carolinianus* Willd., 1572
agents, potential—molephantinin, constituent of *Elephantopus mollis* H.S.K., 1077
agents, potential—synthesis and screening of sparsomycin analogs, 825
agents—synthesis and antitumor evaluation of nitrogen analogs of mycophenolic acid, 84
Antitussives—analysis of pholcodine in cough preparations, 1011
Antiviral activity—gossypol and apogossypol, 1073
—synthesis and screening of isatin *N*-Mannich bases, 881
Apogossypol—screened for antiviral activity, 1073
Arabinosyladenine 5′-formate—synthesized as highly water-soluble prodrug, hydrolysis rates in biological fluids, 392
Aristolochic acid—fluorometric and GLC analyses, 345
Artery preparation—preparation of simple isolated perfused artery described, vasoconstrictor evaluation, 170
Aryapavine—isolation, identification from *Papaver pseudo-orientale*, 1570
3-Aryl acrylamides, *N*-substituted—synthesis and pharmacological screening as possible anticancer agents, 825
2-(*N*-Arylcarboxamide)-3-substituted ethoxyindoles—synthesis, monoamine oxidase inhibitory and anticonvulsant activities, 1001
2-(4-Arylthiosemicarbazidocarbonylthio)benzthiazoles—synthesis, characterization, monoamine oxidase inhibitory and anticonvulsant activities, 1245
Asbestosis—review of chemistry, industrial hygiene, animal and human toxicology, and carcinogenic aspects, 1435
Ascorbic acid—acylation by acetic anhydride in water, kinetics and products *via* hydrolysis and rearrangement, 1300
and sodium ascorbate—automated constant-current coulometric assay system, 1229
Aspidospermine—structural transformation (demethylation) by actinomycetes, UV, IR, and NMR spectral identification of conversion products, 2021
Aspirin—absorption from theobroma oil suppositories, effect of particle size, 878
—analgesic effects of isosteric variations, compared to salicylic acid isosteres, 760
—bioavailability from commercial suppositories, humans, 1064
—effect of pretreatment on ^{14}C-acetaminophen metabolism, guinea pigs, 819
mixtures with salicylamide or salicylamide/acetaminophen—differentiating nonaqueous titration, 1386
phenacetin, and caffeine—automated high-pressure liquid chromatographic analysis, 1029
—solubility and stability in polyglycerol esters, effect of temperature, hydroxyl value, viscosity, 2018
Atenolol—GLC analysis, biological samples, 1992
Atomic absorption spectroscopy, vapor phase—determination, mercury-containing pharmaceuticals, compared to compendial methods, 1863
Atropine and scopolamine, tertiary and quaternary derivatives—central *versus* peripheral cholinolytic activity, mice, 1066
Attapulgite clay—sorption of neomycin sulfate, influence of monovalent and divalent electrolytes, Langmuir isotherms, 1566
Automated analysis—calcium disodium edetate in iodinated contrast media parenterals, 1026
—dissolution rates, analysis of data, variability, 1080
—high-pressure liquid chromatographic equipment developed and discussed, 1557
—spectrophotometric assay of cefazolin, stability indicating, double-probe sampling procedure, 1232
—system for analytical microbiology, calibration lines for antibiotics, 844
5-Azacytidine—kinetics and mechanisms of degradation in aqueous solutions, effect of pH, temperature, and buffer concentration, 1148
Azathioprine dihydrate—crystal and molecular structures, 221
Aziridines—2,2-dimethylaziridine-type alkylating agents, reactions in biological systems, comparative pharmacokinetics in dogs, 230
Azulenes, analogs (azulylamides and azulenecarboxamides)—acute toxicity and local anesthetic activity, 158
1-substituted—reaction with thionyl chloride, antibacterial activity of resulting sulfonic acid derivatives and thioesters, 862
Azulylamides and azulenecarboxamides—acute toxicity and local anesthetic activity, 158
Azure C, radiolabeled—tissue distribution, considerations related to use as pancreas or parathyroid scanning agent, 1068

B

Bacitracin—colorimetric analysis in ophthalmic ointments, 307
Bacteriostatic agents—tribromsalan, analysis, blood and urine, TLC, fluorometry, 2007
Baileya multiradiata—six antineoplastic and cytotoxic components, isolated and evaluated, 2023
Barbiturates—IR characterization of hydrogen bonding with polyethylene glycol 4000, 1787
—stability, quantitation by TLC, 272
Benzalkonium chloride—effect on binding of sulfaethidole to bovine serum albumin, 361
Benzhydrol—fusion of medicinal sulfanilamides, alkylation by secondary alcohols, effect of temperature, 292
Benzocaine—absorption from ointments, rectal administration, rats, 1958
Benzodiazepines—fluorescence characteristics in strong acid, 651
—high-pressure liquid chromatographic analysis of triflubazam and its metabolites in human and animal blood and urine, 1339
—hydrolysis of chlordiazepoxide, velocity constants, conversion to lactam, TLC and extraction procedures compared, 278
Benzoic acid and derivatives—solubilization in polysorbate 20 at controlled pH, partition coefficients between aqueous and micellar phases, 1253
Benzoquinonium—related enantiomeric bisquaternary amines as probes for stereochemical preferences for curarimimetic neuromuscular junction blockade, 67
1,3-Benzothiazin-4-ones, 3-amino-2-imino—synthesized and screened as CNS agents, 1425
Benzoyl peroxide—titrimetric, TLC, and spectrophotometric analyses compared, lotions and creams, 1999
Benzylidinohydrazines—synthesis, characterization, and *in vitro* inhibition of monoamine oxidase, 154
Benzylpenicilloyl antibodies—interaction with penicilloic and penilloic acid haptens, Hansch analysis of inhibition data, hydrophobic and steric effects, 1671
Bethanidine—fluorometric assay in plasma, complexed with eosin Y, 785
Bile acids—binding to cholestyramine at gastric pH, 1887
neurohumoral transmitters and neurohumoral-like agents—technique for determining effect on opening pressure of choledochoduodenal junction, dogs, 1174
Biliary elimination—tetracycline, rats, 1847
excretion—dicumarol and metabolites after intravenous administration of dicumarol-^{14}C, rats, 1158
Bilirubin—effect of plasma protein binding on elimination, 1433
Binary solvent systems—deviation of dielectric constant from ideality, equation developed, 1569
Binding agents—comparison of starch USP and modified cornstarch, 328
—bile acids to cholestyramine at gastric pH, 1887
—drugs to plasma protein, effect of age, adult human subjects, 1711
—fluorocarbon propellants to human serum albumin, determined using partition coefficient method in sealed serum bottles, 1052
—pamaquine to bovine serum albumin, fluorometric determination of association constants, 1677
protein—parameters, interaction between sites, evaluation of method, 1892
sites, acetylcholinesterase—anionic binding site, receptor mapping using model interaction calculations, coulombic forces, 418
—substrate and inhibitors to acetylcholinesterase, studied by NMR, 488
—sulfaethidole to bovine serum albumin, effect of benzalkonium chloride, 361
Bioavailability—aspirin, effect of particle size, correlation with *in vitro* dissolution profiles, 878
—aspirin from commercially available supposi-

tories, humans, 1064
—assessment using 24-hr urinary excretion data, humans, 709
—commercial prednisone tablets, 1723
correlations, animal–human—intestinal pH of rats, dogs, and rabbits as a factor in model selection, 1726
—cyclobarbital calcium, aqueous solution and tablets, 1576
—digoxin, correlation with dissolution, methods of dissolution determination, 1583
—digoxin oral preparations, estimated using cumulative excretion in urine and area under serum concentration curve, intersubject variations, 433
—digoxin tablets, relationship to dissolution, 1264
—diphenoxylate hydrochloride, effect of activated charcoal and chromium oxide, 1877
—doxycycline products, three different brands and three different dosage forms, 2015
—equations for rapid estimation using urinary excretion data, 1721
—estimation under quasi- and nonsteady states, theoretical considerations and equations, 1639
—flumizole, a nonsteroidal anti-inflammatory agent, 1469
—griseofulvin, emulsion, suspension, and tablet dosage forms, humans, 793
—length of time for blood level measurements, analysis of literature data, 10 drugs considered, truncated blood level curves, 1521
ocular, fluorometholone—effect of drug concentration and vehicle composition on corneal penetration, rabbits, 931
—ophthalmic carbachol, interactions with cornea, relation to miotic activity, bioelectrometry, 520
ophthalmic—effect of topical anesthetics on solution drainage and tear turnover, rabbits, 267
—prednisone in humans, 50-mg tablet compared to 10 5-mg tablets, *in vitro–in vivo* correlations discussed, 109
—tocopheryl acetate from parenteral formulations, 655
Biological partitioning—reference systems, structural, polar, and transport properties of solvent and water phases, 599
Biomaterials, segmented polyurethane elastomers—correlation of kinetic parameters and thermal behavior with biological responses, 1492
Biopharmaceutics—drug properties, formulation effects, absorption mechanisms and control, 1085
Biotin analog—synthesis of *dl*-4ξ-(2-carboxyethyl)-*cis*-hexahydropyrrolo[3,4-*d*]imidazol-2-one (bisnorazabiotin), IR, UV, and NMR spectra, 1882
derivatives—16-step synthesis of *N*-carbethoxyazabiotin, 1514
3,3′-Bisbufotenidine analog—synthesized and screened as possible muscle relaxant, neuromuscular blocking activity, 1082
Bis(2-chloroethyl)triazenes—possible mechanism of action, 177
(±)-1,2-Bis(3,5-dioxopiperazinyl)propane—determination of plasma levels, rats, rabbits, and humans, GLC and mass fragmentography, 998
2,3-Bis(*p*-methoxyphenyl)imidazo[1,2-*a*]pyrimidine—fluorometric analysis, biological materials, anti-inflammatory agent, 2011
Bisnorazabiotin—synthesis of biotin analog, *dl*-4ξ-(2-carboxyethyl)-*cis*-hexahydropyrrolo[3,4-*d*]imidazol-2-one, IR, UV, and NMR spectral analyses, 1882
***N,N*-Bis(phenylcarbamoylmethyl)dimethyl ammonium chloride**—disposition in rat, first-pass metabolism, 359
***N,N′*-Bis[3-(3-substituted urea)propyl]piperazines**—synthesis, anticonvulsant activity and relationship to inhibition of pyruvic acid oxidation, 454
Blocking agents, neuromuscular—carnegine, laudanosine, *N*-methylpavine, corydine, isocorydine, glaucine, and boldine (as methiodides), stereochemical preferences for curarimimetic neuromuscular junction blockade, enantiomeric monoquaternary amines as probes, 53
Blood—behavior of erythrocytes in ternary solvent systems, ternary diagrams, critical hemolytic compositions, 1818
flow, mesenteric—influence on intestinal absorption of sulfaethidole and haloperidol, *in situ* canine intestinal preparation, 664
level curves, truncated—comparative bioavailabilities of 10 drugs, analysis of literature data, determination of length of time necessary for blood level measurements, 1521
levels—sustained-release dosage form, fast and slow release components, equations, 1728
pressure and neuromuscular effects—clindamycin phosphate, cats, 861
sampling, hepatic venous—improved method, rats, 895
sampling, serial—simple and reliable method, technique and equipment described, rats, 112
Blue-iodine reaction inclusion compounds—review, 1585
Blue tetrazolium—reduction by corticosteroids, pseudo-first-order rate constants, mechanism discussed, 226
Boiling point—correlation with molecular connectivity, hydrocarbons, alcohols, 1974
Books
Advances in Biochemical Engineering, 366
Advances in Chromatography, Vol. 10, 716
Advances in Drug Research, Vol. 7, 899
Advances in the Biosciences 10, 366
Alicyclic Chemistry, Vol. 2, 2032
The Alkaloids. Volume 4. A Specialist Periodical Report, 2033
The American Journal of Drug and Alcohol Abuse, Vol. 1, 1898
Amino-Acids, Peptides and Proteins, Vol. 5, 900
Analytical Profiles of Drug Substances, Vol. 4, 1584
Antimicrobial Agents in Medicine, 716
Applications of High-Speed Liquid Chromatography, 2034
Aromatic Amino Acids in the Brain, Ciba Foundation Symposium 22, 716
Arzneimittelprufung Arzneimittelrecht, 716
Assay of Vitamins in Pharmaceutical Preparations, 365
Assessment of the Carcinogenicity and Mutagenicity of Chemicals, 366
Atlas of Protein Spectra in the Ultraviolet and Visible Regions, 366
Bilayer Lipid Membranes (BLM) Theory and Practice, 1898
Bioavailability of Drugs: Principles and Problems, 366
Biochemische Und Biopharmazeutische Untersuchungsverfahren, 716
Biomedical Mass Spectrometry, 716
Biosynthesis, Vol. 2, 366
British Medical Bulletin, Research in Medical Care, Vol. 30, 1898
British National Formulary, 1974–76, 366
Central Nervous System Pharmacology. A Self-Instruction Text, 716
Chemical Carcinogenesis. Part B: Cell Transformation and Differentiation, 716
The Chemistry and Biochemistry of the Sulfhydryl Groups in Amino Acids, Peptides and Proteins, 715
A Chemist's Guide to Regulatory Drug Analysis, 899
Clinical Pharmacokinetics: A Symposium, 1735
Comparative Pharmacology, Vol. 1, 1897
Controlled Release of Biologically Active Agents, 366
Cyclic AMP, Cell Growth, and the Immune Response, 366
Drug Actions on Cholinergic Systems, 1898
Drug Design, Vol. IV, 365
Drug Development Communications, Vol. 1, 1898
Drug Interactions and Their Mechanisms, 716
Drug Metabolism Reviews, Vol. 2, 1735
Drug Treatment in Intestinal Helminthiases, 366
Emulsions and Emulsion Technology, Part I, 1434
Essential Immunology, 2nd Ed., 1898
Europaisches Arzneibuch, Vol. 1, 1898
Everything You Wanted To Know About Drug Abuse . . . But Were Afraid To Ask, 180
The Fate of Drugs in the Organism, Vol. 1, 1898
Folk Remedies of the Low Country, 1898
The Four Walls of Pharmacy, Professional Power with and for the People, 366
Frontiers in Catecholamine Research, 715
Handbook of Ocular Pharmacology, 716
Homogeneous Hydrogenation, 366
How Modern Medicines are Discovered, 366
Human Rights in Health, Ciba Foundation Symposium 23, 366
Inorganic Medicinal and Pharmaceutical Chemistry, 2033
International Aspects of Drug Evaluation and Usage, 180
Introduction to Chemical Nomenclature, 366
Isolation and Identification of Drugs (in Pharmaceuticals, Body Fluids and Post-mortem Material), Vol. 2, 2033
Lehrbuch der Pharmazeutischen Chemie, 1898
Manual of Medical Therapeutics, 1898
Metal Ions in Biological Systems, Simple Complexes, Vol. [illegible]
Methods of Biochemical Analysis, Vol. 21, 366
The National Formulary, Fourteenth Edition, 1084
Natural Flavouring Substrates, Their Sources, and Added Artificial Flavouring Substances, 1898
New Developments in Titrimetry, 716
Obstetric Therapeutics, 366
Parasites in the Immunized Host: Mechanisms of Survival, 1898
Pharmaceutical Calculations, 1083
Pharmacy Practice: Social and Behavioral Aspects, 1898
The Physiological Basis of Starling's Law of the Heart, 1898
Pills, Profits, and Politics, 900
Plastic Containers for Pharmaceuticals—Testing and Control, 1897
Platelets and Thrombosis, 716
The Poisoned Patient: The Role of the Laboratory, 1898
Principles of Medicinal Chemistry, 1736
Proceedings of the USP Conference on Radiation Sterilization, 1266
Quality Control in the Pharmaceutical Industry, Vol. 2, 1584
Reaction Mechanisms in Organic Analytical Chemistry, 472
Research Methods in Neurochemistry, Vol. 2, 366
Social Aspects of the Medical Use of Psychotropic Drugs, 1898
Sprowls' American Pharmacy, 7th Ed., 1267
Strategy of Drug Design: A Molecular Guide to Biological Activity, 715
The Study of Enzyme Mechanisms, 366
The Suppository, 899
Synopsis of Endocrine Pharmacology, 365
Synthetic Methods of Organic Chemistry, Vol. 28, 1434
Terpenoids and Steroids, Vol. 3, 472
Terpenoids and Steroids, Vol. 4, 1897
Treatment of Common Acute Poisonings, 1898
The Treatment of Parkinsonism with L-Dopa, 716
Trimethoprim–Sulfamethoxazole, 716
The United States Pharmacopeia, Nineteenth Revision, 1266
USAN 10 and the USP Dictionary of Drug Names, 1974 Supplement, 180
Bottles, sealed—pressure changes during steril-

ization by autoclaving, method for measurement, 333
Bovine serum albumin—pamaquine binding, fluorometric determination of drug–protein association constants, 1677
Bromhexine salts—GLC analysis in pharmaceutical preparations, 1005
Bromoacetylcholine—cytolytic effects on neuroblastoma *in vitro*, 469
2-Bromo-6-methoxyhexanoic acid—starting material for 16-step synthesis of *N*-carbethoxyazabiotin, 1514
9-Bromomethylacridine—quaternization reagent for picomole assay of chlorpromazine and tertiary amine drugs, 950
Bufotenidines—synthesis and screening of 3,3′-bisbufotenidine analog, neuromuscular blocking activity, 1082
Burns—inhibition of *Pseudomonas* burn wound infection by mafenide dry foam, 339
therapy—inhibition of supraeschar and subeschar *Pseudomonas* infection by silver sulfadiazine dry foam, 457
2-Butyl-3-benzofuranyl-4-[2- (diethylamino)-ethoxy]-3,5-diiodophenyl ketone hydrochloride—micelle formation, relationship to solubility, 1830

C

Caffeine and codeine phosphate—GLC analysis in pharmaceutical products, 1686
aspirin, and phenacetin—automated high-pressure liquid chromatographic analysis, 1029
Calamine lotion, phenolated—colorimetric analysis of phenol, 1199
Calcium disodium edetate—automated analysis in iodinated contrast media parenterals, 1026
oxalate—growth of crystals in silica and gelatin gels, relevance to stone formation, 458
phosphate dibasic dihydrate—disintegration time, 166
Cancer chemotherapeutic agents—cytolytic effects of bromoacetylcholine on neuroblastoma *in vitro*, 469
Cannabichromene—analysis, samples of known geographical origin, 892
cannabidiol, and cannabivarin synthetic mixtures—GLC separation and analysis, on-column methylation, 1719
Cannabidiol—analysis, samples of known geographical origin, 892
cannabichromene, and cannabivarin synthetic mixtures—GLC separation and analysis, on-column methylation, 1719
Cannabinoids—separation of cannabidiol and cannabichromene, GLC, 810
—stability in chloroform, 357
synthetic mixtures (cannabidiol, cannabichromene, and cannabivarin)—GLC separation and analysis, 1719
***Cannabis sativa* L.**—constituents, cannabidiol and cannabichromene in samples of known geographical origin, 892
—constituents, method to separate cannabidiol and cannabichromene, GLC conditions discussed, 810
—stability of synthetic and naturally occurring cannabinoids in chloroform, 357
Cannabivarin, cannabidiol, and cannabichromene synthetic mixtures—GLC separation and analysis, on-column methylation, 1719
***Canscora decussata* Schult**—antitubercular activity of polyoxygenated xanthones, 888
Capsules—device for making individually prepared capsules, design and application, 320
dissolution rates—design and evaluation of multichannel continuous-flow apparatus, also applied to powders and tablets, 1692
soft gelatin—oxygen permeability at room temperature, effects of relative humidity, plasticizers, equilibrium water, insoluble additives, and film thickness, 851
Carbachol—interactions with cornea, relation to miotic activity, mechanism, bioelectrometry, 520
2-Carbalkoxycyclopropyl methyl ketones—Baeyer–Villiger reaction, synthesis of stereospecific 2-acetoxycyclopropanecarboxylic acid esters, 1059
Carbamazepine—derivatization, GLC analysis, plasma and urine, 1940
—GLC analysis, whole blood, 2004
—pharmacokinetics, intravenous and oral administrations, monkeys, 302
***N*-Carbethoxyazabiotin**—16-step synthesis from 2-bromo-6-methoxyhexanoic acid, 1514
Carbinoxamine in oily vehicles—correlations between *in vitro* adsorption and *in vivo* percutaneous absorption, physicochemical parameters, 397
Carbohydrate–phosphoric acid solutions—effect on riboflavin bioavailability and salicylamide biotransformation in humans, 1504
Carbomer—effect on timed release of quinine sulfate from slowly eroding tablets, 1033
Carbonate—role in aluminum hydroxide gel, Raman and IR analyses, 468
Carbon disulfide—condensation products with amino, chloro, cyanomethyl, and sulfonamido heterocycles, potential antiradiation agents, 1371
Carbonic anhydrase, erythrocyte—active site, topographical study, spin-labeled sulfanilamide drugs, 512
–ligand interactions—kinetics studied by magnetic resonance relaxation and rapid reaction methods, 501
***dl*-4ξ-(4-Carboxybutyl)-5-carbethoxy-*cis*-hexahydropyrrolo[3,4-*d*]imidazol-2-one**—16-step synthesis from 2-bromo-6-methoxyhexanoic acid, 1514
Carcinogenicity, asbestos—review of chemistry, industrial hygiene, animal and human toxicology, 1435
Cardenolide and cardanolide derivatives—synthesis of 3-deoxydigitoxigenin analogs, inhibition of Na^+,K^+-adenosine triphosphatase, 1248
—isolation and identification from *Parquetina nigrescens*, 1674
Cardiac glycosides—kinetics of uptake and release by Burkitt lymphoma cells, systems approach to drug transport, 631
—separation from cardiac aglycones using dextran gel chromatography, 163
Cardiotonic steroids—synthesis of 3-deoxydigitoxigenin analogs, inhibition of Na^+,K^+-adenosine triphosphatase, 1248
Carnitine analogs—potential hypoglycemic agents, synthesis, biological evaluation, IR and NMR spectra, 1949
(*RS*)-Carnitine chloride—four-step synthesis under mild reaction conditions from crotyl chloride, 1262
Carrageenan—isolation from *Ahnfeltia concinna*, IR identification, 1704
Catha edulis—urinary excretion of *d*-norpseudoephedrine after mastication, humans, 702
Catharanthus roseus—isolation of three dimeric alkaloids, characterization by UV, IR, NMR, and mass spectra, 1953
Cavity surface area—correlation with molecular connectivity, hydrocarbons, alcohols, nonspecific local anesthetics, 1971
Cedrus deodara—spasmolytic constituents, pharmacological evaluation of himachalol, 258
Cefazolin and cefazolin sodium—NMR analysis of free 2-mercapto-5-methyl-1,3,4-thiadiazole, 1396
—automated spectrophotometric assay, stability indicating, double-probe sampling procedure, 1232
—pharmacokinetics, changes due to stress, 712
Cellular respiratory activity—thiosemicarbazides, selective inhibition of NAD-dependent oxidation of pyruvate and α-ketoglutarate, monoamine oxidase, rat brain homogenate, 1329
Cephalosporins—11 antibiotic derivatives, pharmacokinetics, absorption, metabolism, excretion, clinical considerations, review, 1899
Cetrimide–salicylic acid systems—effects of various acids and bases on viscosity, 1037
Cetrimonium bromide—kinetics and mechanisms for time-dependent effects after injection beneath air–aqueous solution interface without previously adsorbed or spread monolayer at different ionic strengths, 1782
Cetylethylmorpholinium ethosulfate—effect on UV photodegradation of menadione, complex formation, 696
Chalcones, heterocyclic—addition products, 1,3-heterocyclic-3-mercaptopropan-1-ones synthesized as potential fungicides, 355
Chelating agents—synthesis of fatty acid and long chain hydrocarbon analogs, 704
Chemical modification—prodrugs, physicochemical and biological considerations, applications, review, 181
Chlordiazepoxide and chlordiazepoxide hydrochloride—UV analysis for lactam impurity (7-chloro-1,3-dihydro-5-phenyl-2*H*-1,4-benzodiazepin-2-one 4-oxide), 1545
—hydrolysis, velocity constants, conversion to lactam, TLC and extraction procedures compared, 278
—radioimmunoassay in plasma, compared to spectrophotofluorometric method, 937
17-Chloroacetylajmaline—*in vitro* hydrolysis, relationship to hydrolysis of 17-acetylajmaline, different animal species, 1561
9-Chloroacridine—colorimetric reagent for determination of isoniazid, 1403
6-Chloro-9-amino-2-hydroxyacridine—synthesis from quinacrine, 1418
7-Chloro-5,11-dihydrodibenz[*b*,*e*][1,4]oxazepine-5-carboxamide—GLC, analysis in serum and plasma as 5-nitrile derivative, 1531
7-Chloro-3,3a-dihydro-2-methyl -2*H*,9*H*- isoxazolo-(3,2-*b*)(1,3)-benzoxazin-9-one—absorption, distribution, and metabolic fate, rats, dogs, and humans, 1316
—anti-inflammatory, analgesic, and antipyretic activities compared to 5-chlorosalicylic acid, rats, 1321
7-Chloro-1,3-dihydro-5-phenyl-2*H*-1,4-benzodiazepin-2-one 4-oxide—UV analysis in chlordiazepoxide and chlordiazepoxide hydrochloride, 1545
Chloroethyltriazene—synthesis, antileukemic activity, 177
(Chloroethyltriazenyl)imidazole—explosive decomposition, hydrolysis to aminoimidazolecarboxamide, 177
19α-Chloro-18α-oleanane-3β-ol (lupeol hydrochloride)—structure determination, 152
1-[[5-(5-Chloro-2-pyrimidinyl)furfurylidene]amino]hydantoin—structural analog of dantrolene, synthesized and screened for muscle relaxant activity, 337
5-Chlorosalicylic acid—anti-inflammatory, analgesic, and antipyretic activities compared to 7-chloro-3,3a-dihydro-2-methyl-2*H*,9*H*-isoxazolo-(3,2-*b*)(1,3)-benzoxazin-9-one, rats, 1321
—identified as major metabolite of 7-chloro-3,3a-dihydro-2 -methyl -2*H*,9*H*- isoxazolo-(3,2-*b*)(1,3)-benzoxazin-9-one in rats, dogs, and humans, 1316
Chlorpheniramine maleate—colorimetric determination in cough syrups, 2001
Chlorpromazine—assay by quaternization and photolysis, picomole quantities, 950
—effects on conditioned avoidance response, conscious cat, 1647
hydrochloride—chemistry of nonaqueous titration, method proposed, compared to official methods, 129
Chlorpropamide tablets—high-pressure liquid chromatographic analysis after homogenization with methanol, 123
Chlortetracycline—automated analysis, evaluation of interpolation formulas, calibration lines, 844
Choledochoduodenal junction, canine—effect of neurohumoral transmitters and neurohumoral-like agents present in bile on opening pressure of choledochoduodenal sphincter, 1174

Cholelithiasis chemotherapy—identification of cholesterol gallstone-dissolving agents, *in vitro* screening system, 362
Cholesterol and triglyceride levels—effect of lysine and tryptophan supplementation, humans, 691
–dipalmitoyl lecithin monolayers—molecular arrangement, force–area isotherms, model, 1534
—effect of polysorbate 60 on interphase transport, mechanisms and equations, 1500
gallstones—dissolution, *in vitro* screening system to identify potential chemotherapeutic agents, 362
levels—effect of lysine supplementation, rats, 690
Cholestyramine—binding of bile acids at gastric pH, 1887
Cholic acid inclusion compounds—review, 1585
Chromaticity data—surface color of series of FD&C and D&C color dispersions, tristimulus colorimetry, 323
Chromatography—separation of cardiac glycosides from cardiac aglycones, dextran gel columns, 163
—separation of 3β-hydroxysterols from other sterols, dextran gel columns, 161
Circular dichroism—intrinsic and extrinsic optical activity as a purity criterion for human serum albumins, binding of four acidic drugs, 1508
Clathrates—crystal structure, preparation, characterization, properties, and pharmaceutical application, review, 1269
***Claviceps* sp. SD 58**—conversion of agroclavine to setoclavine and isosetoclavine, 343
Clindamycin and lincomycin combinations—comparison of effect on *Staph. aureus* and *E. coli*, microbial kinetics, drug–bacteria reactions, generation curves, 1621
—comparison of effects on *Staphylococcus aureus* and *Escherichia coli*, microbial kinetics, 1612
phosphate—neuromuscular and blood pressure effects, cats, 861
2-phosphate—separation from other clindamycin compounds, triethylaminoethyl cellulose column, liquid chromatography, 313
Clorazepate monopotassium and dipotassium salts—determination of plasma levels after oral administration, dogs, GLC analysis of nordiazepam metabolite, 1668
Cloud points—effect of inorganic additives, 658
CMC—determined for 15 aliphatic diamines with one long alkyl chain and varying methylene chain, 883
CNS activity—synthesis and screening of cyclobutanecarbonylureas, biological activity correlated with molecular structure and aqueous solubility, 649
agents, potential—synthesis and screening of seven 3-amino-2-imino-1,3-benzothiazin-4-ones, 1425
depressant activity—synthesis and evaluation of fluorinated quinazolone derivatives, 1428
stimulants—pentylenetetrazol, GLC analysis in biological fluids, 1843
stimulants—urinary excretion of *d*-norpseudoephedrine after mastication of *Catha edulis*, humans, 702
Codeine phosphate and caffeine—GLC analysis in pharmaceutical products, 1686
Coenzyme depletion—effects of 17 compounds, motor activity, sleeping time, toxicity, therapeutic effects, coenzyme binding site, 528
Colchicine derivatives—synthesis and antileukemic activity of alkylthiocolchicines and *N*-deacetyl-alkylthiocolchicines, 646
Color difference and surface color—measurement of tablet colorants by tristimulus colorimetry, 323
Colorimetry—analysis, *N*-acetyl-*p*-aminophenol, degradation product interference examined, 466
—analysis, bacitracin in ophthalmic ointments, 307
—analysis, ethinyl estradiol in progestin–estrogen and vitamin/mineral geriatric preparations, 1221
—analysis, formaldehyde in aqueous solution using 2,3-dimethyl-2,3-bis(hydroxylamino)butane, 1043
—analysis, hexachlorophene in topical formulations, 4-aminoantipyrine dye formation, modified to eliminate interferences, 125
—analysis, 17-hydroxycorticosteroids in human urine, 1050
—analysis, isoniazid with 9-chloroacridine, 1403
—monitoring, in-process cyclic octapeptide biosynthesis, ion-pair formation with bromthymol blue, 1401
—peroxide concentrations, 356
tristimulus—surface color and color difference of tablet colorants, 323
Compaction pressure—effect on particle-size spectrum of disintegrating compacts, aspirin, dicalcium phosphate dihydrate, calcium phosphato-carbonate, alumina, microcrystalline cellulose, 444
Complexation—hexamethylmelamine–gentisic acid species, pH 0–8, effect on solubility, 1850
Complexes, barbiturates and polyethylene glycol 4000—IR characterization, 1787
—iron (III) with pyrrolidone-5-hydroxamic acid, synthesis, characterization, visible and IR spectral data, magnetic moment, 970
—review of various types of inclusion compounds, 1585
Complexing capacity numbers—theoretical considerations, mononuclear aggregations of mixed nucleosides in dilute aqueous solutions based upon osmometric measurements, 770
Compressed tablets—evaluation of particle-size spectra, 444
Compression of lactose granules—effect on physical properties compared, 1213
Conductimetric titrations—automatic apparatus described, applied to solute–solute interactions, 147
Conjugated estrogen mixtures—enzymatic hydrolysis of estrogen sodium sulfate salt formulations, GLC separation and analysis, 1007
Contact angles—human skin, previously developed equations discussed, 1080
Content uniformity—nitroglycerin sublingual tablets, 140
Contraceptives—plants with active constituents, review, 535, 717
—procedure to evaluate drug absorption from vagina, equipment and equations, rabbits, 71
Controlled-release properties of drug formulations—claimed *versus* actual, blood level profiles compared to "plain-release" blood level profiles, 1075
Copper–protein binding interactions—studied using specific ion electrode, 1243
Coralyne salts—photohydration, ring cleavage, pH dependence of solubility, stabilization, formation of 6′-acetylpapaverine, 1825
Corn oil-in-water emulsion, micronized griseofulvin—absorption kinetics compared to aqueous suspension, single and multiple doses, rats, 1475
Correlation analysis—formulation of *de novo* substituent constants, inhibition of dihydrofolate reductase by 2,4-diamino-5-(3,4-dichlorophenyl)-6-substituted pyrimidines, equation with seven indicator variables, 1186
Corticosteroids and iodochlorhydroxyquin formulations—partition chromatographic separation, complexiметric analysis of iodochlorhydroxyquin, blue tetrazolium analysis of corticosteroid, 1013
—reduction of blue tetrazolium, pseudo-first-order rate constants, mechanism discussed, 226
Coulombic forces—role in binding of acetylcholinesterase, anionic site, 418
Coulometry, constant current, automated—analysis, ascorbic acid and sodium ascorbate, 1229
Coumarin anticoagulants—comparative pharmacokinetics of dicumarol and warfarin, rats, 1995
—relationship between protein binding, distribution, and elimination kinetics of warfarin in rats, 1660
Crotyl chloride—starting material in four-step synthesis of (*RS*)-carnitine chloride, 1262
Cryoscopic properties—data for 44 drugs, 1884
Crystalline aspects of pharmaceutical solids—review of crystal habit, amorphous solids, polymorphs, solvates, and clathrates, 1269
Crystallography—determination of structures of azathioprine dihydrate and 6-methylmercaptopurine trihydrate, 221
Crystals, forms—succinylsulfathiazole, effect of additives on interconversion, 1481
growth—calcium oxalate in silica and gelatin gel systems, types of growth, 458
—succinylsulfathiazole, factors affecting growth, particle-size distributions, 1485
Cupric ions—binding to bovine serum albumin, determination of number and classes of binding sites, specific ion electrode, 1243
Curarimimetic activity—stereochemical preferences for neuromuscular junction blockade, enantiomeric bisquaternary amines related to benzoquinonium as probes, 67
activity—stereochemical preferences for neuromuscular junction blockade, seven pairs of enantiomeric monoquaternary amines (carnegine, laudanosine, *N*-methylpavine, corydine, isocorydine, glaucine, and boldine as methiodides) as probes, 53
neuromuscular junction blockade—stereochemical preferences, enantiomeric bisquaternary amines as probes, 62
***N′*-Cyano-*S*-(triorganostannyl)isothioureas,** *N*-substituted—synthesis, IR spectra, antimicrobial activity, 1259
Cyclic nucleotide phosphodiesterases—properties, activators, inhibitors, structure–activity relationships, possible role in drug development, review, 1
Cycloalkanones—synthesis of radiolabeled 2,8-dibenzylcyclooctanone, tissue distribution, effects on triglyceride metabolism, rats, 235
Cyclobarbital calcium—relative bioavailability from aqueous solution and tablets, 1576
Cyclobutanecarbonylureas—synthesis, CNS activity, correlated with molecular structure and aqueous solubility, 649
Cyclodextrin inclusion compounds—review, 1585
Cyclophosphamide—timed-release formulation with poly(lactic acid), release characteristics, electron spectra, 115
Cyclopropyl analogs of stilbene and stilbenediol—synthesis as potential antiestrogens, 1626
Cyproterone acetate—effect on uterine motility, rats, 452
Cysteinol derivatives—synthesis and screening as possible anticancer agents, 825
Cytolytic activity—bromoacetylcholine on neuroblastoma *in vitro*, 469
Cytotoxic agents—coralyne salts, solubilization and stabilization, photohydration, pH dependence, formation of 6′-acetylpapaverine, 1825
—hexamethylmelamine, solubilization by complexation with gentisic acid species, intravenous formulations, 1850
—isolated from *Baileya multiradiata*, biological evaluation, 2023
Cytotoxicity—isolation and identification of cymarin, strophanthidin, and strophanthidin glycoside from *Parquetina nigrescens*, 1674
—6-selenopurine arabinoside and related compounds, 1343
Cytotoxic nucleosides—synthesis of arabinosyladenine 5′-formate as highly water-soluble prodrug, hydrolysis rates in biological fluids, 392

D

Dansyl chloride—preparation of estrogen-dansyl derivatives, fluorometric determination of estrogens in pharmaceutical preparations, compared to compendial method, 674

Dantrolene positional isomer (3-[[5-(*p*-nitrophenyl)furfurylidene]amino]hydantoin)—screened for skeletal muscle relaxant activity, 1047
—synthesis and screening for muscle relaxant activity of 5-chloro-2-pyrimidinyl analog, 337
Dapsone—isolation, identification, and quantitation, pharmaceutical preparations, 1205
Decomposition—aminosalicylic acid in solid state giving rise to first-order kinetics, sorbed moisture theories discussed, 37
—amitriptyline hydrochloride in aqueous solution, identification of products, mechanisms, 1497
—preparation, isolation, and characterization of colored decomposition product from mestranol and similar products from related compounds, 777
—solid state, *para*-substituted salicylic acids, intramolecular mechanism, Bawn kinetics, Hammett relation, 1931
4-Dedimethylamino-11-methoxyanhydrotetracycline—isolation and identification after diazomethane methylation of 4-dedimethylaminoanhydrotetracycline, 1635
Degradation—epinephrine, sulfite induced, kinetics, 45
penicillin G potassium—concentrated micellar aqueous solutions compared to nonmicellar solutions, pH–rate profiles, 1378
Dehydration kinetics—tetracycline, effects of acidity at various temperatures, 352
Dehydroglaucine—isolated from *Liriodendron tulipifera*, screened for antimicrobial activity, 789
Delivery systems, drug—elementary osmotic pump, controlled delivery rate, release characteristics, equations, 1987
Densities, granular—effect on drying rates of tablet granulations, 1023
3-Deoxydigitoxigenin analogs—synthesis and inhibition of Na^+,K^+-adenosine triphosphatase, 1248
Deoxyelephantopin—isolation from *Elephantopus carolinianus* Willd., structure identification, antitumor activity, 1572
Deoxyuridine—effect of coadministration on toxicity and antitumor activity of fluorouracil and floxuridine, 943
Deuterated drugs—barbiturates, hormones, anesthetics, antibiotics, alkaloids, amino acids, sympathomimetic amines, applications, review, 367
Deuterium oxide—toxicity and pharmacological and biological effects, review, 367
Dexamethasone—development and evaluation of timed-release aerosol formulation, preparation of microcapsules, 408
Dextran gel chromatography—decomposition of steroid digitonides, 161
—separation of cardiac glycosides from cardiac aglycones, 163
Dextromethorphan salts—GLC analysis in pharmaceutical preparations, 1005
2-(*N,N*-Dialkylaminoethyl)amino-1,3,4-thiadiazoles, 5-substituted—synthesis and pharmacological activity, 1250
Diamines, aliphatic—synthesis, determination of CMC values, effect of long alkyl and methylene chains on surface activity, 883
3,6-Diaminoacridine derivatives—electronic spectra and electronic structures, 982
Diazoimidazolecarbonitrile—synthesis and stability, 954
2,8-Dibenzylcyclooctanone, radiolabeled—synthesis, distribution to tissues, effects on triglyceride metabolism, rats, 235
α-[(Dibutylamino)methyl]-6,8-dichloro-2-(3′,4′-dichlorophenyl)-4-quinoline methanol—photolytic degradation, 1665
Dichloralantipyrine–acetaminophen—spectrophotometric analysis of capsule formulation, 1547
***cis*-Dichlorodiammineplatinum (II)**—timed-release formulation with poly(lactic acid), release characteristics, electron spectra, 115
Dichlorodifluoromethane—binding to human serum albumin, 1052
—interspecies differences in blood and plasma solubilities, toxicity implications, 1538
Dichlorotetrafluoroethane—binding to human serum albumin, 1052
—interspecies differences in blood and plasma solubilities, toxicity implications, 1538
Dichlorvos—partition coefficients between pure liquids, micellar solutions, and liquid crystalline phases, effect of associated colloid structures, 822
Dicumarol and metabolites—biliary excretion after intravenous administration of dicumarol-^{14}C, rats, 1158
—distribution, half-life, elimination, anticoagulant effect determined, compared to warfarin, rats, 1995
Dielectric constant—binary solvent systems, deviation from ideality, equation developed, 1569
Dienestrol—determination of configuration, single-crystal X-ray diffraction, 1525
2-Diethylaminoethanol benzylic ethers and related diamine—synthesis, screened for blood pressure lowering activity, 1423
Diethylene glycol *versus* triethylene glycol monoethers—mosquito repellency, 693
Die wall pressures—compared for various lactose granules, effect on tablet compressibility, 1213
Differential spectroscopy—analysis, ergocalciferol in pharmaceutical preparations not containing vitamin A, 1196
Diffusion assay—microbiological assay of antibiotics, design and application, 1224
model, convective—transport-controlled dissolution rate process, *p*-aminobenzoates and modified rotating-filter–stationary basket apparatus, 610
—model for fluidized-bed drying, moisture and size relationships, rate-limiting step, 1869
model, hydrodynamic, analog—proposed for pharmacokinetics, applications, equations, 88
model, hydrodynamic, analog—proposed for pharmacokinetics, critical examination, equations, 92
models—eight steady-state models derived and discussed, membranes using suspension cultures of mammalian cells, 622
Digitized tablet hardness values—equipment described, 1578
Digoxin—correlating dissolution and bioavailability, differences in methods, paddle-water method and rotating-basket apparatus, 1583
—effect of antacids on absorption, dogs, 1727
oral preparations—bioavailability in humans, intersubject variations, 433
tablets—dissolution data compared to bioavailability, 1264
Dihydrofolate reductase—inhibition by 2,4-diamino-5-(3,4-dichlorophenyl)-6-substituted pyrimidines, correlation analysis, formulation of *de novo* substituent constants, cross-product terms, 1186
4,4′-Dihydroxybibenzyl—intestinal bacterial reduction from 4,4′-dihydroxystilbene, 471
4,4′-Dihydroxystilbene—intestinal bacterial reduction to 4,4′-dihydroxybibenzyl, 471
***p*-Dimethylaminobenzaldehyde**—reagent, analysis of pholcodine in cough preparations, 1011
2-Dimethylaminomethyl-6-phenylcyclohexanols and esters—screened for antimicrobial activity, 995
2- Dimethylaminomethyl -6- phenylcyclohexanone—conversion to isomeric alcohols and esters, screened for antimicrobial activity, 995
2,2-Dimethylaziridines—reactions in biological systems, comparative pharmacokinetics in dogs, 230
2,3-Dimethyl-2,3-bis(hydroxylamino)butane—colorimetric reagent for determination of formaldehyde in aqueous solution, 1043
α,α - Dimethyl -4- (α,α,β,β- tetrafluorophenethyl)benzylamine—electron-capture GLC determination in biological fluids, 814
Dinoflagellate (*Gymnodinium breve*)—isolation and partial characterization of three neurotoxins, 865
Dinorpropoxyphene (cyclic) and norpropoxyphene—GLC analysis in heroin addict plasma after propoxyphene napsylate administration, 429
Dioctyl sodium sulfosuccinate—effect on absorption of phenosulfonphthalein in rat, urinary excretion and *in situ* intestinal loop data, 987
—effect on phenolsulfonphthalein absorption, humans, 991
—trypsin inhibition, pH 6–8, two different substrates, therapeutic significance, 1858
Dioxans—synthesis and screening of 2-substituted aminomethylnaphtho(2,3-*b*)-1,4-dioxans as potential adrenergic blocking agents, 875
Dioxopiperazines—determination of (±)-1,2-bis(3,5-dioxopiperazinyl)propane plasma level, rats, rabbits, and humans, GLC and mass fragmentography, 998
Dipalmitoyl lecithin–cholesterol monolayers—molecular arrangement, force–area isotherms, model, 1534
Diphenoxylate hydrochloride—adsorption on activated charcoal and chromium oxide, effect on bioavailability, 1877
Diphenylhydantoin—*see* also Phenytoin
Diphenylhydantoin–phenobarbital—simultaneous high-pressure liquid chromatographic determination, plasma, 806
Disintegrants—comparison of starch USP and modified cornstarch, 328
—effect of compressional force on disintegration of starch, cation-exchange resin, calcium sodium alginate, sodium carboxymethylcellulose, sodium starch glycolate, 166
Disopyramide and 20 derivatives—linear relationship between plasma binding and lipophilicity determined, 961
derivatives—determination of plasma binding, partition coefficient and pKb, relationship between pKb and binding, 1632
Disposition—carbamazepine, acute intravenous and oral doses, monkeys, 302
Dissolution—aspirin from suppositories, effect of particle size, 878
—digoxin, methods of determination, correlation with bioavailability, 1583
—error introduced from assumption of monodisperse powders in sieve cuts, 1409
—gallstones, *in vitro*, T-tube infusion treatment with sodium cholate, 2029
multiparticulate—size distribution effects, lognormal powders, three single-particle models investigated, 1981
of monodisperse powders—various rate equations examined, 1651
of polydisperse powders (oxalic acid dihydrate)—dissolution patterns, equations, 1770
—phenylbutazone, nonclassical phase transfer behavior, 706
profile—powders under sink conditions, general equation, relationship of initial particle-size distribution, applicability to dissolution of lognormal powders, 1192
rate—effect of aging, phenylbutazone tablets, 335
rate measurements—design and evaluation of multichannel continuous-flow apparatus, application to powders, tablets, and capsules, 1692
rates—automated determination, analysis of data, variability, 1080
rates—formulations of flumizole, 1469
rates, transport controlled—convective mathematical diffusion model tested using *p*-aminobenzoates and modified rotating-filter–stationary basket apparatus, 610
Distribution—^{14}C-labeled minoxidil after oral and intravenous administration, rats, dogs, and monkeys, 1360
—model compounds, effects of chemical modifications, pharmacokinetic parameters, transport mechanisms, rats, 1804
—nafiverine, intramuscular, intravenous, and oral administrations, rats, rabbits, and mice,

253
—pharmacokinetic parameters, mechanistic evaluation, model organic anions in presence of model renal tubular secretion inhibitor, rats, 1813
—triamcinolone acetonide-^{14}C-21-phosphate after intravenous and intramuscular administration, dog, monkey, and rat, 1351
Disulfides, heterocyclic alkyl—synthesis and antimalarial activity, 211
Dithio acid derivatives—synthesis and antimalarial activity, 211
Diuretic–antihypertensive mixtures—high-pressure liquid chromatographic separation, effect of solvent composition, pH, and stationary phase polarity, 1201
Diuretics—high-pressure liquid chromatographic analysis of polythiazide dosage forms, 1406
DNA—interaction with diaminoacridine dyes, electronic spectra and structure of dyes, 982
1,1′ - Dodecamethylenebis(6,7 - dimethoxy -2-methyl-1,2,3,4-tetrahydroisoquinoline (enantiomeric bisquaternary amines)—probes for stereochemical preferences for curarimimetic neuromuscular junction blockade, 62
Dosage forms—long acting delivery systems for narcotic antagonists, release rates of naltrexone from poly(lactic acid) composites, 348
forms—micronized griseofulvin, bioavailability from corn oil-in-water emulsion, aqueous suspension, and commercial tablets, humans, 793
forms—sustained release, blood levels, fast and slow release drug components, equations, 1728
regimens—dose adjustment in renal failure, 175
Doxorubicin (adriamycin)—reduction of bone marrow toxicity, aortic occlusion, rabbits, 1574
Doxycycline products—bioavailability, three different brands and three different dosage forms, 2015
Drocinonide phosphate potassium—complex with neomycin sulfate, prevention of precipitation by use of inorganic phosphate salts, 1528
Drug–biomolecule interactions—binding of substrate and inhibitors to acetylcholinesterase, NMR, 488
—drug toxicity and vitamin coenzyme depletion, symposium, 528
—effects of anesthetics on membrane lipids, electron spin resonance spectra, 497
—fluorescence studies on interaction of aminonaphthalenesulfonic acid derivatives with serum albumins, 493
—gentamicin with monomolecular films, 516
—mechanism of carbachol interactions with cornea, relation to miotic activity, bioelectrometry, 520
—mechanism of ligand interactions with carbonic anhydrase, magnetic resonance relaxation and rapid reaction methods, 501
—mechanisms and kinetics of interactions of biomolecules at interfaces, 477
—mononucleotides and polybasic amino acids, 473
—PMR studies of complex formation between bovine neurophysins and oxytocin at the molecular level, 507
—topographical study of active site of erythrocyte carbonic anhydrase using spin-labeled sulfanilamide drugs, 512
Drug–macromolecule interactions—determination by permeation rate technique, compared to literature dialysis data, 946
Drug–protein interactions—microbiological determination of drug partitioning, gelatin–acacia complex coacervate systems, four antimicrobial agents, 420
Drugs, absorption—influence of mesenteric blood flow on intestinal absorption of sulfaethidole and haloperidol, *in situ* canine intestinal preparation, 664
abuse—systematic identification, spot tests, flow chart, 841
accumulation under quasi- and nonsteady-conditions—bioavailability estimations, theory and equations, 1639
—commonly used drugs tested for antibacterial activity against human intestinal anaerobic bacteria *in vitro,* 700
delivery systems—contraceptive drugs, development of *in situ* vaginal drug absorption procedure, equipment and equations, rabbits, 71
delivery systems—controlled release, polymeric devices, ethynodiol diacetate in silicone matrix, *in vitro–in vivo* correlation of intravaginal release, rabbits, 1776
delivery systems—elementary osmotic pump, controlled delivery, release rates, equations, 1987
derivatives, biologically reversible—rationale for design of prodrugs, physicochemical and biological considerations, applications, review, 181
deuterated—deuterium biological and isotope effects, toxicity and pharmacological and biological effects of deuterium oxide, heavy water as a drug, various deuterated drugs, applications, review, 367
disposition—nonlinear tissue disposition, salicylic acid in rat brain, model proposed, equations, 99
metabolism—mammals, microorganisms, mechanisms, C-hydroxylation, *N*-dealkylation, *O*-dealkylation, *N*-oxidation, *S*-oxidation, alcohol dehydrogenation, keto reduction, nitro reduction, azo reduction, review, 1737
partitioning—microbiological determination, drug–protein interactions, gelatin–acacia complex coacervate systems, 420
powder dissolution rates—design and evaluation of multichannel continuous-flow apparatus, also applied to tablets and capsules, 1692
release characteristics of polyethylene glycols—relationship to polymer molecular weight, mechanical strength, and elastic moduli, 1162
release from lipophilic ointment bases—chain length effect of added ethoxylated surfactant, 1055
release from polymeric films—first-order and diffusion-controlled mechanisms discussed, 76
release from polymer matrix, controlled—solution–solubility dependency, equations, 1643
release (methapyrilene, pentobarbital, salicylic acid) from laminated hydroxypropyl cellulose–polyvinyl acetate films—linear drug release, effects of membrane thickness and polyvinyl acetate content, 1289
substances—sodium chloride equivalents, cryoscopic properties, and hemolytic effects determined for 44 drugs, 1884
transport—studied using systems approach, across membranes using suspension cultures of mammalian cells, eight steady-state diffusion models derived and discussed, 622
transport—uptake and release kinetics, cardiac glycosides, Burkitt lymphoma cells, influence of serum–drug binding, membrane–drug binding, cell interior binding, and intrinsic membrane permeability, 631
transport—uptake and release kinetics, desmosterol, cholesterol, and β-sitosterol, Burkitt lymphoma cells, effective permeability and partition coefficients determined, related to sterol–serum binding, 627
Drying—fluid bed dryer, diffusion model, sucrose–lactose–starch granulation, rate-limiting step, relationships between moisture and size, 1869
rates, tablet granulations—effect of granulating adjuvants, 135
rates—tablet granulations, effect of particle size and granular densities, lactose and sulfathiazole granules prepared with acacia mucilage and povidone, 1023
Duboisia myoporoides and *Duboisia leichhardtii*—GLC analysis for scopolamine and hyoscyamine, slope ratio method, 1821
Dyes—chromatographic, mass spectral, and visible light absorption characteristics of toluidine blue O and related dyes, 1456

E

Editorials
Achieving the Full Viewpoint (December)
A Painful Prospect—With No Analgesic (April)
Bioavailability Data—Useful or Useless? (September)
Drug Quality: Potential Problems *Versus* Actual Experience (June)
Fragile: Handle with Care (January)
Harmless, but Ineffective, Remedies (October)
National Research Policy (November)
Reflections on a Book (February)
"The Buck Stops Here!" (May)
The Economics of Publication (March)
The Fifth Freedom: Scientific Communication (August)
The Value of Congressional Oversight (July)
Eisenia bicyclis extract—mechanism of anti-inflammatory activity, lysosomal stabilization, 1258
Electrolytes—effect on cloud points of nonionic polyoxyethylated surfactants, 658
Electron density, frontier—metronidazole and four derivatives, correlation with plasma protein binding parameters, 1797
Electronic spectra and structure—diaminoacridine dyes, dependence upon solvent properties and state of protonation, 982
***Elephantopus carolinianus* Willd.**—isolation and structure identification of deoxyelephantopin, antitumor activity, 1572
***Elephantopus mollis* H.S.K.**—isolation and structure determination of molephantinin, antitumor activity, 1077
Eleutherine bulbosa (Iridaceae)—extraction of eleutherin and eleutherol, pharmacological screening, 1305
Eleutherol and eleutherin—extracted from *Eleutherine bulbosa,* pharmacological screening, 1305
Elimination—method for sampling mixed hepatic venous blood proposed, rats, 895
—triamcinolone acetonide-^{14}C-21-phosphate after intravenous and intramuscular administration, dog, monkey, and rat, 1351
Elymoclavine and related compounds—inhibition of nidation, rats, 1045
Emulsions, corn oil-in-water—bioavailability of micronized griseofulvin, humans, 793
—vegetable oil–surfactant–water, effect of polysorbate 60 on interphase transport of cholesterol, 1500
Enzymes, acetylcholinesterase—theoretical studies on nature of anionic binding site, 418
inhibition—trypsin by dioctyl sodium sulfosuccinate, pH 6–8, two different substrates, therapeutic significance, 1858
pulmonary—effects of nitrogen dioxide and 3-methylcholanthrene, 1421
Ephedrine hydrochloride—colorimetric determination in cough syrups, 2001
Epicillin—crystalline modifications, physicochemical properties, 710
Epidermis—permeability, *in vivo* method for monitoring effect of polysorbate 85, treated and untreated human epidermis, 671
Epinephrine—kinetics of sulfite-induced anaerobic degradation, 45
Equilibrium—bisulfite ion addition to fluorouracil, 216
Equipment—apparatus for monitoring flow rate during gravity perfusion, 1730
—rapid production of various capsules and drug dosages, design and application, 320
Ergocalciferol in pharmaceutical preparations—differential spectroscopic analysis using trifluoroacetic acid, absence of vitamin A, 1196

Ergoline-related compounds—inhibition of nidation, relationship to prolactin-inhibiting ability, 1045
Erythrocyte carbonic anhydrase—active site, topographical study, spin-labeled sulfanilamide drugs, 512
Erythrocytes—behavior in ternary solvent systems, ternary diagrams, critical hemolytic compositions, 1818
Erythromycin—automated analysis, evaluation of interpolated formulas, calibration lines, 844
lactobionate—oral absorption efficiency from lipid–drug delivery systems, 869
Escherichia coli—effects of clindamycin, compared to *Staphylococcus aureus*, 1612
—effects of lincomycin and clindamycin combinations, compared to effects on *Staph. aureus*, drug–bacteria reactions, generation curves, microbial kinetics, 1621
—kinetics and mechanisms of aminosidine action, with and without pretreatment, 1936
Esters, acetaminophen, fatty acid—hydrolysis in buffered pancreatic lipase systems, 117
Estradiol—polyethylene–silicone composite implant, diffusion, permeability, and solubility coefficients, release patterns, 832
Estrogenic plants—review of active principles, 535, 717
Estrogens—determination in dosage forms, fluorescence using dansyl chloride, pH, reaction solvent composition, and speed of reaction, compared to compendial method, 674
—determination of configuration of dienestrol, X-ray diffraction, 1525
—GLC analysis of 17α-ethynylestriol 3-cyclopentyl ether, 1210
—release patterns of estradiol from polyethylene–silicone composite implant, 832
Estrogen sodium sulfate salt formulations—enzymatic hydrolysis, GLC separation and analysis of conjugated estrogens, 1007
Ethanol—effect on absorption of theophylline, humans, 299
—effect on intestinal absorption of theophylline, concentration dependence, rats, 897
Ethinyl estradiol in progestin–estrogen and vitamin/mineral geriatric preparations—colorimetric analysis, 1221
Ethylcellulose films containing caffeine or salicylic acid—timed release, first-order and diffusion-controlled models discussed, 76
Ethylene oxide—residual analysis, comparison of four analytical methods by six laboratories, 1412
5-Ethyl- 5-methyl-2,4- oxazolidinedione—paramethadione metabolite, GLC determination of serum levels, single oral dose, humans, 1702
Ethynodiol diacetate—intravaginal release from silicone matrix, *in vitro–in vivo* correlation, rabbits, 1776
17α-Ethynylestriol 3-cyclopentyl ether—GLC analysis as trimethylsilyl derivative, 1210
Excipients—comparison of starch USP and modified cornstarch, 328
—effect of granulating adjuvants on drying rates of tablet granulations, 135
Excretion, biliary—role in tetracycline elimination, rats, 1847
—11 cephalosporin antibiotic derivatives, pharmacokinetics, clinical considerations, review, 1899
—^{14}C-labeled minoxidil after oral and intravenous administration, rats, dogs, and monkeys, 1360

F

Factorial experimental design—utility for optimizing pharmaceutical process conditions, 1688
Fatty acid analogs containing chelating groups—synthesis, potential radiopharmaceutical imaging agents, 704
esters of acetaminophen—acetaminophen blood concentration after oral administration with pancreatic lipase, dogs, 1489
Ferguson principle—applicability to thermodynamics of gaseous anesthetics, 2025
Fibrinolytic agents, potential—synthesis of 4-(branched alkyl)benzoic acids *via* β-mono- or β,β-disubstituted styrene-4-carboxylic acids, 1170
Films—adhesion to tablets, effect of surface roughness and coating solvent, 1554
—molecular arrangement in cholesterol–dipalmitoyl lecithin mixed monolayers, model, 1534
monomolecular—interaction of gentamicin with lipids, 516
First-pass effect, hepatic—acetaminophen, estimation, oral administration, humans, 1734
Flavones—chromatographic separation and spectral identification from *Achillea millefolium*, 1838
Flavoring oils—effect on preservative concentrations in oral liquid dosage forms, partitioning of parabens, 414
Flow properties of cohesive powders—application of powder failure testing equipment (shear cell and tensile tester), 1216
rates—apparatus for continuous monitoring during perfusion studies, 1730
Floxuridine—effect of deoxyuridine coadministration on toxicity and antitumor activity, 943
Flucloronide—suspension, release from oleaginous ointment bases containing various adjuvants, model predictions, 754
Flucytosine and furosemide—high-pressure liquid chromatographic analysis in plasma and urine, 1334
Fluid bed drying—diffusion model, moisture and size relationships, rate-limiting step, equations, 1869
Fluidized antacid suspensions—preparation using colloidal polyelectrolyte, viscosity correlated with ζ-potential, electrophoretic and viscometric measurements, 1697
Flumizole—anti-inflammatory activity, bioavailability, and formulation, 1469
Fluocinonide—suspension, release from oleaginous ointment bases containing various adjuvants, model predictions, 754
Fluorescamine—reactions with levodopa and derivatives, fluorometric analysis for 3-methoxy-4-hydroxyphenylalanine, 839
—reagent in fluorometric analysis of procainamide hydrochloride dosage forms, 1207
—used to prepare sulfadiazine derivative, specific TLC tissue residue determination of sulfadiazine, 973
Fluorescence characteristics—10 substituted 1,4-benzodiazepines in strong acid, fluorometric and absorptiometric titrations, 651
Fluorescent labeling agents—synthesis of polycyclic aromatic isothiocyanates, relative fluorescence, 925
Fluorocarbon aerosol propellants—binding to human serum albumin determined using partition coefficient method in sealed serum bottles, 1052
—interaction with human and bovine globulins, partition coefficient method, 1577
—interspecies differences in blood and plasma solubilities, toxicity implications, 1538
—pharmacokinetics of trichloromonofluoromethane following single and multiple doses, dogs, 763
Fluoromethalone—effect of drug concentration and vehicle composition on corneal penetration, rabbits, 931
Fluorometry—analysis, aristolochic acid, 345
—analysis, bethanidine in plasma, 785
—analysis, 2,3-bis(*p*-methoxyphenyl)imidazo-[1,2-*a*]pyrimidine, anti-inflammatory agent, biological materials, 2011
—analysis, estrogens in dosage forms, 674
—analysis, procainamide hydrochloride dosage forms, 1207
—analysis, tribromsalan, blood and urine, 2007
—determination, drug–protein association constants, binding of pamaquine by bovine serum albumin, 1677
—reaction of fluorescamine with levodopa and derivatives, analysis for 3-methoxy-4-hydroxyphenylalanine, 839
Fluorouracil—bisulfite-ion-catalyzed degradation, 216
—effect of deoxyuridine coadministration on toxicity and antitumor activity, 943
Flurazepam—isolation of new metabolite using *in vitro* liver drug-metabolizing enzyme system, 1732
Foams, dry—silver sulfadiazine, inhibition of *Pseudomonas* burn infections, 457
Formaldehyde—stabilized colorimetric analysis in aqueous solution *via* reaction with 2,3-dimethyl-2,3-bis(hydroxylamino)butane and sodium periodate, 1043
Formulations—naltrexone–poly(lactic acid) composites, release rates, 348
pharmaceutical—selecting key parameters by principal component analysis, examples, 966
Fungi, marine—determination of free amino acids, 176
Fungicides, potential—synthesis of Michael-type adducts, 1,3-heterocyclic-3-mercaptopropan-1-ones, 355
Furosemide and flucytosine—high-pressure liquid chromatographic analysis in plasma and urine, 1334
Fusidate sodium micelles—molecular weights determined by ultracentrifugation, effects of buffer salts, pH, and sodium chloride and drug concentrations, 873

G

Gallstones, cholesterol—dissolution, identification of drugs, *in vitro* screening systems, 362
—*in vitro* dissolution, T-tube infusion treatment with sodium cholate, 2029
Gastric emptying rates—effects of phosphoric acid and phosphoric acid–carbohydrate solutions, riboflavin bioavailability and salicylamide biotransformation in humans, 1504
mucosa—effect of uridine diphospho-*N*-acetylglucosamine and sodium salicylate on L-glutamine-D-fructose-6-phosphate aminotransferase activity, 1182
Gelatin capsules—rapid production of various capsule sizes and drug dosages, device described, 320
—substrate for growing calcium oxalate crystals, 458
Gels—effect of dilution on reactivity and structure of aluminum hydroxide gel, 940
Genetic effects—povidone-iodine, 1235
Gentamicin—interaction with lipid monomolecular films, surface pressure, π–*A* curves, 516
Gentianaceae—chemical constituents, five tetraoxygenated and three pentaoxygenated xanthones isolated and identified from *S. purpurascens*, screened for pharmacological activity, 80
Geriatric formulations containing vitamins, minerals, and estrogens—colorimetric analysis of ethinyl estradiol, 1221
GLC—analysis, aristolochic acid, 345
—analysis, atenolol, biological samples, 1992
—analysis, caffeine and codeine phosphate, 1686
—analysis, carbamazepine derivative, plasma and urine, 1940
—analysis, carbamazepine in whole blood, 2004
—analysis, 7-chloro-5,11-dihydrodibenz[*b,e*]-[1,4]oxazepine-5-carboxamide in serum and plasma as 5-nitrile derivative, 1531
—analysis, 7-chloro-3,3a-dihydro-2-methyl-2*H*,9*H* -isoxazolo -(3,2-*b*) (1,3)-benzoxazin-9-one in plasma, 1316
—analysis, dextromethorphan and bromhexine salts in pharmaceutical preparations, 1005
—analysis, 17α-ethynylestriol 3-cyclopentyl ether, 1210
—analysis, griseofulvin, collaborative study, 1020
—analysis, heroin and metabolites in human

urine, 1237
—analysis, hexadiphane in pharmaceutical formulations, 1866
—analysis, metronidazole in human plasma, 1048
—analysis, nicotinamide in multivitamin formulations, nicotinonitrile measured after dehydration, 311
—analysis, nordiazepam as clorazepate metabolite after oral administration, determination of clorazepate plasma levels, 1668
—analysis, paramethadione and metabolite serum levels, humans, 1702
—analysis, pentylenetetrazol in plasma and urine, 1843
—analysis, phendimetrazine in human serum, 1041
—analysis, procainamide in biological fluids, 1967
—analysis, saccharin in pharmaceutical products, silyl derivatives formed, 133
—analysis, timolol, biological fluids, 1879
—analysis, tolmetin in plasma, 1965
—determination, ibuprofen enantiomers in biological specimens, 798
—determination, plasma levels of (±)-1,2-bis(3,5-dioxopiperazinyl)propane, rats, rabbits, and humans, 998
—determination, sorbitol and mannitol in pharmaceuticals using tris-*n*-butyldiboronate esters, 128
electron capture—analysis, α,α-dimethyl-4-(α,α,β,β-tetrafluorophenethyl)benzylamine in biological fluids, 814
electron-capture detection—analysis, hydrochlorothiazide in human blood and plasma, 1309
–mass spectrometry—analysis, propoxyphene and metabolites in heroin addict plasma, 429
–mass spectrometry—analysis, scopolamine in plasma and urine, 288
—separation and analysis, cannabidiol, cannabichromene, and cannabivarin synthetic mixtures, on-column methylation, 1719
—separation and analysis, conjugated estrogens in estrogen sodium sulfate salt formulations, 1007
—separation of cannabidiol and cannabichromene, 810
Glidant—effect on flow factor for powder mixtures, optimum concentration, mode of action, 1216
Globulins, human and bovine—interaction with fluorocarbon aerosol propellants, partition coefficient method, 1577
Glutamic acid analogs—syntheses, inhibition of plasmodia, bacteria, and fungi, toxicity in mice, potential antimalarial activity, 1855
L-Glutamine-D-fructose-6-phosphate aminotransferase activity—inhibition by sodium salicylate and uridine-5′-diphospho-*N*-acetylglucosamine, rat gastric mucosa, 1182
Glutaraldehyde—aqueous equilibria determined using ^{13}C-NMR, estimation of free aldehyde, relationship to pH, antibacterial activity, 1078
Glutarimide derivatives—6-alkyl-3-phenylglutarimides synthesized and screened as possible antineoplastic agents, 262
Glycosyl bonds—analysis of bond length in crystal structures of nucleosides and nucleotides, 1707
Goldfish—model for determining structure–activity relationships of local anesthetics, 1713
Gossypol—isolated from *Montezuma speciosissima*, PMR, UV, IR, and mass spectra, tumor inhibitory activity, 1889
—screened for antiviral activity, 1073
Granulating adjuvants—effect on drying rates of tablet granulations, 135
Granulations, tablet—drying rates, effect of particle size and granular densities, 1023
Griseofulvin—bioavailability, use of 24-hr urinary excretion data, humans, 709
—GLC analysis, collaborative study, 1020
micronized, absorption kinetics—corn oil-in-water emulsion compared to aqueous suspension, single and multiple doses, rats, 1475
micronized—bioavailability from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms, humans, 793
Guaiacolsulfonate potassium—colorimetric determination in cough syrups, 2001
***Gymnodinium breve* Davis**—isolation and partial characterization of three neurotoxins, 865

H

Haloperidol—influence of mesenteric blood flow on intestinal absorption, *in situ* canine intestinal preparation, 664
Hansch analysis—interaction of haptens with benzylpenicilloyl antibodies, 1671
Heavy water—carcinolytic agent, measure of total body water, neutron radiography, review, 367
Hemolytic effects—data for 44 drugs, 1884
Hepatic blood samples, venous—improved method for sampling in the rat, 895
metabolism, first-pass effect—comparison of observed and predicted nortriptyline bioavailability in humans, 1036
Herbadine—structure elucidation, *V. libanotica* alkaloid, 341
Heroin and metabolites—GLC analysis in human urine, 1237
Heterocycles (amino, chloro, cyanomethyl, and sulfonamido)—condensation products with carbon disulfide, antiradiation activity, 1371
Heterocyclic alkyl disulfides, thiosulfates, and dithio acid derivatives—synthesis and antimalarial activity, 211
1,3-Heterocyclic-3-mercaptopropan-1-ones—synthesized as potential fungicides, 355
Hexachlorophene—colorimetric analysis in topical formulations, modified 4-aminoantipyrine dye formation method, elimination of interferences, 125
Hexadiphane—GLC analysis in pharmaceutical formulations, 1866
Hexamethylmelamine—solubilization by complexation with gentisic acid species, intravenous formulations, 1850
High-pressure liquid chromatography—analysis, acetazolamide in plasma, 402
—analysis, ampicillin and penicillins G and V, 1542
—analysis, antispasmodic mixtures, 1389
—analysis, chlorpropamide tablets, 123
—analysis, flucytosine and furosemide in plasma and urine, 1334
—analysis, penicillin G potassium and degradation products, 1384
—analysis, pilocarpine–isopilocarpine mixtures, 1700
—analysis, polythiazide dosage forms, 1406
—analysis, triflubazam (a 1,5-benzodiazepine) and its metabolites in human and animal blood and urine, 1339
—assay of sulfacetamide ophthalmic solutions, 1017
—automated analysis, aspirin, phenacetin, and caffeine, 1029
—automated equipment developed and discussed, 1557
—determination, dapsone impurities in pharmaceutical preparations, 1205
—residue analysis, sulfamethazine, bovine tissue, 1657
—separation, diuretic–antihypertensive mixtures, 1201
—simultaneous determination of phenobarbital and diphenylhydantoin in plasma, development and evaluation of method, 806
High-speed liquid chromatography—analysis, simultaneous, rolitetracycline and tetracycline in rolitetracycline and rolitetracycline nitrate formulations, 316
—analysis, sulfasalazine bulk and tablet forms, 1549
—simultaneous identification and quantitation of methandrostenolone and related steroid impurities, 441
Himachalol—spasmolytic constituent of *C. deodara*, pharmacological evaluation, 258
Hormonal interactions—bovine neurophysins–oxytocin, PMR, 507
Hydrochlorothiazide—GLC analysis in human blood and plasma, 1309
Hydrogen bonding of barbiturates and primidone with polyethylene glycol—characterized by IR spectrophotometry, 1787
peroxide-induced hydroxylation—reactions with anhydronucleoside 2,2′-anhydro-1-β-D-arabinofuranosylcytosine and cytarabine, 424
Hydrolysis, 5-azacytidine in aqueous solutions—kinetics and mechanisms, effect of pH, temperature, and buffer concentration, 1148
—benzodiazepines, velocity constants for chlordiazepoxide hydrolysis, TLC and extraction procedures compared, 278
—fatty acid esters of acetaminophen, buffered pancreatic lipase systems, 117
—glycosyl bonds, analysis of bond length in crystal structures of nucleosides and nucleotides, 1707
—quantitation of procaine stability by TLC, rate constants, 275
4-Hydroxyantipyrine—effect on metabolism of antipyrine and sulfanilamide, rats, 1928
2-(4′-Hydroxybenzeneazo)benzoic acid—used to determine binding of sulfonylureas and phenothiazines to bovine serum albumin, difference spectrophotometry, 1177
17-Hydroxycorticosteroids—colorimetric analysis in human urine, 1050
18-Hydroxydeoxycorticosterone—synthesis, 168
6β-Hydroxynaltrexone—isolation and identification as naltrexone metabolite in guinea pig, 618
6α-Hydroxynaltrexone—synthesis *via* chemical reduction of naltrexone, 618
β-Hydroxyphenethylamines, 4-methoxy and *N*-methyl derivatives—synthesis, screened for monoamine oxidase inhibition, 1431
18-Hydroxyprogesterone—synthesis, 168
Hydroxypropyl cellulose–polyvinyl acetate films, laminated—linear drug release, 1285
8-Hydroxyquinoline analogs—synthesis and antibacterial and antiplaque activities, 1563
3β-Hydroxysterols—separation from other sterols by dextran gel chromatography, 161
Hymenocles salsola (Asteraceae)—isolation and identification of ambrosin, a tumor inhibitory agent, 837
Hypoglycemic agents, potential—carnitine analogs, synthesis, biological evaluation, IR and NMR spectra, 1949
potential—synthesis and screening of indolizine derivatives, 249
potential—synthesis and screening of *N*-substituted indanamines, 172
—synthesis and screening of sulfonylureas, tissue distribution of ^{99m}Tc-chelates, 687
Hypolipidemic activity—2,8-dibenzylcycloctanone, 235
Hypothermia—effect of intraperitoneal and intraventricular administration of allylglycine, rats, 835

I

Ibuprofen—GLC determination of enantiomers in biological specimens, 798
Imidazoles, triazenyl—preparation, antileukemic activity, 177
Iminoacridan—confirmed as structure of singly protonated 9-aminoacridine, 1256
Imipramine—effects on conditioned avoidance response, conscious cat, 1647
Implants—estradiol polyethylene–silicone composite, use as a timed-release device, 832
Inclusion compounds—polymolecular, monomolecular, blue-iodine reaction products, and macromolecular, review, 1585
Indanamines, *N*-substituted—synthesized and screened as hypoglycemic agents, 172
Indeno[1,2-*c*]pyrazoles, 1-ethyl-3-substituted-4-

aryl-4-hydroxy (mazindol analogs)—synthesis, effect on forced and spontaneous motor activity, mice, 1375
Indolizine derivatives—synthesized and screened as possible oral hypoglycemic agents, 249
Inorganic additives—effect on solutions of nonionic surfactants, 658
Inorganic salts—as stabilizers of antibiotic–steroid ophthalmic preparations, 1528
Interactions—drugs with biomolecules, symposium, 473, 479, 488, 493, 497, 501, 507, 512, 516, 520, 528
gas–albumin—binding of fluorocarbon propellants to human serum albumin, 1052
—20 orally administered drugs with sodium nitrile, formation of *N*-nitroso, C-nitroso, and nitro compounds under physiological conditions, 1579
—parabens–flavoring agents in aqueous medium, effect on preservative concentrations, oral liquid dosage forms, 414
potential—metronidazole and divalent metal ions, studied using NMR spectroscopy and ac polarography, 957
Interfaces—mechanisms and kinetics of interactions, surface pressure and surface potential, 477
Intestinal net water flux—effect of various alcohols, glycerin and propylene glycol effect on theophylline absorption in the rat, 607
pH, rats, dogs, and rabbits—*in situ* determination, factor in selection of animal model for bioavailability testing, 1726
Intravenous preparations—behavior of erythrocytes in ternary solvent systems, 1818
Iodine—analysis of individual thyroid tablets, 1393
Iodochlorhydroxyquin and corticosteroid formulations—partition chromatographic separation, complexiметric analysis of iodochlorhydroxyquin, blue tetrazolium analysis of corticosteroid, 1013
Ionization—phenylbutazone, nonclassical phase transfer behavior, 706
Ion-pair extraction—prostaglandin B_2 with aliphatic amines, methylene group contribution, partition coefficients, 1894
Irradiation, cobalt-60—effects on viscosity of acacia and sodium alginate, 802
IR spectrophotometry—association of carbonate and aluminum in aluminum hydroxide gel, 468
—characterization, hydrogen bonding between barbiturates and polyethylene glycol 4000, 1787
—identification, carrageenan isolated from *Ahnfeltia concinna,* 1704
—monitoring, structural changes in aluminum hydroxide gel during aging, compared to X-ray diffraction method, 1166
Isatin *N*-Mannich bases—synthesis, screened for antiviral, antibacterial, and antifungal activities, 881
Isoniazid—colorimetric analysis with 9-chloroacridine, 1403
Isothiocyanates—antidermatophytic activity, 164
polycyclic aromatic—synthesized as fluorescent labeling agents, relative fluorescence, 925

J

K

Ketonitrophenols—isolated and prepared from mestranol on silica gel, mechanism, 777
Kinetics—benzodiazepine hydrolysis, 278
—rapid nonisothermal–isothermal method for stability prediction, 1381

L

Lactose granules—effect of physical properties on compression characteristics, 1213
Laminated hydroxypropyl cellulose–polyvinyl acetate films—linear drug release, 1289
Lasalocid—spectrophotofluorometric analysis in blood after intravenous administration, dogs, 1874
Latentiated drugs—design of prodrugs, review, 181
Laurocolombine—isolation from *Catharanthus roseus,* UV, IR, NMR, and mass spectral structure identification, 1953
Levodopa and derivatives—reaction with fluorescamine, fluorometric analysis for 3-methoxy-4-hydroxyphenylalanine, 839
Lidocaine derivatives—disposition of *N,N*-bis-(phenylcarbamoylmethyl)dimethyl ammonium chloride in rat, first-pass metabolism, 359
hydrochloride—absorption from subcutaneous site, design of closed subcutaneous absorption cell, 781
Ligand–carbonic anhydrase interactions—kinetics studied by magnetic resonance relaxation and rapid reaction methods, 501
Lignans—isolation and identification from *L. album,* screened for anticancer and cytotoxic properties, 95
Lincomycin and clindamycin combinations—comparison of effect on *Staph. aureus* and *E. coli,* microbial kinetics, drug–bacteria reactions, generation curves, 1621
Linum album (Linaceae)—isolation and identification of antitumor and cytotoxic lignans, 95
Lipase—enzymatic hydrolysis of fatty acid esters of acetaminophen, 117
Lipid–drug delivery systems—oral absorption efficiency of penicillin G potassium, penicillin V potassium, and erythromycin lactobionate from cholesterol, cholesteryl acetate, and β-sitosterol protective carriers, 869
Lipids, membrane—effects of anesthetics, electron spin resonance spectra, 497
Lipophilic binding of 13 disopyramide derivatives to human plasma—relationship to pKb, 1632
ointment bases—effect of ethoxylated surfactant chain length on drug release, 1055
Lipophilicity and structure of disopyramide and 20 derivatives—relationship to protein binding, 961
Liquid chromatography, high performance—determination of acetaminophen in pharmaceutical preparations and body fluids, electrochemical detection, 680
high speed—simultaneous determination in plasma of phenylbutazone and oxyphenbutazone, 284
—separation, clindamycin 2-phosphate from other clindamycin compounds, 313
Liquid texture—predicting subjective spreadability, viscosity, and stickiness, 976
Liriodendron tulipifera **L.**—isolation and identification of two antimicrobial alkaloids from heartwood, 789
Liriodenine—isolated from *Liriodendron tulipifera,* screened for antimicrobial activity, 789
Literature review—pharmaceutical sciences 1974, 1085
19α-H-Lupeol—isolation, identification from Osage orange (*Maclura pomifera*), 104
Lupeol and 19α-H-isomer—structure determination, 152
Lysergide—isolation, agarose-bound antibodies to lysergic acid, column chromatography, 1890
Lysine and tryptophan supplementation—effect on human plasma cholesterol and triglyceride levels, 691
supplementation—effect on rat serum cholesterol levels, 690

M

Maclura pomifera (Osage orange)—reinvestigation of constituents, isolation and identification of 19α-H-lupeol, 104
Macromolecular inclusion compounds—zeolites, dextrans, and silica gels, review, 1585
Mafenide—dry foam formulation, inhibition of *Pseudomonas* burn wound infection, 339
Magnesium and aluminum hydroxides suspension—effect on urine pH, 2003
Mammalian biotransformations—parallel microbial transformations, review, 1737
cells, suspension culture—uptake and release of cardiac glycosides, systems approach to study of drug transport across membranes, 631
cells, suspension cultures—uptake and release of sterols, systems approach to study of drug transport across membranes, 627
Mangiferin—activity against *Mycobacterium tuberculosis,* 888
Mannich bases (related to styryl ketones)—antitumor evaluation, 241
Mannitol—GLC determination in pharmaceuticals using tris-*n*-butyldiboronate esters, 128
Marijuana—constituents of *Cannabis sativa,* samples of known geographical origin, 892
—stability of synthetic and naturally occurring cannabinoids in chloroform, 357
Marine fungi (higher)—determination of free amino acids from Ascomycetes and Fungi Imperfecti, 176
Mass fragmentography—determination, plasma levels of (±)-1,2-bis(3,5-dioxopiperazinyl)propane, rats, rabbits, and humans, 998
Mass spectrometry—identification, 4-dedimethylamino - 11 - methoxyanhydrotetracycline, 1635
—impurities, toluidine blue O and related dyes, 1456
mixed electron impact–chemical ionization—structure determination, 1581
Maternal–fetal transfer—phthalate diesters (radiolabeled), distribution and persistence in maternal blood, fetal tissue, amniotic fluid, and placenta, intraperitoneal administration, rats, 1347
Matrix systems—controlled release of ethynodiol diacetate from silicone rubber devices, comments, 1731
Mazindol analogs—synthesis, effect on forced and spontaneous motor activity, mice, 1375
—solvolysis in aqueous solutions, pH up to 7.6, 1833
—structure determination, diffuse UV reflectance spectroscopy, 829
Medicinal plants—*Achillea millefolium,* isolation and identification of flavone components, 1838
—antitubercular activity of xanthones of *Canscora decussata* Schult, 888
—extraction of eleutherin and eleutherol from *Eleutherine bulbosa,* pharmacological screening, 1305
—isolation and identification of tetraoxygenated and pentaoxygenated xanthones from *S. purpurascens,* screened for pharmacological activity, 80
—pharmacological evaluation of himachalol from *C. deodara,* 258
—sources of antifertility agents, classified by anatomical mechanism and folkloric route of administration, review, 535, 717
Membrane diffusion—systems approach to drug transport, uptake and release of cardiac glycosides by Burkitt lymphoma cells, influence of serum–drug binding, membrane–drug binding, cell interior binding, and intrinsic membrane permeability, 631
diffusion—systems approach to drug transport, uptake and release of desmosterol, cholesterol, and β-sitosterol by Burkitt lymphoma cells, effective permeability and partition coefficients determined and related to sterol–serum binding, 627
permeation—osmotic process, controlled rate drug delivery system, 1986
Menadione—effect of quaternary ammonium compound on UV photodegradation rate, complex formation, 696
2-Mercapto -5-methyl- 1,3,4- thiadiazole—NMR analysis in cefazolin and cefazolin sodium, 1396
Mercaptopurine derivatives—crystal and molecular structures of azathioprine dihydrate and 6-methylmercaptopurine trihydrate, 221
Mercurials—determination by vapor phase atomic absorption spectroscopy, compared to compendial methods, 1863

Mescaline—synthesis of conformationally constrained analog, methyl-2-(3,4,5-trimethoxyphenyl)-2-(2-piperidyl) acetate, IR and NMR spectra, 2013
Mesothelioma, asbestos induced—review of asbestos chemistry, industrial exposure, animal and human toxicology, and carcinogenic aspects, 1435
Mestranol—ketonitrophenols as decomposition products, mechanism, 777
Metabolism—acetaminophen, estimation of hepatic first-pass effect, oral administration, humans, 1734
—11 cephalosporin antibiotic derivatives, pharmacokinetics, clinical considerations, review, 1899
—chlorpromazine assayed by quaternization and photolysis, picomole quantities, 950
first pass—*N,N*-bis(phenylcarbamoylethyl)dimethyl ammonium chloride in rat, 359
—flurazepam, isolation of potent metabolite, *in vitro* liver drug-metabolizing enzyme system, 1732
—8-(methylthio)cyclic 3′,5′-adenosine monophosphate in dogs and rats after oral and intravenous doses and *in vitro* by subcellular dog liver preparations, 1604
minoxidil—biotransformation in rat, dog, and monkey after oral administration, compared to reported human metabolism, 1366
—nafiverine, rats, rabbits, and mice, 253
—nicotinamide, coenzymes, nicotinamide dinucleotides, apoenzymes, 528
—oxyphenbutazone, phenytoin, antipyrine, sulfanilamide, effect of hydroxylated metabolites, rats, 1928
—*trans*-stilbene, intestinal reduction of 4,4′-dihydroxystilbene, 471
—triamcinolone acetonide-^{14}C-21-phosphate after intravenous and intramuscular administration, dog, monkey, and rat, 1351
Metal ions, divalent—potential interaction with metronidazole studied using NMR spectroscopy and ac polarography, 957
Methandrostenolone and related steroid impurities—simultaneous identification and quantitation by high-speed liquid chromatography, 441
(±)-4-Methoxy-β-hydroxyphenethylamine and *N*-methyl derivatives—synthesis, screened for monoamine oxidase inhibition, 1431
3-Methycholanthrene—effects on guinea pig lung enzymes, 1421
Methylation of 4-dedimethylaminoanhydrotetracycline with diazomethane—isolation and identification of one reaction product, 1635
6-Methylmercaptopurine trihydrate—crystal and molecular structures, 221
***N*-Methylpavine** (enantiomeric bisquaternary amines)—probes for stereochemical preferences for curarimimetic neuromuscular junction blockade, 62
2-*N*-Methylpiperazinyl-1,3,4-thiadiazoles, 5-substituted—synthesis and pharmacological activity, 1250
8-(Methylthio)cyclic 3′,5′-adenosine monophosphate—metabolism, dogs and rats after oral and intravenous doses, *in vitro* metabolism by subcellular dog liver preparations, 1604
Methylthionine, radiolabeled—tissue distribution, considerations related to use as pancreas or parathyroid scanning agent, 1068
Methyl-2-(3,4,5-trimethoxyphenyl)-2-(2-piperidyl) acetate—analog of mescaline, synthesis, IR and NMR spectra, 2013
Metrizamide—pharmacokinetics after intrathecal administration, concentration in cerebrospinal fluid, humans, 405
Metronidazole and four derivatives—plasma protein binding, correlation with frontier electron density, 1797
—GLC analysis in human plasma, 1048
—interaction with divalent metal ions studied using NMR spectroscopy and ac polarography, 957
Micellar–aqueous partition coefficients—benzoic acid and derivatives in polysorbate 20, 1253
Micellar solutions of penicillin G—degradation compared to nonmicellar solutions, pH–rate profiles, 1378
Micelles— 2-butyl- 3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride, relationship to solubility, 1830
size of fusidate sodium—determined by ultracentrifugation, effects of buffer salts, pH, and sodium chloride and drug concentrations, 873
Microbial kinetics—drug action on Gram-positive and Gram-negative organisms, comparison of clindamycin action on *Staphylococcus aureus* and *Escherichia coli,* 1612
kinetics—effect of lincomycin and clindamycin combinations on *Staph. aureus* and *E. coli,* drug–bacteria reactions, generation curves, 1621
transformations—parallel mammalian metabolism, review, 1737
Microbiology, analytical—automated system, calibration lines for antibiotics, 844
—determination of drug partitioning, drug–protein interactions, four antimicrobials, gelatin–acacia complex coacervates, 420
—diffusion assay of antibiotics, design and application, 1224
Microencapsulation—soluble pharmaceuticals, 889
Minoxidil—biotransformation in rat, dog, and monkey after oral administration, compared to reported human metabolism, 1366
^{14}C-labeled—absorption, distribution, and excretion after oral and intravenous administration, rats, dogs, and monkeys, 1360
Models, hydrodynamic analog—proposed for pharmacokinetics, applications, equations, 88
hydrodynamic diffusion analog—proposed for pharmacokinetics, critical examination, equations, 92
Moisture—decomposition of aminosalicylic acid in solid state, 37
Molecular connectivity—correlation with polarizability, cavity surface areas, and biological potencies, hydrocarbons, alcohols, nonspecific local anesthetics, 1971
—correlation with water solubility and boiling point, hydrocarbons, alcohols, 1974
—relationship to octanol–water partition coefficients of various chemical classes, 1978
Molephantinin—isolation, structure determination, and antitumor activity, 1077
Monoamine oxidase inhibitors—substituted benzthiazoles, relationship between enzyme inhibitory and anticonvulsant activities, rat brain homogenate, 1245
—synthesis and screening of 2-(*N*-arylcarboxamide)-3-substituted ethoxyindoles, rat brain homogenate, 1001
—synthesis and screening of (±)-4-methoxy-β-hydroxyphenethylamine and *N*-methyl derivatives, 1431
—synthesis of benzylidinohydrazines, 154
—thiosemicarbazides, relationship to antihemolytic (membrane stabilizing) and anticonvulsant properties, inhibition of cellular respiratory activity, selective inhibition of NAD-dependent oxidation, 1329
17-Monochloroacetylajmaline and ajmaline—TLC determination in plasma, 643
Monoethers, alkyl triethylene glycol—synthesis, evaluation as mosquito repellents, 693
Monolayers—cholesterol and dipalmitoyl lecithin, molecular arrangement, force–area isotherms, model, 1534
interactions—kinetics and mechanisms for time-dependent effects of cetrimonium bromide injected beneath air–aqueous solution interface without previously adsorbed or spread monolayer at different ionic strengths, 1782
phospholipid—mechanisms and kinetics of interactions of biomolecules of interfaces, 477
Monomolecular films—interaction of biologically important lipids with gentamicin, surface pressure, π–*A* curves, 516
inclusion compounds—cyclodextrins, review, 1585
Mononucleotides—interactions with polybasic amino acids, 473
Montezuma speciosissima—extract, PMR, UV, IR, and mass spectra, gossypol isolated, 1889
Montmorillonite clay—sorption of neomycin sulfate, influence of monovalent and divalent electrolytes, Langmuir isotherms, 1566
Morphine—isolated from *Papaver somniferum* germinated and cultivated from commercial poppy seeds, TLC, column chromatography, IR and mass spectra, 2024
normorphine, and 6-monoacetylmorphine (heroin metabolites)—GLC analysis in human urine, 1237
Mosquito repellents, topical—synthesis, evaluation of alkyl triethylene glycol monoesters, 693
Multicomponent dosage forms—high-pressure liquid chromatographic separation of diuretic–antihypertensive mixtures, 1201
Multiple dosing, nonuniform—mathematical derivation of pharmacokinetic equation, 464
Multivitamin formulations—GLC analysis of nicotinamide, conversion to nicotinonitrile, 311
Muscle relaxants, activity—5-chloro-2-pyrimidinyl analog of dantrolene, 337
potential—synthesis and screening of 3,3′-bisbufotenidine analog, neuromuscular blocking activity, 1082
Mutagenicity—povidone-iodine, 1235
Mycophenolic acid—synthesis and antitumor evaluation of nitrogen analogs, 84
Mydriasis induction as measure of peripheral anticholinergic activity—tertiary and quaternary derivatives of atropine and scopolamine, compared to physostigmine-induced lethality inhibition (central activity), mice, 1066

N

Nafiverine—stability, absorption, excretion, and distribution, intramuscular, intravenous, and oral administrations, rats, rabbits, and mice, 253
Naltrexone—chemical reduction to 6α-hydroxynaltrexone, metabolism in dog, rat, and guinea pig, 618
—release rates from poly(lactic acid) composites, long acting delivery systems for narcotic antagonists, 348
Narcotics, antagonists—long acting delivery systems, naltrexone–poly(lactic acid) formulation, release rates, 348
—morphine, isolated from *Papaver somniferum* germinated and cultivated from commercial poppy seeds, TLC, column chromatography, IR and mass spectra, 2024
Neomycin sulfate—sorption to attapulgite and montmorillonite clays, influence of monovalent and divalent electrolytes, Langmuir isotherms, 1566
Neuroblastoma—cytolytic effects of bromoacetylcholine *in vitro,* 469
Neuromuscular and blood pressure effects—clindamycin phosphate, cats, 861
blocking activity—3,3′-bisbufotenidine analog, effect of size, 1082
junction blockade, curarimimetic—stereochemical preferences, enantiomeric bisquaternary amines as probes, 62
junction blockade, curarimimetic—stereochemical preferences, enantiomeric bisquaternary amines related to benzoquinonium as probes, 67
junction blockade, curarimimetic—stereochemical preferences, seven pairs, of enantiomeric monoquaternary amines as methiodides as probes, 53
Neurophysins, bovine—complex formation with oxytocin, PMR, 507
Nickel complex formation—analysis, iodochlorhydroxyquin after separation from iodochlorhydroxyquin and corticosteroid formulations, 1013
Nicotinamide—GLC determination in multivitamin

formulations, conversion to nicotinonitrile, 311
Nidation—inhibition by four ergoline-type compounds, rats, relationship to prolactin-inhibiting ability, 1045
Nitrite–drug interactions—formation of *N*-nitroso, C-nitroso, and nitro compounds from sodium nitrite and 20 drugs under physiological conditions, 1579
Nitrofurantoin—absorption, effect of propantheline, 1729
—solubility in aqueous urea solutions, 886
5-Nitro-2-furfurylidene polyhalophenoxyacethydrazides—synthesis, antibacterial and antifungal activities, 858
Nitrogen dioxide—effects on guinea pig lung phenol-*O*-methyltransferase, catechol-*O*-methyltransferases, and benzpyrene hydroxylase, 1421
Nitroglycerin sublingual tablets—stability study, loss of strength, uniformity of tablets, and degradation of drug, 140
3- [[5 -(*p*- Nitrophenyl)furfurylidene]amino]hydantoin (dantrolene positional isomer)—screened for skeletal muscle relaxant activity, 1047
Nitroso compounds—formation from sodium nitrite and 20 orally administered drugs under physiological conditions, 1579
NMR spectroscopy—analysis, 2-mercapto-5-methyl-1,3,4-thiadiazole in cefazolin and cefazolin sodium, 1396
—determination, aqueous glutaraldehyde equilibria, estimation of free aldehyde, relationship to pH, 1078
—evaluation, binding of substrate and inhibitors to acetylcholinesterase, 488
Nonaqueous titration—chlorpromazine hydrochloride, chemistry, 129
Nonisothermal kinetic studies—rapid nonisothermal–isothermal method for stability prediction, 1381
Nonsink dissolution of monodisperse powders—various rate equations examined, 1651
Nordiazepam—GLC analysis in plasma as clorazepate metabolite, dogs, 1668
***l*-Norepinephrine** accumulation by nonstriatal synaptosomes—inhibition by *N*-arylalkyl- and *N*-aryloxyalkyl-substituted amphetamines, 1462
Norepinephrine—analysis in plasma and cerebrospinal fluid of rats by pithed blood pressure method, 1733
Norpropoxyphene and cyclic dinorpropoxyphene—GLC analysis in heroin addict plasma after propoxyphene napsylate administration, 429
***d*-Norpseudoephedrine**—urinary excretion after mastication of *Catha edulis*, humans, 702
Nortriptyline bioavailability in humans—predicted by first-pass equation, compared retrospectively to oral administration in twin pairs, 1036
Nucleosides and nucleotides—analysis of *N*-glycosyl bond length in crystal structures, 1707
mixed—mononuclear aggregations, dilute aqueous solutions, osmometric measurements, theoretical considerations, 770
Nucleotide phosphodiesterases, cyclic—review of properties, possible role in drug development, 1
Nutrition—effect of lysine and tryptophan supplementation on human plasma cholesterol and triglyceride levels, 691
—effect of lysine supplementation on rat serum cholesterol levels, 690
Nylon (formalin treated) gelatin microcapsules—preparation, physical properties, 889

O

Octapeptide (cyclic) antibiotic biosynthesis—colorimetric monitoring in fermentation broths, ion-pair formation with bromthymol blue, 1401
Ocular bioavailability—effect of vehicle viscosity, polyvinyl alcohol and methylcellulose solutions, rabbits, 1312
drug bioavailability, fluorometholone—effect of drug concentration and vehicle composition on corneal penetration, rabbits, 931
Ointments, bases, lipophilic—effect of ethoxylated surfactant chain length on drug release, 1055
bases—release of corticoids in suspension, 754
—benzocaine absorption, rectal administration, rats, 1958
ophthalmic—colorimetric analysis of bacitracin, 307
Ophthalmic drug bioavailability—effect of topical anesthetics on solution drainage and tear turnover, rabbits, 267
formulations—antibiotic–steroid preparations, stabilizing effect of inorganic phosphate salts, drocinonide phosphate potassium–neomycin sulfate complex studied, 1528
ointments—colorimetric analysis of bacitracin, 307
solutions—carbachol interactions with cornea, relation to miotic activity, mechanism, bioelectrometry, 520
vehicles—evaluation of polyvinyl alcohol, compared to methylcellulose, optimum viscosity range, rabbits, 1312
Opium alkaloids—isolation and identification of (−)-stepholidine, 1040
Optical activity, intrinsic and extrinsic—purity criterion for human serum albumins, circular dichroism studies, 1508
Organophosphorus compounds—partitioning of dichlorvos between liquid and liquid crystalline phases, effect of associated colloid structures, 822
Osage orange (*Maclura pomifera*)—reinvestigation of constituents, isolation and identification of 19α-H-lupeol, 104
Osmotic pump—osmotic process, controlled rate drug delivery system, release rates, equations, 1987
Oxalic acid dihydrate (polydisperse powder)—dissolution patterns, equations, 1770
Oxidation, pyruvic acid—effect of piperazinoureas, relationship to anticonvulsant activity, 454
18,20-Oxido-20-hydroxy-4-pregnen-3-one—synthesis, 168
5-Oxo-1-thiocarbamoyl-3-pyrazoline-4-alkanoic acid derivatives—synthesis, antitubercular activity, 1057
Oxygen permeability of soft gelatin capsules—effects of relative humidity, plasticizers, equilibrium water, insoluble additives, and film thickness, 851
Oxyphenbutazone—effect on metabolism of phenytoin and sulfanilamide, rats, 1928
–phenylbutazone—simultaneous determination in plasma, high-speed liquid chromatography, 284
Oxytocics—plants with active constituents, review, 535, 717
Oxytocin—complex formation with bovine neurophysins, PMR, 507

P

Pamaquine—binding by bovine serum albumin, fluorometric determination of drug–protein association constants, 1677
Pancreatic imaging agents, potential—synthesis and tissue distribution of ^{99m}Tc-sulfonylureas, 687
***Papaver* alkaloids**—isolation and identification from *P. orientale* and *P. pseudo-orientale*, 1570
Papaver somniferum—germination and cultivation from commercial poppy seeds, morphine content, TLC, column chromatography, IR and mass spectra, 2024
Parabens, alkyl—role in formation of phenol by bacteria, 1071
—partitioning from aqueous systems, effect of flavoring oils on concentrations in oral liquid dosage forms, 414
Paramethadione and metabolite—serum levels, single oral dose, humans, GLC analysis, 1702
Parenteral dosage forms—lidocaine hydrochloride absorption from subcutaneous site, design of closed subcutaneous absorption cell, 781
Parquetina nigrescens (Afzel.) Bullock (Asclepiadaceae)—isolation and identification of cytotoxic principles, 1674
Particle dissolution—size distribution effects, log-normal powders, three single-particle models investigated, 1981
size, disintegrating compacts—determination, relationship between particle size and nature of compaction process, 444
size, distribution—effect on dissolution profile, general equation, applicability to dissolution of log-normal powders, 1192
size, effect—aspirin absorption from suppositories, 878
size—effect on drying rates of tablet granulations, 1023
size—sieve cuts, monodisperse powders from sieve cuts, introduction of error, 1409
Partition chromatography—separation, iodochlorhydroxyquin and corticosteroid formulations, 1013
coefficients, dichlorvos—determination in pure liquids, micellar solutions, and liquid crystalline phases, effect of associated colloid structures, 822
coefficients, disopyramide and 20 derivatives—determination, 961
coefficients, 13 disopyramide derivatives—determination, 1632
coefficients—ion-pair extraction of prostaglandin B_2 with aliphatic amines, methylene group contribution, 1894
coefficients—octanol–water, relationship to molecular connectivity of various chemical classes, 1978
coefficients—10 quinoline monocarboxylic acid derivatives in chloroform–water system, sigma and pi constants, 867
Partitioning systems—selection of a reference for drug design work, structural, polar, and transport properties of solvent and water phases, *n*-octanol–water system and others, 599
Penicillins G and V—high-pressure liquid chromatographic analysis, 1542
(potassium)—oral absorption efficiency from lipid–drug delivery systems, 869
Penicillin G potassium and degradation products—high-pressure liquid chromatographic analysis, 1384
degradation—concentrated aqueous micellar solutions compared to nonmicellar solutions, pH–rate profiles, 1378
Penicilloic acid and penilloic acid haptens—interaction with benzylpenicilloyl specific antibodies, Hansch analysis of inhibition data, 1671
Pentobarbital—effects on conditioned avoidance response, conscious cat, 1647
Pentylenetetrazol—GLC analysis in plasma and urine, 1843
Perchloric acid—catalyst for acylation of phenol in anhydrous acetic acid, rate constants, mechanisms, 1766
—catalyst for solvolytic reactions of cyclic anhydrides in anhydrous acetic acid, 1759
Percutaneous absorption—review of *in vitro* and *in vivo* penetration methods, skin transport, physicochemical factors, sorption promoters, 901
Perfusion studies—apparatus for continuous monitoring of flow rate, 1730
Permeability, epidermal—*in vivo* method for monitoring effect of polysorbate 85, relative water loss rates, 671
Permeation rate technique for determining drug–macromolecule interactions—tested using methylparaben with polyvinylpyrrolidone and polysorbate 80, 946
pH—saliva and urine, relationship, 890
urine—effect of magnesium and aluminum hydroxides suspension, 2003
Pharmaceutical applications of solids—review of crystal habit, amorphous solids, polymorphs, solvates, and clathrates, 1269
formulations—selecting key parameters by principal component analysis, examples,

966
sciences—1974 literature review of pharmaceutics, 1085
Pharmacokinetics—carbamazepine, intravenous and oral administrations, monkeys, 302
—cefazolin, changes due to stress, 712
—11 cephalosporin antibiotic derivatives, absorption, metabolism, excretion, clinical considerations, review, 1899
—2,2-dimethylaziridine-type alkylating agents in biological systems, dogs, 230
—distribution parameters, mechanistic evaluation of modifications, model organic anions in presence of model renal tubular secretion inhibitor, rats, 1813
—distribution parameters, use of model compounds to evaluate effects of chemical modifications, mechanisms of transmembrane transport, rats, 1804
—dose adjustment in renal failure, rate constants, 175
—hydrodynamic analog model proposed, evaluation of elimination rate constant, volume of distribution, and permeability properties, 88
—hydrodynamic diffusion analog model proposed and critically examined, equations, 92
—literature review, 1085
—mathematical derivation of nonuniform multiple-dosing equation, 464
—metrizamide absorption from subarachnoid space after intrathecal administration, humans, 405
models—primary antibody response, 1325
—polychlorinated biphenyls in swine and sheep after single oral dose, 1294
—prednisone in humans, absorption rate constants and serum half-lives, *in vitro–in vivo* implications, 109
—trichloromonofluoromethane, single and multiple doses, dogs, 763
Phenacetin, aspirin, and caffeine—automated high-pressure liquid chromatographic analysis, 1029
Phendimetrazine—GLC analysis in human serum, 1041
Phenobarbital–diphenylhydantoin—simultaneous high-pressure liquid chromatographic determination, plasma, 806
Phenol—acylation by cyclic and acyclic anhydrides in anhydrous acetic acid, rate constants, mechanisms, 1766
—formation from alkylparabens by bacteria, 1071
Phenolated calamine lotion—colorimetric analysis of phenol, 1199
Phenolic drugs—use of amino acid esters as prodrugs, 1070
Phenolsulfonphthalein absorption—dioctyl sodium sulfosuccinate effect, humans, 991
Phenothiazines and sulfonylureas—binding to bovine serum albumin, difference spectrophotometry using 2-(4′-hydroxybenzeneazo)benzoic acid, 1177
—antibacterial activity against human intestinal anaerobic bacteria determined *in vitro,* 700
Phenylacetyltropine—internal standard in GLC analysis of scopolamine and hyoscyamine in *Duboisia* samples, 1821
Phenylbutazone—nonclassical phase transfer behavior, pH and buffer effects, dissolution and ionization rates, 706
–oxyphenbutazone—simultaneous determination in plasma, high-speed liquid chromatography, 284
tablets—effect of aging on physical properties, 335
Phenytoin—biotransformation, effect of oxyphenbutazone, rats, 1928
—*see* also Diphenylhydantoin
Pholcodine—analysis in cough preparations, 1011
Phosphodiesterases, cyclic nucleotide—properties, activators, inhibitors, structure–activity relationships, possible role in drug development, review, 1
Phospholipid monolayer interactions—mechanisms and kinetics at interfaces, 477
Phosphoric acid and phosphoric acid–carbohydrate solutions—effect on riboflavin bioavailability and salicylamide biotransformation in humans, 1504
Photodegradation of menadione by UV light—effect of quaternary ammonium compound, complex formation, 696
Photolysis—degradation of α-[(dibutylamino)-methyl]-6,8-dichloro-2-(3′,4′-dichlorophenyl)-4-quinoline methanol, 1665
Phthalate diesters, radiolabeled—distribution and persistence in maternal blood, fetal tissue, amniotic fluid, and placenta, intraperitoneal administration, rats, 1347
Physical pharmacy—dissolution, solubility, permeability, complexation, surface phenomena, 1085
Physostigmine-induced lethality inhibition as measure of central anticholinergic activity—tertiary and quaternary derivatives of atropine and scopolamine, compared to mydriasis induction (peripheral activity), mice, 1066
Pi constants—quinolinium acid derivatives, 867
Pilocarpine-*N*-$^{14}CH_3$—synthesis *via dl*-homopilopic acid, 1700
Piperazines, *N,N′*-bis[3-(3-substituted urea)propyl]—synthesis, anticonvulsant activity and relationship to inhibition of pyruvic acid oxidation, 454
Plant extracts—potential sources of antifertility agents, review, 535, 717
Plasma binding, disopyramide and 20 derivatives—determination, relationship to lipophilicity and structure, 961
binding, 13 disopyramide derivatives—determination, relationship to pKb, 1632
protein binding—drugs, effect of age, adult human subjects, 1711
protein binding—interaction of fluorocarbon aerosol propellants with human and bovine globulins, partition coefficient method, 1577
protein binding—metronidazole and four derivatives, correlation with frontier electron density, 1797
protein binding, warfarin—relationship to distribution and elimination, rats, 1660
Plastics—analysis of residual ethylene oxide, comparison of four analytical methods by six laboratories, 1412
PMR—monitoring bovine neurophysins–oxytocin complex formation, 507
Poison oak—isolation and characterization of urushiol components, 1715
Polarizability—correlation with molecular connectivity, hydrocarbons, alcohols, nonspecific local anesthetics, 1971
Poloxamer 188—effect on absorption of phenolsulfonphthalein in rat, urinary excretion and *in situ* intestinal loop data, 987
Polychlorinated biphenyl components—pharmacokinetics in swine and sheep after single oral dose, 1294
Polyene antibiotics, alkyl esters—synthesis, antifungal activity, 462
Polyethylene glycols—peroxide impurity, corticosteroid stability, 356
suppositories—relationships between physical characteristics (mechanical strength, molecular weight, and elastic moduli) and drug (prednisolone) release rates, 1162
Polyglycerol esters—as solvents for aspirin, stability, effect of temperature, hydroxyl value, viscosity, 2018
Polymer films containing drugs—kinetics of drug release, first-order and diffusion-controlled models discussed, 76
films, laminated hydroxypropyl cellulose–polyvinyl acetate—linear drug release (methapyrilene, pentobarbital, salicylic acid), 1289
films—polyethylene–silicone composite, use as estradiol timed-release implant, 832
matrix—controlled drug release, solution–solubility dependency, equations, 1643
Polymolecular inclusion compounds—urea and thiourea, choleic acids, 4,4′-dinitrobiphenyl, hydroquinone, water, phenol, Dianin's reagent, cycloveratril, and tri-*o*-thymotide, review, 1585
Polymorphs—occurrence, dissolution kinetics, and pharmaceutical application, review, 1269
Polysorbate 20—effect on solubilization of benzoic acid and derivatives at controlled pH, partition coefficients between aqueous and micellar phases, 1253
Polysorbate 60—effect on interphase transport of cholesterol, mechanism, 1500
Polysorbate 85—effect on epidermal permeability, *in vivo* method for determining relative water loss rates, 671
Polythiazide—high-pressure liquid chromatographic analysis in pharmaceutical dosage forms, 1406
Polyurethane elastomers, segmented—correlation of kinetic parameters and thermal behavior with biological responses, 1492
Polyvinyl alcohol—effect of vehicle viscosity on ocular drug bioavailability in rabbits, compared to methylcellulose, 1312
Povidone-iodine—genetic effects, 1235
Powders—dissolution profile under sink conditions, general equation, relationship of initial particle-size distribution, applicability to dissolution of log-normal powders, 1192
dissolution—size distribution effects, log-normal distribution profile, three single-particle models investigated, 1981
distribution—sieve cuts, assumption of monodisperse powders, introduction of error in dissolution testing, 1409
—effect of glidants on flowability determined using powder failure testing equipment, 1216
monodisperse—various nonsink dissolution rate equations examined, 1651
polydisperse—dissolution, oxalic acid dihydrate, equations, 1770
Prednisolone—effects of normal alcohols on intestinal absorption, rats, 1450
Prednisone—bioavailability and pharmacokinetics in humans, absorption rate constants and serum half-lives, 50-mg tablet compared to 10 5-mg tablets, *in vitro–in vivo* correlations discussed, 109
—*in vitro* and *in vivo* bioavailability of commercial tablets, 1723
Preservatives—effect of flavoring oils on concentrations in oral liquid dosage forms, partitioning of parabens, 414
—phenol formation from alkylparabens by bacteria, 1071
Pressure, compaction—effect on particle-size spectrum of disintegrating compacts, 444
Primidone—interaction with polyethylene glycol 4000, 1787
Principal component analysis—selecting key parameters in pharmaceutical formulations, 966
Probes—binding of three aminonaphthalenesulfonic acid derivatives to serum albumins, fluorescence enhancement, 493
Procainamide—GLC analysis, biological fluids, therapeutic range, 1967
hydrochloride—rapid fluorometric determination, bulk and dosage forms, fluorescamine reagent, 1207
—pH-dependent secretion into saliva, ratio of saliva to serum concentration, humans, 2008
Procaine—quantitation of stability by TLC, rate constants, 275
Prodrugs—consideration of amino acid esters of phenolic drugs, 1070
—rationale for design, physicochemical and biological considerations, applications, modifications affecting absorption, site direction, depot, taste and odor, and irritation, review, 181
—synthesis of highly water-soluble arabinosyladenine 5′-formate, hydrolysis rates in biological fluids, 392
Proflavine derivatives—electronic spectra and electronic structures, 982
Progestin–estrogen contraceptive tablets—colorimetric analysis of ethinyl estradiol, 1221

Propantheline—effect on nitrofurantoin absorption, 1729
Propellants—pharmacokinetics of trichloromonofluoromethane following single and multiple dosing, dogs, 763
Propoxyphene and metabolites—GLC analysis in heroin addict plasma, 429
Prostaglandin B_2—ion-pair extraction with aliphatic amines, methylene group contribution, partition coefficients, 1894
Protein binding characteristics—chloramphenicol, furazolium chloride, benzalkonium chloride, and phenylmercuric nitrate, partitioning behavior in gelatin–acacia complex coacervate systems, microbiological determination, 420
—determination of parameters in systems involving interaction between sites, evaluation of method, 1892
plasma—effect on elimination of bilirubin, 1433
Protoberberine alkaloids—isolation and identification of (−)-stepholidine from opium, 1040
Pseudomonas infection in burns—inhibition by mafenide dry foam, 339
infections in burns—inhibition by silver sulfadiazine dry foam, 457
Pseudovincaleukoblastine diol—isolation from *Catharanthus roseus*, UV, IR, NMR, and mass spectral structure identification, 1953
Pyrazolin-5-one derivatives—synthesis, antitubercular activity, 1057
2-Pyridyl-α-toluenesulfonates—synthesis, screened for antimalarial activity, 1961
Pyrimidines, 2,4-diamino-5-(3,4-dichlorophenyl)-6-substituted—inhibitors of dihydrofolate reductase, correlation analysis, formulation of *de novo* substituent constants, cross-product terms, 1186
(Pyrrolidone-5-hydroxamato)iron (III) complexes—synthesis, characterization, visible and IR spectral data, magnetic moment, 970
Pyrrolidone-5-hydroxamic acid—synthesis, acidity, chelating properties, 970

Q

Quinacrine and quinacrine mustard metabolite—synthesis of 6-chloro-9-amino-2-hydroxyacridine from quinacrine, 1418
Quinazolone derivatives, fluorinated—synthesis and CNS depressant activity, 1428
Quinidine—plasma and saliva concentrations compared, humans, 2028
Quinine sulfate timed-release tablets—release rates, effect of carbomer and cellulose acetate hydrogen phthalate concentrations, 1033
Quinolinium acid derivatives—partition coefficients in chloroform–water system, sigma and pi constants, 867
(4 - Quinolinoamino)aminoalkyltetrahydronaphthalene derivatives—synthesized and screened for antimalarial activity, 460

R

Radioimmunoassay—chlordiazepoxide in plasma, compared to spectrophotofluorometric method, 937
Radiolabeled sulfonylureas—tissue distribution of ^{99m}Tc-chelates, potential pancreatic imaging agents, 687
Radiology—pharmacokinetics of metrizamide absorption from subarachnoid space after intrathecal administration, humans, 405
Radiopaques (water soluble)—automated determination of free aromatic amine impurities, 684
Radiopharmaceuticals—pharmaceutical aspects, 1085
Raman spectroscopy—association of carbonate and aluminum in aluminum hydroxide gel, 468
Receptor mapping using model interaction calculations—theoretical studies on nature of anionic binding site of acetylcholinesterase, 418
Release, controlled—ethynodiol diacetate from silicone rubber devices, comments, 1731
rates—corticoid suspensions from oleaginous ointment bases containing various adjuvants, 754
Renal failure—problems of dose adjustment, rate constants, 175
Repellents, mosquito, topical—synthesis, evaluation of alkyl triethylene glycol monoethers, 693
Reversible drug derivatives—rationale for design for prodrugs, physicochemical and biological considerations, applications, review, 181
Review Articles
Asbestosis: A Reassessment of the Overall Problem, 1435
Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications, 1269
Cyclic Nucleotide Phosphodiesterases: Properties, Activators, Inhibitors, Structure–Activity Relationships, and Possible Role in Drug Development, 1
Inclusion Compounds, 1585
Microbial Models of Mammalian Metabolism, 1737
Percutaneous Absorption, 901
Pharmaceutical Sciences—1974: Literature Review of Pharmaceutics, 1085
Pharmacokinetics and Clinical Use of Cephalosporin Antibiotics, 1899
Potential Value of Plants as Sources of New Antifertility Agents I, 535
Potential Value of Plants as Sources of New Antifertility Agents II, 717
Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs, 181
Studies with Deuterated Drugs, 367
Rolitetracycline and rolitetracycline nitrate formulations—simultaneous high-speed liquid chromatographic analysis of tetracycline and rolitetracycline, 316

S

Saccharin—GLC determination in pharmaceutical products, silyl derivatives formed, 133
Salicylamide mixtures with aspirin or aspirin/acetaminophen—differentiating nonaqueous titration, 1386
Salicylates—comparison of analgesic effects of isosteric variations of salicylic acid and aspirin, 760
Salicylazosulfapyridine—high-speed liquid chromatographic analysis, bulk powder and tablet dosage form, 1549
Salicylic acid—analgesic effects of isosteric variations, compared to aspirin isosteres, 760
and thiosalicylic acid derivatives—synthesis, spectra, and antibacterial activity as precursors of macrocyclic oxa- and thia-substituted benzolactones and benzoketones, 1240
–cetrimide systems—effects of various acids and bases on viscosity, 1037
—effects of normal alcohols on intestinal absorption, rats, 1450
in oily vehicles—correlations between *in vitro* adsorption and *in vivo* percutaneous absorption, physicochemical parameters, 397
—nonlinear tissue disposition in rat brain, model proposed, equations, 99
para substituted—decomposition in the solid state, intramolecular mechanism, Bawn kinetics, Hammett relation, 1931
Saliva—concentration of secreted procainamide, pH dependent, compared to serum concentration, humans, 2008
—determination of quinidine levels, correlated with plasma levels, 2028
Salivary pH—relationship to urinary pH, 890
Sampling, blood—time necessary for bioavailability studies, analysis of literature data, truncated blood level curves, 1521
Scanning agents—tissue distribution of radiolabeled azure C, 1068
Scopolamine and atropine, tertiary and quaternary derivatives—central *versus* peripheral cholinolytic activity, mice, 1066
and hyoscyamine—GLC determination in *Duboisia* samples, slope ratio method, 1821
—submicrogram assay in plasma and urine, heptafluorobutyryl derivatives, 288
Seals, bottles—effects of sterilization by autoclaving, pressure changes in bottles measured, 333
Segmented polyurethane elastomers—correlation of kinetic parameters and thermal behavior with biological responses, 1492
Selenium analogs—synthesis and cytotoxicity of 6-selenopurine arabinoside and related compounds, 1343
6-Selenopurine arabinoside and related compounds—synthesis and cytotoxicity, 1343
Sequestering agents—automated analysis of calcium disodium edetate in iodinated contrast media parenterals, 1026
Serial sampling, blood—simple and reliable method, technique and equipment described, rats, 112
Serum protein binding—binding of cupric ions to bovine serum albumin, studies using specific ion electrode, 1243
Setoclavine and isosetoclavine—converted from agroclavine, cell-free extracts from *Claviceps* sp. SD 58 and thioglycolate–iron (II), 343
Sieve cuts—dissolution studies, assumption of monodisperse powders, 1409
Sigma constants—quinolinium acid derivatives, 867
Silica—substrate for growing calcium oxalate crystals, 458
Silicone matrix—ethynodiol diacetate delivery system, *in vitro–in vivo* correlation for intravaginal release, rabbits, 1776
rubber matrix—release of ethynodiol diacetate, comments on controlled release, 1731
Silver sulfadiazine dry foam—inhibition of supraeschar and subeschar *Pseudomonas* infection, guinea pigs, 457
Skeletal muscle relaxant activity—3-[[5-(*p*-nitrophenyl)furfurylidene]amino]hydantoin (dantrolene positional isomer) screened, 1047
Skin, human—determination of contact angles, equations, 1080
transport—review of percutaneous absorption, 901
Sodium alginate—viscosity changes after sterilization by cobalt-60, 802
Sodium bisulfite—role in degradation of 5-fluorouracil, nucleophilic addition, 216
Sodium chloride effect—micelle size of fusidate sodium, 873
equivalents—data for 44 drugs, 1884
Sodium cholate—infusate for *in vitro* dissolution of gallstones by T-tube infusion, 2029
Sodium salicylate—inhibition of L-glutamine-D-fructose-6-phosphate aminotransferase activity from rat gastric mucosa, 1182
Soft gelatin capsules—oxygen permeability at room temperature, effects of relative humidity, plasticizers, equilibrium water, insoluble additives, and film thickness, 851
Solids and their pharmaceutical applications—review of crystal habit, amorphous solids, polymorphs, solvates, and clathrates, 1269
Solid-state decomposition—*para*-substituted salicylic acids, intramolecular mechanism, Bawn kinetics, Hammett relation, 1931
Solubility—alkyl *p*-aminobenzoates in polar and mixed solvents, equation developed for predicting solubility, compared to Scatchard–Hildebrand approach, 48
—2-butyl-3-benzofuranyl-4- [2- (diethylamino)-ethoxy]-3,5-diiodophenyl ketone hydrochloride, micelle formation, 1830
—coralyne chloride and sulfoacetate, pH dependence, 1825
—correlation with molecular connectivity, hydrocarbons, alcohols, 1974
—nitrofurantoin in aqueous urea solutions, 886
Solubilization, benzoic acid and derivatives—effect of various polysorbate 20 concentrations at controlled pH, 1253
—hexamethylmelamine by complexation with gentisic acid species, pH 0–8, intravenous formulations, 1850

Solute binding—systems approach, drug transport across membranes using suspension cultures of mammalian cells, eight steady-state diffusion models derived and discussed, 622
Solvates—preparation, characterization, properties, and pharmaceutical application, review, 1269
Solvents—binary systems, deviations from ideality, equation developed relating the dielectric constant to mole fraction, 1569
coating—effect on polymer film adhesion to tablet substrates, 1554
—effect of ternary solvent systems on erythrocytes, ternary diagrams, critical hemolytic compositions, 1818
polar—solubility of nonelectrolytes (alkali *p*-aminobenzoates), 48
Solvolysis, alcoholic—medicinally active 5-aminodibenzo[*a,d*]cycloheptenes, rate constants, 437
—mazindol, a substituted imidazoline, pH values up to 7.6, 1833
of cyclic anhydrides in anhydrous acetic acid—rate constants, mechanisms, 1759
Sorbitol—GLC determination in pharmaceuticals using tris-*n*-butyldiboronate esters, 128
Sparsomycin analogs—synthesis and screening as potential antitumor agents, 825
Spasmogens—pharmacological evaluation of himachalol, 258
Spectrophotofluorometry—analysis, lasalocid in dog blood, 1874
—determination, thioguanine, 121
Spectrophotometry—analysis, benzoyl peroxide in lotions and creams, compared to titrimetric and TLC analyses, 1999
—analysis, individual thyroid tablets, measurement of triiodide ion, 1393
—analysis, tolmetin in plasma, 1965
automated—assay of cefazolin, stability indicating, double-probe sampling procedure, 1232
difference—determination, binding of sulfonylureas and phenothiazines to bovine serum albumin using 2-(4′-hydroxybenzeneazo)benzoic acid, 1177
Spheronization—process variables, effect on granulation properties, 1688
Spin-labeled drugs—sulfanilamide, topographical study of active site of erythrocyte carbonic anhydrase, 512
Spot tests—drugs of abuse, systematic identification, 841
Spreadability, subjective—predicted from fluid mechanics, equations, 976
Stability—aluminum hydroxide gel, vehicles investigated, 2030
—aspirin in decaglycerol tetraoleate, decaglycerol octaoleate, and decaglycerol decaoleate, 2018
—barbiturates, quantitation by TLC, 272
constants—stannous fluoride complexes, potentiostatic titration, 350
—decomposition of aminosalicylic acid in solid state, sorbed moisture theories discussed, first-order decomposition patterns, 37
—effect of aging on physical properties of phenylbutazone tablets, 335
—epinephrine, kinetics of sulfite-induced degradation, 45
—nafiverine, aqueous solution and rabbit plasma, 253
—nitroglycerin sublingual tablets, loss of strength, uniformity of tablets, and degradation of drug, 140
prediction—rapid nonisothermal–isothermal kinetic method, 1381
procaine—TLC determination, 275
—synthetic and naturally occurring cannabinoids in chloroform, 357
—tetracycline, dehydration, effects of acidity at various temperatures, 352
Stannous fluoride complexes—determination of stability constants, potentiostatic titration, 350
Staphylococcus aureus—effects of clindamycin, compared to *Escherichia coli*, 1612
—effect of lincomycin and clindamycin combinations, compared to effects on *E. coli*, drug–bacteria reactions, generation curves, microbial kinetics, 1621
Starch—comparison of starch USP and modified cornstarch, 328
(−)-Stepholidine—isolation, identification as opium alkaloid, 1040
Sterilants—residual ethylene oxide analysis, comparison of four analytical methods by six laboratories, 1412
Sterilization, autoclaving—pressure changes in bottles, method for measurement, 333
cobalt-60—effects on viscosity of acacia and sodium alginate, 802
Steroid–antibiotic ophthalmic preparations—stabilizing effect of inorganic phosphate salts, 1528
Steroids—colorimetric analysis of 17-hydroxycorticosteroids in human urine, 1050
—reaction of corticosteroid and corticosteroid esters with blue tetrazolium, mechanism, 226
Sterols—kinetics of uptake and release of desmosterol, cholesterol, and β-sitosterol by Burkitt lymphoma cells, systems approach to drug transport, 627
Stickiness, subjective—predicted from fluid mechanics, equations, 976
Stilbene and stilbenediol cyclopropyl analogs—synthesis as potential antiestrogens, 1626
Stress—effects on pharmacokinetics of drugs, cefazolin, 712
Structure–activity relationships—azulene analogs–local anesthetic activity, 158
—benzylidinohydrazines, anticonvulsant activity and inhibition of monoamine oxidase activity of rat brain homogenates, 154
—*N,N′*-bis[3-(3-substituted urea)propyl]piperazines, anticonvulsant activity, rats, inhibition of pyruvic acid oxidation, 454
—cyclic nucleotide phosphodiesterases, review, 1
—decomposed amino sugar–antitumor activity, 295
—3-deoxydigitoxigenin analog inhibition of Na^+,K^+-adenosine triphosphatase, 1248
—interaction of penicilloic and penilloic acid haptens with benzylpenicilloyl specific antibodies, 1671
—local anesthetics, goldfish overturn, 1713
—sesquiterpene lactones as antitumor agents, 1077
—sesquiterpene lactones (deoxyelephantopin) as antitumor agents, 1572
—*N*-substituted amphetamine inhibition of synaptosomal accumulation of *l*-norepinephrine, 1462
—thiazolidones, anticonvulsant activity, inhibition of NAD-dependent oxidations, rats, 614
—thiosemicarbazides, antihemolytic activity, anticonvulsant activity, enzyme inhibitory properties, 1329
Structure determination—application of mixed electron-impact–chemical ionization high-resolution mass spectrometry, 1581
—mazindol in solution and solid state, diffuse UV reflectance spectroscopy, 829
Styrene-4-carboxylic acids, β-mono- and β,β-disubstituted—precursors in synthesis of 4-(branched alkyl)benzoic acids, potential fibrinolytic agents, 1170
Styryl ketones, nuclear substituted—synthesis, spectroscopy, and antitumor evaluation, 241
Succinylsulfathiazole—crystal forms, interconversion, effect of structurally related compounds, viscosity-imparting agents, surfactants, and coloring agents, 1481
—crystal growth, effect of temperature, agitation, seeding, methylcellulose, and polysorbate 80, particle-size distributions, 1485
Sugars, amino—active antitumor components in decomposed samples, effect of structure on activity, 295
Sulfacetamide sodium—ophthalmic solutions, assay, high-pressure liquid chromatography, 1017
Sulfadiazine—specific TLC tissue residue determination following fluorescamine derivatization, 973
Sulfaethidole—influence of mesenteric blood flow on intestinal absorption, *in situ* canine intestinal preparation, 664
—reduced binding to bovine serum albumin in presence of benzalkonium chloride, 361
Sulfamethazine—residues, high-pressure liquid chromatographic determination, bovine tissue, 1657
Sulfamoylphenyltriazines—synthesis of 22 derivatives, six screened for antitumor activity, 698
Sulfanilamide—assay as hydrolysis product of sulfacetamide sodium in ophthalmic solutions, high-pressure liquid chromatography, 1017
—biotransformation, effect of oxyphenbutazone and 4-hydroxyantipyrine, rats, 1928
drugs, spin labeled—topographical study of active site of erythrocyte carbonic anhydrase, 512
—fusion with benzhydrol, effect of reaction temperature, isolation and identification of products, 292
Sulfapyridine—effects of normal alcohols on intestinal absorption, rats, 1450
Sulfasalazine—high-speed liquid chromatographic analysis, bulk powder and tablet dosage form, 1549
Sulfathiazole sodium—microencapsulation, dissolution, 889
Sulfites—role in anaerobic degradation of epinephrine, kinetics, 45
Sulfonylureas and phenothiazines—binding to bovine serum albumin, difference spectrophotometry using 2-(4′-hydroxybenzeneazo)benzoic acid, 1177
—synthesized and screened as hypoglycemics, tissue distribution of ^{99m}Tc-chelates, potential pancreatic imaging agents, 687
Sulfuration reactions—1-substituted azulenes with thionyl chloride, antibacterial activity of resulting sulfonic acid derivatives and thioesters, 862
Suppositories—bioavailability of aspirin, humans, 1064
polyethylene glycol—relationships between physical characteristics and drug release rates, 1162
Surfactants effect—dioctyl sodium sulfosuccinate on phenolsulfonphthalein absorption, humans, 991
—effects of dioctyl sodium sulfosuccinate and poloxamer 188 on absorption of phenolsulfonphthalein in rat, 987
nonionic—effect of inorganic additives, cloud points, salting-in and salting-out process, 658
Swertia purpurascens Wall. (Gentianaceae)—five tetraoxygenated and three pentaoxygenated xanthones isolated and identified, screened for pharmacological activity, 80
Sympathomimetics—norepinephrine, assay, pithed rat blood pressure, 1733
Syringe, motorized automatic—component of automatic conductimetric titration apparatus, application to solute–solute interactions, 147

T

Tablets, compressed—evaluation of particle-size spectra, 444
disintegrants (starch, sodium carboxymethylcellulose, sodium starch glycolate, cation-exchange resin)—water sorption of powders and calcium phosphate dibasic dihydrate tablets, disintegration, dissolution, 447
dissolution rates—design and evaluation of multichannel continuous-flow apparatus, also applied to powders and capsules, 1692
—effect of surface roughness and coating solvent on film adhesion, 1554
—granulations, drying rates, effect of particle

size and granular densities, 1023
granulations—effect of granulating adjuvants on drying rates, 135
granulations—spheronization method utilized to control granule properties, 1688
hardness tester—modified to give digitized values, 1578
sublingual nitroglycerin—stability, 140
Tear dynamics and ophthalmic drug bioavailability—effect of topical anesthetics, rabbits, 267
Technology, pharmaceutical—sterility, dosage forms, cosmetics, packaging equipment, 1085
Tertiary amine drugs—assay by quaternization and photolysis, picomole quantities, 950
Tetracycline and rolitetracycline in rolitetracycline and rolitetracycline nitrate formulations—simultaneous high-speed liquid chromatographic analysis, 316
—dehydration kinetics, effect of acidity at various temperatures, 352
—intestinal absorption from bile and aqueous solutions, elimination, rats, 1847
—separation and analysis of impurities, 1681
Thalamic recruitment—effects of chlorpromazine, imipramine, and pentobarbital, conditioned avoidance response, conscious cat, 1647
Thalidomide derivatives—6-alkyl-2-[3′- or 4′-nitrophthalimido]glutarimides synthesized and screened as possible antineoplastic agents, 262
Theophylline absorption—effect of glycerin and propylene glycol, rats, related to effect of various alcohols on intestinal net water flux, 607
—effect of ethanol on absorption, humans, 299
—intestinal absorption, concentration dependence of ethanol, rats, 897
Thermodynamics—gaseous anesthesia, evaluation of Ferguson principle, mice, 2025
Thermoregulation—effect of allylglycine intraperitoneal and intraventricular administration on hypothermic response, rats, 835
1,3,4-Thiadiazoles, 5-substituted 2-(*N,N*-dialkylaminoethyl)amino and 2-*N*-methylpiperazinyl—synthesis, antihistaminic, anticholinergic, and norepinephrine-potentiating activities, 1250
Thiazolidones, 2-arylimino-3-(3-*N*-morpholinopropyl)—synthesis, inhibition of NAD-dependent oxidations and relationship to anticonvulsant activity, 614
Thiocolchicines, alkyl, and *N*-deacetyl-alkylthiocolchicines—synthesized from colchicine, antileukemic activity, 646
Thioguanine—spectrophotofluorometric assay, 121
Thiosemicarbazides, 1-(2,4-dichloro and 2,4,5-trichlorophenoxyacetyl) -4- alkyl/aryl—synthesis, antihemolytic and anticonvulsant activities, and relationship to inhibition of cellular respiratory activity and inhibition of monoamine oxidase, 1329
Thiosulfates, heterocyclic alkyl—synthesis and antimalarial activity, 211
2-Thiotetrahydro -1,3,5- thiadiazines—antidermatophytic activity, 164
Thyroid—analysis of individual tablets, spectrophotometric method measuring triiodide ion, 1393
Timed release, caffeine or salicylic acid from ethylcellulose films—first-order and diffusion-controlled models discussed, 76
dosage forms—blood levels, fast and slow release components, equations, 1728
formulations—claimed *versus* actual "controlled-release" properties, blood level profiles compared to "plain-release" blood level profiles, 1075
formulations—cyclophosphamide and *cis*-dichlorodiammineplatinum (II) with poly(lactic acid), 115
formulations—dexamethasone aerosol, development and evaluation, 408
quinine sulfate tablets—effect of carbomer concentration on release rate, 1033
Timolol—extraction, derivatization, GLC analysis, biological fluids, 1879
Tissue disposition, nonlinear—model proposed, equations derived, salicylic acid in rat brain as an example, 99
Titration, nonaqueous—chlorpromazine hydrochloride, chemistry, 129
potentiostatic—determination of stability constants of stannous fluoride, 350
Titrimeter, automated conductimetric—design, application to studying solute–solute interactions, 147
Titrimetry, analysis—benzoyl peroxide in lotions and creams, compared to TLC and spectrophotometric analyses, 1999
nonaqueous, differentiating—mixtures of aspirin, salicylamide, and acetaminophen, 1386
TLC—analysis, benzoyl peroxide in lotions and creams, compared to titrimetric and spectrophotometric analyses, 1999
—analysis, tribromsalan, blood and urine, 2007
—determination, dapsone impurities in pharmaceutical preparations, 1205
—determination, 17-monochloroacetylajmaline and ajmaline in plasma, 643
—determination, procaine stability, 275
—monitoring and quantitating barbiturate stability, 272
—quantitative analysis, triclocarban in human and rabbit blood, 860
—separation, tetracycline impurities, 1681
—tissue residue determination, sulfadiazine, fluorescamine derivatization, 973
Tocopheryl acetate—biopharmaceutic factors, parenteral administration, rate-limiting step, 655
Tolmetin—GLC and spectrophotometric analyses, plasma, 1965
Toluidine blue O and related dyes—chromatography, mass spectra, and visible light absorption, 1456
Topical preparations—dexamethasone timed-release aerosol formulation, development and evaluation, 408
Toxicity, bone marrow—doxorubicin, reduction by aortic occlusion technique, rabbits, 1574
—phthalate diesters (radiolabeled), maternal–fetal transfer, rats, 1347
—pyridine compounds, salicylates, phenylbutazone, nicotinic acid site, nicotinamide site, coenzyme binding site, 528
Toxicodendron diversilobum—isolation and characterization of urushiol components, 1715
Toxicology, asbestos—review of chemistry, industrial exposure, carcinogenic aspects in animals and humans, 1435
Toxins—isolation from *Gymnodinium breve,* partial characterization, 865
Transformations, crystal—succinylsulfathiazole, various factors affecting growth, particle-size distributions, 1485
Transport—as controlling factor in dissolution rate process, convective mathematical diffusion model proposed and tested, 610
drug—nonlinear tissue disposition, salicylic acid in rat brain, model proposed, equations, 99
interphase—cholesterol, effect of polysorbate 60, stirred diffusion cell, mechanism, 1500
mechanisms—eight steady-state diffusion models derived and discussed, membranes using suspension cultures of mammalian cells, 622
—mechanistic evaluation of modifications of distribution pharmacokinetic parameters, model organic anions in presence of model renal tubular secretion inhibitor, rats, 1813
—model compounds, effects of chemical modifications, distribution pharmacokinetic parameters, rats, 1804
—selection of a reference partitioning system for drug design work, 599
Triamcinolone acetonide-21-phosphate, ^{14}C-labeled—absorption, distribution, and elimination after intravenous and intramuscular administration, dog, monkey, and rat, 1351
Triazenes, derivatives—synthesis of 22 1-*p*-sulfamoylphenyl-, 1-*p*-dialkylsulfamoylphenyl-, and 1-*p*-[*N,N*-bis(2-chloroethyl)sulfamoylphenyl]-substituted 3,3-dialkyltriazenes, six compounds screened for antitumor activity, 698
—synthesis of 5-(3,3-disubstituted-1-triazenyl)-imidazole-4-carbonitriles, screened against leukemia L-1210, 954
Triazenylimidazoles—derivatives of imidazole-4-carbonitrile, synthesis, 954
Triazine derivatives—hexamethylmelamine, solubilization by complexation with gentisic acid species, intravenous formulations, 1850
Tribromsalan—analysis, blood and urine, TLC, fluorometry, 2007
Trichloromonofluoromethane—binding to human serum albumin, 1052
—interspecies differences in blood and plasma solubilities, toxicity implications, 1538
—pharmacokinetics following single and multiple doses, dogs, 763
Triclocarban—quantitative analysis in human and rabbit blood, 860
Triethylaminoethyl cellulose—used for liquid chromatographic separation of clindamycin 2-phosphate from other clindamycin compounds, 313
Triflubazam (a 1,5-benzodiazepine) and its metabolites—high-pressure liquid chromatographic analysis in human and animal blood and urine, 1339
Triglyceride metabolism—effects of 2,8-dibenzylcyclooctanone, 235
Tristimulus colorimetry—measurement of surface color and color difference of tablet colorants, 323
Tropine alkaloids and synthetic analogs—unit-dose analysis, charge-transfer UV spectrophotometry, 1398
Trypsin—inhibition by dioctyl sodium sulfosuccinate, pH 6–8, two different substrates, therapeutic significance, 1858
Tryptophan and lysine supplementation—effect on human plasma cholesterol and triglyceride levels, 691
Tumor inhibition—gossypol, isolated from *Montezuma speciosissima,* PMR, UV, IR, and mass spectra, 1889

U

Ultracentrifugation—determination of fusidate sodium micelle molecular weights in varying counterion concentrations, 873
Urea and thiourea inclusion compounds—review, 1585
—effect on cloud points of nonionic polyoxyethylated surfactants, 658
—solubility of nitrofurantoin in aqueous solutions, 886
Uridine-5′-diphospho-*N*-acetylglucosamine—inhibition of L-glutamine-D-fructose-6-phosphate activity from rat gastric mucosa, 1182
Urinary excretion data—equations for rapid estimation of bioavailability, 1721
pH—relationship to salivary pH, 890
Urushiol components of poison oak (*Toxicodendron diversilobum*)—isolation and characterization, 1715
Uterine motility—effect of cyproterone acetate, rats, 452
UV spectrophotometry—analysis, acetaminophen and dichloralantipyrine in capsules, 1547
—analysis, 7-chloro-1,3-dihydro-5-phenyl-2*H*-1,4-benzodiazepin-2-one 4-oxide in chlordiazepoxide formulations, 1545
—analysis, tropine alkaloids, and synthetic analogs, unit-dose sensitivity, 1398
diffuse reflectance—structure determination, mazindol, 829
—quantitative analysis, triclocarban in human and rabbit blood, 860

V

Vaginal devices—controlled release of ethynodiol diacetate from silicone matrix, *in vitro–in*

vivo correlation, rabbits, 1776
drug delivery system—development of *in situ* vaginal drug absorption procedure, equipment and equations, rabbits, 71
Vascular smooth muscle—description of simple isolated perfused artery preparation, vasoconstrictor evaluation, 170
Vasoconstrictor evaluation—simple isolated perfused artery preparation described, response to catecholamines determined, 170
Vehicles, oily—percutaneous absorption of salicylic acid and carbinoxamine from liquid paraffin, hexadecyl alcohol, oleic acid, and isopropyl myristate, 397
Vinamidine—isolation from *Catharanthus roseus*, UV, IR, NMR, and mass spectral structure identification, 1953
Vinca libanotica **alkaloids**—structure elucidation of herbadine, 341
Vinca rosea—isolation of three dimeric alkaloids, characterization by UV, IR, NMR, and mass spectra, 1953
Viscosity—salicylic acid–cetrimide systems, effects of various acids and bases, 1037
subjective—predicted from fluid mechanics, equations, 976
Vitamin D_2 in pharmaceutical preparations—differential spectroscopic analysis using trifluoroacetic acid, absence of vitamin A, 1196
Vitamin E—biopharmaceutic factors, parenteral administration, rate-limiting step, 655
Volatility, alkyl triethylene glycol monoethers—relationship to mosquito repellency, 693

W

Warfarin—distribution, half-life, elimination, anticoagulant effect determined, compared to dicumarol, rats, 1995
—relationship between protein binding, distribution, and elimination kinetics in rats, 1660
Water inclusion compounds—review, 1585
loss rates—human epidermis, *in vivo* method, 671
sorption of tablet disintegrants (starch, sodium carboxymethylcellulose, sodium starch glycolate, cation-exchange resin)—disintegration and dissolution, powders and calcium phosphate dibasic dihydrate tablets, 447

X

Xanthones, polyoxygenated—activity against *Mycobacterium tuberculosis*, 888
tetraoxygenated and pentaoxygenated—isolated and identified from *S. purpurascens*, screened for pharmacological activity, 80
X-ray diffraction—determination of dienestrol configuration, 1525
—monitoring, structural changes in aluminum hydroxide gel during aging, compared to IR spectrophotometric method, 1166

Y

Z